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Abstract 
Control of cellular tRNA repertoires can drive specific programmes of translation 
to favour the maintenance of proliferative or differentiated phenotypes. tRNAiMet 
is the initiator methionine tRNA, responsible for recognising the start codon and 
initiating translation. We have investigated how increased expression of tRNAiMet 
can influence cell behaviour, using both immortalised cell lines in vitro and 
mouse models in vivo. 
Levels of tRNAiMet are increased in carcinoma-associated fibroblasts compared to 
normal fibroblasts. To understand the cellular effects of tRNAiMet overexpression 
in more detail we generated immortalised mouse embryonic fibroblasts (iMEFs) 
that overexpressed tRNAiMet (iMEF.tRNAiMet) or an empty vector as control 
(iMEF.Vector). Full characterisation of iMEF.Vector and iMEF.tRNAiMet cell lines 
showed that overexpression of tRNAiMet did not affect cell size, energy 
metabolism, cell spreading, rate of cellular protein synthesis or proliferation. 
Increased expression of tRNAiMet did, however, have marked effects on cell 
migration; with iMEF.tRNAiMet cells migrating approximately 1.5 fold faster than 
iMEF.Vector controls when assessing both directional and random migration. This 
tRNAiMet-driven increase in cell speed was dependent on the levels of 
phosphorylated eIF2α, indicating that fibroblast migration might be influenced 
by tRNAiMet in the ternary complex.  Furthermore, the ability of tRNAiMet to 
increase cell migration depended on the ability of integrin α5β1 to bind its 
extracellular ligand fibronectin. However, despite the robust and reproducible 
role of both phospho-eIF2α and integrin α5β1 in this process, the way in which 
these are mechanistically linked to tRNAiMet levels is yet to be determined. 
To investigate whether increased stromal tRNAiMet expression may contribute to 
tumour progression, we utilised a mouse that expressed additional copies of the 
tRNAiMet gene (2+tRNAiMet mouse), and performed syngeneic allografts into these 
animals.  Subcutaneous allograft tumours of a number of different cancer cell 
lines became more vascularised and grew significantly more rapidly in 2+tRNAiMet 
mice by comparison with tumours grown in littermate control animals. The 
extracellular matrix (ECM) that was deposited by fibroblasts from 2+tRNAiMet 
mice was found to support enhanced endothelial cell and fibroblast migration. 
We used SILAC mass spectrometry to compare the secretome of iMEF.Vector and 
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iMEF.tRNAiMet cell lines and found that overexpression of tRNAiMet significantly 
increased synthesis and secretion of certain types of collagen, in particular 
collagen II.  Moreover, knockdown of collagen II using siRNA and CRISPR 
approaches opposed the ability of tRNAiMet overexpressing fibroblasts to deposit 
a pro-migratory ECM.  We used the prolyl hydroxylase inhibitor, ethyl-3,4-
dihydroxybenzoate (DHB), to determine whether collagen synthesis contributed 
to the ability of tRNAiMet to drive a pro-tumorigenic stroma in vivo.  
Administration of DHB had no effect on the growth of syngeneic allografts in 
wild-type mice, but opposed the ability of 2+tRNAiMet animals to support 
increased angiogenesis and tumour growth. Collectively these data indicate that 
increased expression of tRNAiMet contributes to tumour progression by enhancing 
the ability of stromal fibroblasts to synthesise and secrete a collagen II-rich ECM 
that supports endothelial cell migration and angiogenesis.  
Taken together these data provide evidence that the tRNAome, and in particular 
cellular levels of tRNAiMet, influence both the migration of fibroblasts and the 
composition of their secretome in a way that promotes the generation of a 
microenvironment supportive of endothelial cell migration, angiogenesis and 
tumour growth.   
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Chapter 1 Introduction 
1.1 The regulation of gene expression 
The control of gene expression is a fundamental aspect of both health and 
disease that is governed by a number of highly sophisticated mechanisms. The 
initial pioneering work into the structure of DNA by Watson, Crick, Wilkins and 
Franklin provided the early suggestion of “a possible copying mechanism for 
genetic material” (Watson and Crick, 1953), and the consequent transcription of 
DNA into RNA and translation of RNA to protein are well established processes 
that play key roles in regulating gene expression (Crick, 1970). Advances in 
epigenetics, in addition to progress in understanding post-transcriptional and 
post-translational modifications, continue to add additional layers of complexity 
to these processes, and it is now apparent that what may once have been 
considered basic biology is actually anything but, as investigating the intricacy of 
transcriptional and translational regulation again comes to the fore-front of 
biological research (Gingold et al., 2014, Rubio et al., 2014, Truitt et al., 2015). 
1.2 General transcription 
In order to express the information stored within the genome, genes must first 
be transcribed from DNA to RNA by an RNA polymerase. In eukaryotes three 
major RNA Polymerases have evolved, each catalysing the transcription of a 
specific set of genes (Table 1-1). 
RNA Polymerase Gene Product 
 Product Abbreviation Function 
Pol I ribosomal RNA rRNA ribosome 
Pol II messenger RNA 
small nucleolar 
micro RNA 
mRNA 
snRNA 
miRNA 
protein coding  
pre-mRNA splicing 
gene expression 
Pol III transfer RNA 
specific rRNA 
specific snRNA 
other small RNAs 
tRNA 
5S rRNA 
U6 snRNA 
Inc. MRP, 7SL 
adaptor molecule 
ribosome 
pre-mRNA splicing 
various 
Table 1-1- Major eukaryotic RNA polymerases and their products.  
 
In plants two additional nuclear RNA polymerases have also been identified, 
namely RNA polymerase IV and V, which are related to RNA polymerase II and 
encode non-coding RNAs involved in gene silencing (Haag and Pikaard, 2011). 
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Eukaryotic cells also express a specific RNA polymerase responsible solely for the 
transcription of the mitochondrial genome, encoding the 13 transcripts required 
for the components of the electron transport chain in addition to the 2 rRNAs 
and 22 tRNAs required for their translation (reviewed in (Arnold et al., 2012)).  
Of the main RNA polymerases, RNA Polymerase II (Pol II) is responsible for 
transcription of all protein-coding genes and some non-coding RNA products such 
as microRNAs (miRNA) and small nuclear RNAs (snRNA). RNA Polymerase I (Pol I) 
is dedicated only to production of ribosomal RNA (rRNA), and this occurs through 
transcription of a large 47S pre-rRNA template which is then processed into 
mature 5.8S, 18S and 28S rRNAs to form essential components of the ribosomal 
machinery (Moss and Stefanovsky, 2002, Moore and Steitz, 2002). RNA 
Polymerase III (Pol III) is responsible for transcription of small non-coding RNAs, 
including transfer RNAs (tRNAs) and 5S rRNA, and in collaboration with Pol I, 
transcribes essential components of the protein synthesis machinery (White, 
1998). The level of Pol III transcription, therefore, tends to be coordinated with 
regulation of cell growth, and so is increased in conditions supportive of 
proliferation and inhibited in times of stress. 
1.3 RNA polymerase III 
1.3.1 Pol III machinery 
Pol III is a large multi-subunit enzyme, composed of 17 subunits with a total 
mass of 600 – 700kDa (White, 2001, Dieci et al., 2007). Dedicated to the 
transcription of small structural and catalytic RNAs, Pol III can initiate 
transcription through interaction with its associated transcription factors TFIIIC 
and TFIIIB. TFIIIC is composed of 6 subunits (TFIIIC220, TFIIIC110, TFIIIC102, 
TFIIIC90, TFIIIC63 and TFIIIC35) that come together in two major subdomains 
connected by a flexible linker, with the intrinsic histone acetyltransferase (HAT) 
activity of TFIIIC220, TFIIIC110 and TFIIIC90 being central to their role in Pol III 
transcription (Hsieh et al., 1999a, Hsieh et al., 1999b, Kundu et al., 1999). TFIIIB 
is a complex of 3 independent subunits composed of TBP (TATA-binding protein), 
Bdp, and BRF1 or BRF2 (TFIIB-related factor 1 or 2) (Wang and Roeder, 1995), 
and gene structure determines which Pol III specific factors are recruited. 
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1.3.2 Pol III transcription 
1.3.2.1 Initiation 
Initiation of Pol III transcription can occur at three different promoter types 
(Figure 1-1) (Dieci et al., 2007, Schramm and Hernandez, 2002). For type 1 and 
type 2 promoters, the promoter sequence is positioned within the transcribed 
region. Type 1 structures are only found within 5S rRNA genes and consist of a 
pair of conserved motifs (A box and C box) separated by an intermediate 
element sequence (IE). To initiate transcription at type 1 promoters, TFIIIC 
recognises and binds to the A and C box internal promoter sequences and this is 
assisted by an additional transcription factor, TFIIIA, which can bind the IE. 
TFIIIB can then associate upstream of the transcription start site (TSS) to enable 
recruitment of Pol III and formation of the pre-initiation complex (PIC). Type 2 
promoters are found in all tRNA genes (with the exception of tRNASelCys). They 
initiate transcription in a similar manner to that described for type 1 promoters, 
with the exception of TFIIIA requirement and the internal promoters recognised 
by TFIIIC are defined as A and B box sequences. For both type 1 and type 2 
promoters TFIIIB is composed of TBP, Bdp and BRF1, and the rate-limiting step of 
PIC formation is TFIIIB recruitment (Oler et al., 2010, Moqtaderi and Struhl, 
2004). However, at type 3 promoters a variant TFIIIB is required, which is 
comprised of TBP, Bdp and BRF2 subunits. Type 3 genes include U6, and this 
gene structure is reminiscent of that found in protein-coding genes. External 
promoter sequences upstream of the TSS include a distal sequence element 
(DSE), proximal sequence element (PSE) and a TATA box. TFIIIB binds the TATA 
box to recruit a multi subunit complex known as SNAPC to the PSE, and this then 
enables Pol III to bind the TSS. Following recruitment of additional factors, 
including Oct-1 and STAF at the DSE, the PIC can then initiate Pol III 
transcription (Dieci et al., 2007, Schramm and Hernandez, 2002). A transcription 
bubble is formed as the helicase activity of the polymerase unwinds the double-
stranded DNA to expose the template strand, ribonucleotides are then 
incorporated into a complementary RNA transcript, and TFIIIB releases Pol III 
allowing elongation to begin (Kassavetis et al., 1990, White, 2002).  
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Figure 1-1- RNA Polymerase III promoter types.  
A schematic representation of the three types of Pol III promoter. Type I promoters, eg 5S rRNA, 
have internal A and C block promoters separated by an intermediate element (IE), and Pol III 
binding is aided by the transcription factors TFIIIC, TFIIIA, and TFIIIB (consisting of BRF1, Bdp and 
TBP). Type 2 promoters, eg tRNAs, have two internal A and B box sequences that function as 
internal promoters, and are bound as above but without the requirement for TFIIIA. Type 3 
promoters, eg U6 RNA, are more similar to protein coding genes and have a distal sequence 
element (DSE), a proximal sequence element (PSE) and a TATA box, and are bound by a TFIIIB 
variant consisting of BRF2, Bdp1 and TBP, in addition to a SNAPC multi-protein complex and Pol 
III. Image made using items from Image Bank in Servier Medical Art. 
1.3.2.2 Elongation and termination  
Pol III transcription generates non-coding RNAs that are generally less than 300 
base pairs (bp) in length, and so it requires no additional accessory factors 
(Schramm and Hernandez, 2002, Canella et al., 2010).  Elongation is followed by 
termination, which is signalled by a short run of thymine residues. The poly-T 
signal pauses the polymerase causing catalytic inactivation and backtracking 
which commits the enzyme to termination and enables release of the newly 
synthesised RNA (Nielsen et al., 2013).  
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1.3.2.3 Regulation of Pol III transcription 
The rate of Pol III transcription is tightly linked to the rate of cell growth and 
proliferation. For cells to be able to grow and divide they need to accumulate 
mass, and as the majority of a cells dry mass is protein, the Pol III mediated 
transcription of essential components of the protein synthesis machinery is 
regulated in-line with cell growth requirements. Serum and increased nutrient 
availability therefore increase Pol III transcription, while growth arrest and other 
cell stresses oppose it (Clarke et al., 1996, Mauck and Green, 1974). 
The level of Pol III transcription can be regulated in a number of different ways. 
The short length of Pol III products means that assignment of control to the 
elongation step would be insufficiently effective, and so the rate-limiting step of 
Pol III transcription tends to be PIC formation in initiation. Increased expression 
of TFIIIC and TFIIIB are associated with increased Pol III activity (White, 2004), 
and phosphorylation of BRF1 by a number of different kinases, including ERK and 
PLK1 (Polo-like kinase 1), is also thought to increase TFIIIB’s binding affinity for 
TFIIIC to increase the rates of Pol III transcription (Fairley et al., 2012, Felton-
Edkins et al., 2003). 
Specific regulators are also able to bind and modulate components of the Pol III 
machinery (Figure 1-2). Through its association with BRF1, c-Myc can localise to 
tRNA genes and recruit the co-factors GCN5 and TRRAP to promote Pol III 
transcription (Gomez-Roman et al., 2003, Kenneth et al., 2007). Overexpression 
of c-Myc, therefore, increases the rate of Pol III transcription (Aaronson, 1991, 
Johnson et al., 2008, Gomez-Roman et al., 2006). Retinoblastoma protein (Rb) 
and p53 can also bind TFIIIB, but their association is inhibitory to Pol III 
transcription, as they block the interaction between TFIIIC and TFIIIB to prevent 
the recruitment of Pol III to its promoters (White et al., 1996, Cairns and White, 
1998). Maf1 is another repressor of Pol III transcription, and this inhibition can 
occur through its ability to associate with both TFIIIB and Pol III (Boguta, 2013). 
Maf1 activity is regulated by its phosphorylation status (Pluta et al., 2001). 
Inactivation of Maf1 by mTOR-dependent phosphorylation increases Pol III 
transcription in response to nutrient availability (Kantidakis et al., 2010, Boguta, 
2013), and increased growth driven by aberrant TORC1 activity can be blocked in 
mutant BRF1 cells (Marshall et al., 2012). The level of Pol III-mediated 
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transcription is therefore intricately linked to the rate of protein synthesis and 
cell growth, and the abnormal Pol III activity which is reported as a common 
feature of cancer cells is therefore not surprising considering its regulation by a 
number of well-characterised tumour promoters and suppressors (Figure 1-2) 
(White, 2004). 
 
Figure 1-2- Regulation of Pol III transcription.  
Pol III-mediated transcription is regulated by a variety of different factors, and is increased in 
response to growth stimuli. Phosphorylation of Pol III specific transcription factors by kinases such 
as ERK can increase the affinity of TFIIIB for the Pol III machinery, whilst c-Myc can recruit histone 
acetyltransferases (HATs) to increase gene expression. Negative regulators of Pol III transcription 
include Maf1, p53 and Rb, and release of repression by these factors can increase Pol III 
transcription. Pol III transcribes essential components of the protein synthesis machinery, and as a 
consequence is associated with processes such as cell growth. Image made using items from 
Image Bank in Servier Medical Art.  
1.3.3 Pol III products 
Although all the products transcribed by Pol III are small non-coding RNAs, they 
can have a number of versatile functions within the cell including roles in RNA 
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processing and protein localisation, in addition to more well-known functions in 
ribosome biogenesis and protein synthesis.  
U6 is a small nuclear RNA (snRNA) that forms the RNA component of the small 
nuclear ribonucleoprotein (snRNP). This RNA-protein complex associates with 
other snRNPs and additional proteins to form the spliceosome, and is responsible 
for splicing pre-mRNA (Will and Luhrmann, 2011).  
7SL is the RNA component of the signal recognition particle (SRP) 
ribonucleoprotein complex (Walter and Blobel, 1982). Once bound to its 6 
associated protein subunits, the SRP complex facilitates trafficking of newly 
synthesised proteins into the endoplasmic reticulum (ER) and can also play a role 
in post-translational sorting (Shan and Walter, 2005, Abell et al., 2004).    
5S rRNA is an essential component of the large subunit of the ribosome, and its 
expression is coordinated with the transcription of the other rRNAs produced by 
Pol I. Ribosomal RNA conducts most of the functional and catalytic roles of the 
ribosome, while the associated ribosomal proteins are mainly required to provide 
structural support (Moore and Steitz, 2002).  
Transfer RNAs (tRNAs) are some of the most abundant Pol III products (Dieci et 
al., 2007), and as they function as adaptor molecules in protein synthesis, they 
have long been considered housekeepers that recognise codons of the mRNA and 
bring the corresponding amino acids to the translation machinery (Hoagland et 
al., 1958). However, recent work has suggested that tRNAs play a much more 
complex role in translational control (Gingold et al., 2014), and so further 
investigating tRNA biology could be of great value in understanding the 
complexities of gene expression. 
1.4 Transfer RNAs 
There are currently 516 annotated genes known to encode nuclear tRNAs 
dispersed throughout the human genome, and 22 known mitochondrial tRNA 
genes (Genomic tRNA database, (Lowe and Eddy, 1997)). They can be 
categorised into 61 isoacceptor classes depending on the anticodon they contain, 
and into 21 isotypes depending on the amino acid they decode (20 standard 
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amino acids plus selenocysteine) (Dittmar et al., 2006). For example, tRNAs with 
the anticodons AAG and CAG can both specify leucine, and are therefore of the 
same isotype. However, the difference in their anticodon sequence means they 
belong to different isoacceptor classes. Since there are only 61 possible 
anticodons specified by the triplet code (Table 1-2), there are many tRNA 
species in the same isoacceptor family that have sequence differences 
throughout the body of the tRNA. 
 
Table 1-2- RNA codon table. 
The genetic code describing the codons encoding each of the standard amino acids.    
1.4.1 Transcription  
tRNA genes are highly transcribed, producing 3 million new tRNAs per yeast cell 
division cycle compared to around 60,000 mRNAs (Ares et al., 1999, Waldron and 
Lacroute, 1975). tRNA synthesis begins with Pol III-mediated transcription in the 
nucleus from type 2 promoters (as described in 1.3.2), and the pre-tRNA 
generated is then processed into a mature transcript (White, 2002). This occurs 
through RNase P and RNase Z cleavage at the 5’ and 3’ ends respectively, and a 
CCA sequence is then added to the 3’ end by a nucleotidyl-transferase (Frank 
and Pace, 1998, Ceballos and Vioque, 2007). Splicing occurs, for intron-
containing tRNAs, through reactions with tRNA-splicing endonucleases, and this 
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is invariably performed adjacent to the anticodon loop between positions 37 and 
38 of the tRNA (Tocchini-Valentini et al., 2009). Nucleotides can then be 
modified and this acts not only to stabilise the tRNA but also has functional 
consequences, as will be described further in 1.4.2 (Figure 1-3).  Nuclear export 
to the cytoplasm is mediated by the Ran-GTPase pathway and Xpo-t, a member 
of the Ran-binding β-importin family (Kutay et al., 1998, Arts et al., 1998). Xpo-t 
directly binds the tRNA and associates with Ran-GTP, allowing the Ran-GTP:Xpo-
t:tRNA complex to move through the nuclear pores to the cytoplasm, where 
increased Ran-GAP activity hydrolyses Ran-GTP to Ran-GDP, facilitating 
dissociation of the complex and tRNA release. The tRNA is then available to be 
charged with its cognate amino acid via an aminoacylation reaction that will also 
be described in more detail later in the text (1.4.3). Subsequent data, however, 
have suggested that the process is not necessarily this simple and that, at least 
in yeast, splicing can occur out-with the nucleus (Yoshihisa et al., 2003), 
movement between the nucleus and the cytoplasm can be bidirectional, and 
aminoacylation does not only occur in the cytoplasm (Hopper and Shaheen, 
2008, Lund and Dahlberg, 1998).  
Mature tRNAs are 70 to 100 nucleotides in length with a cloverleaf secondary 
structure and a complex L-shaped tertiary structure. The main functional regions 
of the tRNA are the anticodon, which reads the codons of the mRNA, and the 3’ 
CCA nucleotides which enable attachment of the corresponding amino acid. The 
tRNA anticodon is located at positions 34, 35 and 36 of the tRNA, and position 34 
can pair with various nucleotides through wobble and non-Watson-Crick 
interactions at the third position of the mRNA codon, allowing for the 
degeneracy of the genetic code (Agris et al., 2007).  Other regions important in 
defining the identity of a tRNA include sequences within the acceptor stem and 
the D, T and variable loops (Goodenbour and Pan, 2006). In addition to 
differences in sequence, tRNA bases can also be highly modified, with 105 
different chemical modifications of tRNAs currently described that primarily 
have structural and stabilising roles (The RNA modification database 
http://mods.rna.albany.edu/home). 
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Figure 1-3- tRNA processing.  
Schematic representation of the processes that occur in generation of a mature tRNA. The pre-
tRNA is processed by RNase P and Z, and a 3’ CCA then added by a tRNA nucleotidyl-
transferase. Splicing can occur in intron containing tRNAs, and the bases that are commonly 
modified are highlighted in red. The functional domains important in specifying tRNA identity are 
also identified, and numbers refer to the nucleotide positions. Image made using items from Image 
Bank in Servier Medical Art. 
1.4.2 Modification 
The post-transcriptional modification of selected tRNA nucleotides is an 
important part of the tRNA maturation process that is essential for correct tRNA 
structure, function and stability. There are a number of specific bases that are 
commonly modified (as represented in Figure 1-3) and tRNAs that lack the 
correct modifications are targeted to degradation pathways (Phizicky and 
Hopper, 2010). For example, modifications at position 37 (adjacent to the 
anticodon loop) can stabilise codon:anticodon interactions to prevent 
frameshifts in translation (El Yacoubi et al., 2012), modifications at position 34 
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(the wobble position of the anticodon) are important in decoding the degeneracy 
of the amino acid code, and modifications in the main body of the tRNA tend to 
have structural and stabilising roles (Novoa et al., 2012). Common modifications 
at the wobble position include incorporation of thiol, hydroxyl and methyl 
groups on uridine (U), and adenosine-to-inosine (A-to-I) editing, while the 2’O-
ribosyl phosphate modification at position 64 of tRNAMet distinguishes the 
initiator methionine tRNA (tRNAiMet) from the elongator  methionine tRNA 
(tRNAeMet) (Astrom and Bystrom, 1994). Correct tRNA modifications are therefore 
important in specifying the identity of tRNAs to maintain correct aminoacylation 
reactions and fidelity in protein synthesis.  
1.4.3  Aminoacylation  
By recognising embedded identity elements within the tRNA, including 
discriminatory bases, unique base-pair interactions and specific modifications, 
aminoacyl-tRNA synthetases (aaRSs) charge tRNA molecules with their 
corresponding amino acid, and this process is completed via a two-step reaction. 
The first stage consumes ATP to activate the amino acid with an active 
phosphate moeity to form an aminoacyl-adenylate intermediate, and in the 
second phase the charged amino acid is covalently attached to the 3’-CCA of the 
corresponding tRNA (Beuning and Musier-Forsyth, 1999). aaRSs are categorised 
into two classes, Class I are monomeric and aminoacylate the 2’-OH of a 
terminal adenosine nucleotide on the tRNA, while Class II aaRSs are oligomeric 
and generally aminoacylate the 3’-OH of the terminal adenosine (Pang et al., 
2014). Both classes of aaRSs have proofreading abilities and are able to edit 
amino acid loading errors via hydrolytic domains in their catalytic core, and so 
represent the final but important step of tRNA biosynthesis to generate a mature 
charged tRNA for use in translation.   
1.4.4 Turnover 
Mature tRNAs are very stable, with half-lives reported to range from 50 hours in 
chicken muscle (Nwagwu and Nana, 1980) to 3 days in avian liver (Kanerva and 
Maenpaa, 1981). However, two pathways are now known to monitor tRNA quality 
and modulate turnover. The first pathway ensures the integrity of pre-tRNAs by 
nuclear surveillance, and allows pre-tRNAs that are not modified in the correct 
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manner to be degraded from the 3’ end by the nuclear exosome (Kadaba et al., 
2004). The other pathway is specific to mature tRNAs and is known as the Rapid 
tRNA Decay (RTD) pathway. In this instance mutated tRNAs, or tRNAs with a 
destabilised structure, are degraded from the 5’ end via a reaction catalysed by 
the 5’-3’exonucleases Rat1 and Xrn1 (Chernyakov et al., 2008). Furthermore, the 
nucleotidyl transferase that catalyses addition of the 3’ CCA sequence to tRNAs 
can also add a CCACCA sequence to tRNAs with unstable structures to prevent 
aminoacylation and mark them for degradation via the RTD pathway (Wilusz et 
al., 2011). These turnover pathways provide a quality control mechanism to 
ensure that only mature, stable and functional tRNAs are available to engage 
with the protein synthesis machinery.  
1.4.5 tRNAome 
Modification, aminoacylation and targeted degradation are essential to produce 
functional tRNAs for synonymous decoding. However, the specific complement of 
tRNAs expressed within a cell (the tRNAome) varies depending on the cell type 
and its requirements. The degeneracy of the genetic code enables bias in codon 
use and the efficiency at which a given codon is translated depends upon the 
amount of activated cognate amino acid available. The abundance of tRNAs 
corresponding to those codons can therefore determine the speed of translation 
(Tuller et al., 2010). Thus, transcripts with a codon bias towards highly 
expressed tRNAs have increased expression levels, and increased translation of 
proteins can be artificially induced by mutating sequences to improve their 
codon-tRNA complement (Percudani et al., 1997, Tuller et al., 2007, Mahlab et 
al., 2012). Furthermore, because controlling ribosome density along the length 
of the transcript can influence co-translational protein folding, codon bias and 
tRNA abundance can not only effect the overall speed of translation but also the 
kinetics of protein folding and final protein structure (O'Brien et al., 2014). 
Whilst codon use correlates with tRNA gene copy number in non-complex 
organisms (Iben and Maraia, 2012), work has now shown that in human cells 
epigenetic modification of tRNA genes, and the consequent levels of tRNA 
transcription, drive changes in expression of particular pools of tRNAs to 
subsequently influence specific patterns of gene expression through increasing 
the translational efficiency of particular pathways (Gingold et al., 2014). tRNAs 
are therefore not just housekeeping components of the translation machinery, as 
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precise coordination of their expression levels with codon-usage in transcripts 
they are translating adds another level of control to the regulation of protein 
synthesis.       
1.4.6 Canonical function 
1.4.6.1 Protein synthesis 
The canonical and most well-defined function of tRNAs is their role in 
translation, where they operate as adaptor molecules to read mRNA codons and 
bring the corresponding amino acid to the translation machinery. The process of 
translation is divided into four stages: initiation, elongation, termination and 
recycling, with each step involving the coordinated action of multiple binding 
partners.   
The first stage of translation initiation requires assembly of the ternary complex 
(TC), which is composed of eIF2 + GTP + the initiator methionine tRNA 
(tRNAiMet). With the aid of other initiation factors (including eIFs 1A and 3), the 
TC is able to bind the 40S ribosomal subunit to form the 43S pre-initiation 
complex. eIF4E can then bind the 5’ cap of the mRNA, and in conjunction with 
eIF4A, eIF4B and eIF4H, unwinds structures within the 5’ UTR. Additional 
factors, including eIF4G and poly (A) binding protein (PABP), bind the 3’ poly (A) 
tail of the mRNA and load it onto the 43S pre-initiation complex. This complex is 
then able to sequentially scan the 5’ mRNA region to search for the correct start 
codon. Following anticodon:codon base pairing of tRNAiMet and the start codon, 
the GTP of the TC is then hydrolysed by eIF2 and eIF5. eIF2 is then able to 
release the tRNA into the P site of the 40S subunit, and eIFs 1A, 3 and 5 can 
dissociate. This enables eIF2-GDP to dissociate from the 40S ribosomal subunit, 
allowing eIF5B-GTP to facilitate binding of the 60S ribosomal subunit to the 40S-
tRNAiMet-mRNA complex. Upon GTP hydrolysis, eIF5B is released from the 
complex, marking the end of translation initiation and the beginning of 
elongation (Kapp and Lorsch, 2004) (Figure 1-4). 
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Figure 1-4- The process of eukaryotic translation initiation.  
The ternary complex (TC) is composed of eIF2, GTP and tRNAiMet. Initiation factors eIF3 and 1A 
enable the TC to bind the 40S ribosomal subunit to form the 43S pre-initiation complex. eIF4E 
binds the 5’ cap of the mRNA, and additional initiation factors including eIF4A, 4B and 4H unwind 
the 5’ UTR. Poly (A) binding protein (PABP) and eIF4G can bind the 3’ Poly (A) tail of the mRNA to 
assist ribosomal loading, and the 48S pre-initiation complex is formed. Following base pairing of 
the tRNAiMet anticodon with the start codon, the GTP of the TC is hydrolysed, tRNAiMet is released 
into the P site of the 40S ribosomal subunit and the initiation factors can dissociate. eIF5B-GTP 
assists binding of the 60S ribosomal subunit and upon GTP hydrolysis eIF5B is released from the 
initiation complex (Klann and Dever, 2004). Image made using items from Image Bank in Servier 
Medical Art.  
At the start of elongation, a peptidyl tRNA sits in the ribosomal P site. An 
aminoacyl-tRNA is brought to the vacant A site by eEF1A-GTP and when correct 
anticodon:codon base pairing occurs the aminoacyl-tRNA is released into the A 
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site by eEF1A’s GTPase activity and conformational changes in the small 
ribosomal subunit. A ribosomal peptidyl transferase catalyses peptide bond 
formation between the amino acids situated in the A and P sites. The complex is 
then translocated, so that the deacylated tRNA is moved to the E site, the 
peptidyl tRNA sits within the P site, and the mRNA is shifted by three 
nucleotides so that the next mRNA codon is in the ribosomal A site (Kapp and 
Lorsch, 2004) (Figure 1-5). 
 
Figure 1-5- The process of elongation in eukaryotic protein synthesis.  
Aminoacyl-tRNAs are brought to the vacant A site of the ribosome by the elongation factor eEF1A, 
and are released into the A site by conformation changes and GTP hydrolysis following suitable 
anticodon:codon base pairing between the tRNA and mRNA. A peptide bond is formed between 
the amino acids in the P and the A site, and the complex translocated to allow the deacylated tRNA 
to be released from the E site and the cycle repeated until a stop codon is detected within the A 
site. Image made using items from Image Bank in Servier Medical Art. 
The elongation cycle is repeated until a stop codon is detected in the A site. The 
peptidyl transferase centre of the ribosome catalyses the release of the 
synthesised polypeptide by hydrolysing the ester bond that links the polypeptide 
chain to the P site tRNA, and this process is assisted by Class I and Class II 
release factors. The ribosomal subunits can then be recycled for further rounds 
of translation initiation, although the precise mechanism of recycling in 
eukaryotes is still unclear (Kapp and Lorsch, 2004). 
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1.4.7 Non-canonical functions 
In addition to their well-characterised participation in protein synthesis, a 
number of other functional roles for tRNAs have been described within 
eukaryotic cells. Observations that these processes can be stress-induced, or 
part of programmed cellular processes, demonstrates that tRNAs are more than 
just translational adaptor molecules required for the synthesis of proteins.  
1.4.7.1 Targeting proteins for degradation 
Aminoacylated tRNAs are able to donate their associated amino acid for N-
terminal conjugation reactions to proteins being marked for degradation. The N-
rule pathway is used in regulated proteolysis, based on the fact that the half-life 
of a protein can be determined by the identity of its N-terminal amino acid 
residue. Aminoacyl-tRNA transferases can recognise destabilising residues and 
transfer specific amino acids from tRNAs to particular proteins to enable their 
delivery to the proteosome (Mogk et al., 2007). Regulated degradation of 
proteins in this way not only removes misfolded or abnormal proteins, but is also 
used in a number of physiological processes including the regulation of DNA 
repair pathways and cardiovascular development (Varshavsky, 2011).  
1.4.7.2 Nutrient deprivation response  
Uncharged tRNAs can also have functional effects and are involved in the 
nutrient deprivation response in both yeast and mice. In yeast, increased levels 
of uncharged tRNAs provide an amino acid starvation signal, and this is detected 
by GCN2 (Wek et al., 1995). Binding of uncharged tRNAs to GCN2 activates the 
GCN2 kinase domain, enabling phosphorylation of the translation initiation factor 
eIF2 (Dong et al., 2000, Dever et al., 1992). Phosphorylation of eIF2 inhibits TC 
formation, therefore inhibiting protein synthesis and limiting amino acid 
consumption in starved cells. Similar processes can also occur in mice to control 
feeding behaviour and maintain amino acid homeostasis (Maurin et al., 2005, 
Hao et al., 2005). Thus cytoplasmic accumulation of uncharged tRNAs acts as a 
basic mechanism in nutritional stress management and enables activation of 
stress response pathways.   
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1.4.7.3 Apoptosis 
Intrinsic apoptosis pathways are characterised by cytochrome c release and 
caspase activation. In such pathways, mitochondrial cytochrome c that has been 
released into the cytosol can bind Apaf-1 which can then assemble into the 
apoptosome complex. This recruits caspase 9, which, once activated by 
autoproteolytic activity, can activate effector caspases to induce cell death 
(Riedl and Salvesen, 2007). tRNAs are able to bind cytochrome c and impair its 
association with Apaf-1, blocking apoptosome formation and inhibiting caspase-9 
activation (Mei et al., 2010b). This provides a mechanism to regulate sensitivity 
to apoptosis and could also provide a way for cells to develop apoptotic 
resistance. 
1.4.8 tRNA derived fragments 
A number of recent publications have also highlighted how tRNAs can be 
processed into smaller fragments, and how these tRNA derived fragments (tRFs) 
may have specific functional effects within the cell including roles in 
translational inhibition, long-distance signalling and acting as guide RNAs. tRNAs 
can be cleaved in the anticodon loop to produce tRFs by the stress activated 
ribonuclease angiogenin, and the resulting tRFs are able to inhibit protein 
synthesis by displacing eIF4G/eIF4A from the 5’ cap of mRNAs to activate a 
protective stress response (Ivanov et al., 2011). Smaller tRFs may also be 
generated through cleavage of the 3’ and 5’ ends of the tRNAs, and this can 
occur through a number of mechanisms including RNase Z cleavage and Dicer-
dependent processing (Haussecker et al., 2010). These smaller tRFs are able to 
associate with argonaute proteins, and may have roles in regulating gene 
expression through RNA-silencing mechanisms. And so, in addition to the effects 
of charged and uncharged tRNAs, the directed cleavage of tRNAs into defined 
fragments represents another way in which these ancient molecules have 
evolved to influence gene expression.  
1.4.9 tRNA expression in disease  
Expression and mutation of tRNAs and tRNA processing enzymes have been linked 
to a diverse range of disease states, and this can be attributed to a number of 
different mechanisms; including compromised aminoacylation and effects on 
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tRNA modification, folding and splicing. Mitochondrial tRNA (mt-tRNA) genes 
have been described as “hotspots” for mutation, with over 200 mt-tRNA 
mutations currently linked to disease processes (Abbott et al., 2014). The two 
most characterised disorders associated with mt-tRNA mutations are 
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) and myoclonic epilepsy with red tagged fibers (MERRF). These disorders 
are due to mutations in mt-tRNALeu and mt-tRNALys respectively, both of which 
effect wobble position modifications to disrupt correct decoding by the 
mitochondrial ribosome (Suzuki et al., 2011). Tissues that are highly dependent 
on mitochondrial ATP production, such as the heart, can also be sensitive to mt-
tRNA mutations, and a number of cases of cardiomyopathy have been found to 
be owing to mt-tRNA mutations (Shin et al., 2000, Taylor et al., 2003, 
Hollingsworth et al., 2012). With regard to nuclear encoded tRNAs and their 
associated enzymes, mutations in the tRNA splicing machinery have been 
associated with Pontocerebellar hypoplasia (PCH, a neurodegenerative disorder 
characterised by defective growth, development and brainstem/cerebellum 
function) (Budde et al., 2008), and mutations in the aaRS glycyl-tRNA synthetase 
(GARS) gene are responsible for Charcot-Marie-Tooth disease (Antonellis et al., 
2003), although the underlying mechanisms are not fully understood.      
Pol III mediated transcription of tRNAs is under the control of a number of well 
described oncogenic/tumour suppressor pathways (Figure 1-2), and increased Pol 
III activity in cancer is well documented across a number of different cancer 
types (Winter et al., 2000, Chen et al., 1997). As a consequence, tRNA 
expression is increased in a variety of cancers (Daly et al., 2005, Pavon-Eternod 
et al., 2009, Zhou et al., 2009). Moreover, increased levels of tRNAs and tRFs 
have been shown to drive increased cell growth and proliferation (Pavon-Eternod 
et al., 2013, Rideout et al., 2012, Lee et al., 2009a). Specifically, increased 
levels of the initiator methionine tRNA, tRNAiMet, in human epithelial cells was 
found to promote cell proliferation (Pavon-Eternod et al., 2013), while an extra 
copy of the tRNAiMet gene was also able to increase growth in Drosophila larvae 
(Rideout et al., 2012). With regard to tRFs, a fragment derived from the 3’ end 
of Ser-TGA pre-tRNA was also found to have increased expression in cancer cell 
lines, with expression levels tightly correlating with proliferation rate, and 
impaired proliferation observed when expression of the fragment was knocked 
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down (Lee et al., 2009a). These observations collectively suggest that tRNA 
levels themselves could influence the increased growth and proliferation seen in 
carcinogenesis. Furthermore, recent work characterising the tRNAome has also 
demonstrated that proliferating cells can change the repertoire of tRNAs they 
express to direct specific programmes of translation (Gingold et al., 2014). 
These data suggested that expression of specific complements of tRNAs could 
increase the efficiency of translational pathways associated with cellular 
proliferation, and essentially help to channel a cell into a more proliferative 
state. Further understanding the mechanisms by which tRNA expression can 
affect the rate of protein synthesis may therefore provide insight into how 
aberrant tRNA expression could influence disease progression.  
1.5 Protein synthesis 
1.5.1 Control of translation initiation 
The rate limiting step of eukaryotic translation is thought to be the initiation of 
protein synthesis, and the canonical model of cap-dependent translation is 
described previously (Figure 1-4). This multi-step process is highly regulated and 
can be controlled by a number of different mechanisms, the most common being 
the phosphorylation state of the initiation factor eIF2 (Krishnamoorthy et al., 
2001). eIF2 is a heterotrimeric protein that, when loaded with GTP by the 
guanine nucleotide exchange factor (GEF) eIF2B, associates with tRNAiMet to form 
the TC, which enables association with the small ribosomal subunit to generate 
the 43S pre-initiation complex required for global initiation of translation. 
However, when eIF2 is phosphorylated on serine 51 of its α subunit, it becomes a 
competitive inhibitor of eIF2B, preventing GDP-GTP exchange and therefore 
reducing global translation rates by decreasing the amount of TC available 
(Krishnamoorthy et al., 2001). Phosphorylation of eIF2α is stimulated in response 
to cell stress, and is performed by a variety of kinases including GCN2, PERK, HRI 
and PKR depending on the nature of the stress (Dever et al., 1992, Kline et al., 
2006, Sequeira et al., 2007). This consequently enables suppression of global 
protein synthesis, and increases translation of specific transcripts to allow the 
cell to respond to the stress or external cue (Figure 1-6). These specific 
transcripts must therefore have distinguishing features to enable their selective 
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translation, and this information tends to be found within the untranslated 
regions. 
 
Figure 1-6- Exposure to cell stresses inhibits global protein synthesis through P-eIF2α.  
Protein kinases such as PERK and GCN2 can phosphorylate eIF2α and inhibit eIF2α activity, 
whilst GADD34 can recruit Protein Phosphatase 1 (PP1) to dephosphorylate eIF2α. Salubrinal is a 
drug that can inhibit PP1 to block eIF2α dephosphorylation. Phosphorylation of eIF2α sequesters 
the initiation factor away from ternary complex formation, decreasing amounts of ternary complex 
available for global protein synthesis, and as a result drives only the translation of specific 
transcripts required under conditions of cellular stress. Image made using items from Image Bank 
in Servier Medical Art.   
1.5.2 The influence of untranslated regions 
The rate of translation initiation is not only dependent on the assembly of the 
translation initiation machinery, but also on the structure of the flanking 
untranslated regions (UTRs). Particular features of these regions, whether they 
be structural or sequence specific, are able to influence translational efficiency 
and hence provide another means to regulate gene expression. 
1.5.2.1 Internal ribosome entry sites  
Internal ribosome entry sites (IRES) were originally identified in viruses, but have 
since been identified in approximately 10% of eukaryotic mRNAs (Mitchell et al., 
2005). They are structured RNA elements found in many stress-response mRNAs 
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and, in association with transacting factors, can facilitate binding of the mRNA 
to the 40S ribosomal subunit to enable translation when cap-dependent 
initiation is compromised (Spriggs et al., 2008). c-Myc is known to contain a well 
characterised IRES motif and this has been shown to be important in maintaining 
increased levels of c-Myc translation during conditions of ER stress in multiple 
myeloma (MM) (Shi et al., 2015). A number of other oncogenes and growth 
factors also contain IRES sites within their 5’ UTR, leading to the hypothesis that 
selective translation of these factors through IRES-mediated mechanisms could 
contribute to the survival of cancer cells under stressful conditions (Holcik, 
2004). 
1.5.2.2 Upstream open reading frames 
Upstream open reading frames (uORFs) are in-frame start and stop codons that 
occur in the 5’ UTR, and the presence of numerous uORFs has the tendency to 
be inhibitory under conditions of normal global protein synthesis. Cap-dependent 
translation initiation relies on scanning of the 5’ UTR for the AUG start codon. 
When conditions are optimal, translation is initiated at the first uORF, and the 
ribosome can then continue to scan and reinitiate translation at downstream 
uORFs by recruitment of additional TC. Because subsequent uORFs tend to 
overlap with coding sequence, this process is usually inhibitory to translation of 
the correct coding sequence. However, in conditions of increased phospho-eIF2α 
and consequent decreased TC formation, re-initiating ribosomes are less likely to 
recruit TC to subsequent uORFs due to decreased TC availability, therefore 
allowing translation of the correct coding sequence. Examples of genes 
regulated in this way include the stress induced transcription factor ATF4 (Blais 
et al., 2004) which has been described as a master regulator of genes for 
adaptive functions (B'Chir et al., 2013), and GADD34, which provides a feedback 
mechanism to control absolute levels of phospho-eIF2α (Lee et al., 2009b). 
1.5.2.3 5’ UTR structure 
5’ UTRs tend to have an average length of 100 to 220 nucleotides (Pesole et al., 
2001). However, significantly longer 5’ UTRs can be found in transcripts 
encoding transcription factors, proto-oncogenes, growth factors and their 
receptors, and these tend to be poorly translated under normal conditions 
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(Davuluri et al., 2000). GC content and short repeat sequences can further 
contribute to secondary structure and add additional complexity to 5’ UTRs. 
Stable secondary structures can resist the helicase activity of eIF4A (Rozen et 
al., 1990), and this can significantly affect the ability of the translation 
initiation machinery to scan from the 5’ m7G cap structure through the UTR in 
search for the translation start site. Terminal oligopyrimidine (TOP) motifs, 
pyrimidine-rich translational elements (PRTE), and other regulatory sequence 
motifs within the 5’ UTR can also affect the assembly of the translation 
initiation machinery (Hsieh et al., 2012, Thoreen et al., 2012). Complex 5’ UTRs 
are therefore another effective mechanism to control efficient translation 
initiation and protein synthesis under normal conditions. 
1.5.3 Localised translation  
In addition to the structure of mRNAs, transcript localisation can also play an 
important role in directing protein synthesis. While the signal recognition 
particle (SRP) can facilitate localised translation on the ER, RNA localisation 
sequences (found within UTRs) and transacting factor (TAF)-mediated mRNA 
localisation can also dictate the intracellular position of RNA molecules 
(Oleynikov and Singer, 1998). mRNA-mediated localised translation is an 
important mechanism for organising cellular architecture and function, and 
coordination between mRNA distribution and consequent protein localisation is 
seen throughout Drospohila embryogenesis (Lecuyer et al., 2007). Targeting of 
mRNAs to the site of protein synthesis can save cellular energy, as transported 
mRNA transcripts can subsequently be translated into numerous protein 
molecules, whilst also minimising inappropriate protein-protein interactions and 
facilitating specific associations for protein complex assembly (Liao et al., 
2015).  
The most studied form of localised protein synthesis is that found in neurons. 
Although the majority of protein synthesis occurs within the soma of the neuron, 
axons can be up to 1 metre in length, and so the site of action of certain 
proteins may be some distance from the soma, and this could place considerable 
demands on the protein transport machinery. Polyribosomes have been found at 
the base of dendritic spines (Steward and Levy, 1982), and metabolic labelling 
experiments have shown de novo protein synthesis in both axons and dendrites 
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(Torre and Steward, 1992). Such localised protein synthesis can influence growth 
cone adaptation, gradient sensing and directional turning of axons (Leung et al., 
2006, Ming et al., 2002, Piper et al., 2005, Yao et al., 2006), and so this may 
underlie a number of fundamental neuronal processes.  
Specific mRNA localisation has also been found in the cell protrusions of 
fibroblasts and tumour cells (Mili et al., 2008, Stuart et al., 2008), and 
components of the translation machinery are found at the leading edge of 
migrating cells consistent with a role of localised protein synthesis in cell 
migration (Willett et al., 2010, Willett et al., 2011, Willett et al., 2013). Local 
translation of β-actin has been studied in migrating cells, and its localisation 
requires an intact actin cytoskeleton in addition to activation of Rho and its 
downstream effector myosin IIB (Liao et al., 2015). Rho-regulated transport of 
translationally silent β-actin mRNA by myosin II motor-mediated transport is 
thought to occur along actin filament tracts (Kislauskis et al., 1994, Latham et 
al., 1994, Latham et al., 2001). A short nucleotide sequence in the 3’ UTR of β-
actin acts as a localisation signal, and the transcript is bound by ZBP1/IMP1 to 
repress its synthesis through the transportation process (Ross et al., 1997). Local 
β-actin translation in cell protrusions can consequently effect cell motility, and 
the translation elongation factor EF1α can also bind to actin mRNA and increase 
its translational efficiency (Perez and Kinzy, 2014), linking the actin 
cytoskeleton to the protein synthesis machinery (Woods et al., 2005, Woods et 
al., 2002). Tumour cell migration and invasion can consequently be influenced 
by expression of transacting factors that facilitate mRNA transport, with 
ZBP1/IMP1 levels correlating with poor prognosis in ovarian cancer through 
mechanisms that can stabilise transcripts associated with both cell proliferation 
and migration (Kobel et al., 2007, Vikesaa et al., 2006, Weidensdorfer et al., 
2009). The localisation of protein synthesis therefore represents another means 
by which translational control can influence cellular behaviour. Moreover, these 
particular effects on cell migration and invasion indicate that translational 
control is a mechanism that could contribute to tumour progression through 
supporting the increased cell motility displayed during metastatic dissemination.  
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1.6 Translational control in cancer  
Development of cancer is a multistep process, and the original hallmarks 
described by Hanahan and Weinberg form a framework of six distinct but 
complementary processes that enable normal cells to become tumourigenic, 
namely sustained proliferation, evasion of growth suppression, activation of 
invasive and metastatic processes, replicative immortality, induction of 
angiogenesis and resistance to cell death (Hanahan and Weinberg, 2000). This 
paradigm has now been updated to include reprogrammed energy metabolism 
and evasion of immune destruction into the process of cancer development 
(Hanahan and Weinberg, 2011). Control of translation plays an important role in 
each of these processes, with regulation of both global and directed protein 
synthesis contributing to cancer development and progression. In general, 
increased cancer cell proliferation requires increased rates of protein synthesis 
and ribosomal number (Johnson et al., 1976), and in neoplastic tissues enlarged 
nucleoli (the sites of ribosomal RNA synthesis and ribosome assembly) are often 
considered to be indicative of malignancy (Gani, 1976). Active polyribosome 
fractions from proliferating cells contain an additional 2-5% of unique mRNAs 
that are absent in quiescent cells (Getz et al., 1976), indicating that selective 
translation is also associated with altered patterns of gene expression, and this 
could contribute to transformation.  
The phosphorylation state of the initiation factor eIF2α dictates availability of 
the TC and, as a consequence, can regulate the balance of global and selective 
translation. Its contribution to cancer progression is complicated, with some 
studies showing that tumourigenesis in mice is promoted by inhibiting phospho-
eIF2α levels (Donze et al., 1995, Koromilas et al., 1992b) while others find that 
modifying the levels of phospho-eIF2α has no impact on cancer development 
(Tejada et al., 2009, Yang et al., 1995, Abraham et al., 1999). The role of eIF2α 
in tumourigenesis may therefore depend on the cancer type and stage, with 
increased phosphorylation of eIF2α perhaps playing a role in the early stages of 
cancer cell survival to protect against stresses such as hypoxia (Bi et al., 2005, 
Koritzinsky et al., 2006), whilst in the later stages of disease progression 
decreased phospho-eIF2α may promote increased global protein synthesis and 
aberrant expression of a number of pathways to increase tumour cell growth.  
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The interaction between ribosomes and mRNA is coordinated by a number of 
different initiation and elongation factors, and the expression of each of them 
provides another opportunity to regulate translation. eIF4F is a core complex 
required for cap-dependent translation, and is composed of eIF4E (cap binding 
protein), eIF4A (ATP-dependent RNA helicase) and eIF4G (scaffolding protein) 
(Sonenberg and Hinnebusch, 2009). eIF4E activity is regulated by its availability, 
which can be controlled through phosphorylation by eIF4G-associated kinases 
and expression of eIF4E inhibitory binding proteins (4E-BPs). Regulation of eIF4E 
expression through phosphorylation of 4E-BP1 enables TORC1 to influence 
translational control (Hsieh et al., 2012), and eIF4E overexpression has been 
found to promote increased translation of a subset of mRNAs that have specific 
structures within their 5’ UTRs to drive transformation and tumourigenesis 
(Koromilas et al., 1992a, Hsieh et al., 2012). An eIF4A-dependent mechanism of 
translational control has also been described in T-cell acute lymphoblastic 
leukaemia (T-ALL) (Wolfe et al., 2014). These workers found that transcripts 
that were sensitive to the expression of eIF4A possessed G-quadruplex structures 
in their 5’UTRs. These transcripts included oncogenes and transcriptional 
regulators such as Myc, Notch and Bcl-2, and indicated that RNA G-quadruplexes 
in the 5’ UTR were associated with eIF4A-dependent oncogene translation in 
cancer. The binding of eIF4E to eIF4G can also stimulate the helicase activity of 
eIF4A to increase the rate of translation (Feoktistova et al., 2013). Increased 
availability of eIF4E and eIF4A can therefore promote increased formation and 
activity of eIF4F to enhance the translation of transcripts that are normally 
poorly transcribed due to the presence of inhibitory structures in and around 
their translational start site. Oncogenes tend to have a number of inhibitory 
features within their UTRs (Willis, 1999), and so increased expression of 
initiation factors in disease can increase the favoured translation of 
oncoproteins, providing a mechanism to enable cancer cells to drive their own 
growth and proliferation to contribute to tumour progression. 
1.7 The tumour microenvironment  
Tumours have a complex architecture and are composed of multiple cell types in 
addition to cancer cells; these include cancer stem cells, inflammatory cells, 
endothelial cells, pericytes, and fibroblasts (Hanahan and Weinberg, 2011). 
However, in addition to uncontrolled tumour growth due to aberrant control of 
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autonomous gene expression pathways, the surrounding tumour 
microenvironment (TME) also plays an integral role in carcinogenesis. The TME is 
a domain that supports the relationship between tumours and their stromal 
neighbours, and is composed of a complex collection of different cell types 
within an extracellular scaffold. Mesenchymal stem cells, immune cells, 
endothelial cells, capillaries and fibroblasts are all found within the extracellular 
matrix (ECM), and all are able to contribute to the TME to influence cancer 
progression. Communication between tumours and their microenvironments is 
reciprocal, with tumour cells releasing extracellular signals to influence their 
surroundings, while the TME can also activate specific gene expression pathways 
within cancer cells to influence proliferation, migration and invasion, in addition 
to contributing to immune evasion mechanisms. The importance of this 
relationship has been reinforced by the advent of a number of therapeutic 
strategies aimed at targeting the tumour stroma (Tchou and Conejo-Garcia, 
2012, Hofmeister et al., 2008, Li et al., 2012), and highlights the need to 
understand how components of the TME can contribute to tumour progression.  
1.8 Cancer-associated fibroblasts 
Fibroblasts are the most common type of cell found in connective tissue, and 
they are predominantly responsible for synthesis of the ECM within which they 
reside (Tarin and Croft, 1969). Fibroblasts are elongated spindle-shaped cells 
with extended processes that can acquire an activated phenotype in response to 
a number of stimuli, including injury and growth factors, to become more 
myofibroblast-like (Gabbiani et al., 1971). These activated, myofibroblast-like 
fibroblasts, commonly express markers such as α-smooth muscle actin and 
fibroblast-activation protein (FAP), and are characterised by their increased ECM 
deposition and changes in the complement of matrix-degrading enzymes they 
secrete to remodel the surrounding ECM (Kalluri and Zeisberg, 2006). In addition 
to contributing to the physical structure of the TME, activated fibroblasts can 
also secrete growth factors to provide proliferative signals to surrounding 
epithelial cells (Tomasek et al., 2002), which contribute to normal physiological 
processes such as tissue re-modelling during development and wound healing.  
Cancer-associated fibroblasts (CAFs) are activated fibroblasts that are found in 
association with cancer cells. CAFs are thought to arise through myofibroblast 
Chapter 1  44 
 
transdifferentiation (FMT) of resident normal stromal fibroblasts (Untergasser et 
al., 2005) which can be stimulated through release of growth factors such as 
transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) 
from cancer cells (Anderberg et al., 2009, Ronnov-Jessen and Petersen, 1993). 
CAFs may also be derived from malignant epithelial cells via epithelial to 
mesenchymal transition (EMT); a process through which epithelial cells lose their 
apical basal polarity and adhesive properties in favour of a more migratory and 
invasive phenotype (Petersen et al., 2003). Another reported source of CAFs is 
mesenchymal stem cells (MSCs), which although normally resident in bone 
marrow can be attracted to the TME where they are able to differentiate into 
cells with a more myofibroblast-like phenotype (Direkze et al., 2004, Mishra et 
al., 2008).  
CAFs are one of the most abundant cell types in the TME and, in addition to 
having a multi-faceted role in tumour progression, their relatively stable genome 
(by comparison with cancer cells which commonly display gross chromosomal 
abnormalities) has also made them an attractive target for potential cancer 
therapies (Cirri and Chiarugi, 2012). They have a higher proliferative activity 
than normal fibroblasts (NFs) and secrete an altered ECM that is characteristic of 
the desmoplastic stroma found in advanced carcinomas (Kalluri and Zeisberg, 
2006). Their ability to influence tumour growth and development can occur 
through a number of different mechanisms, including secretion of growth 
promoting soluble factors, and deposition of a matrix that facilitates tumour 
progression. 
1.8.1 Secretion of soluble factors 
The pro-tumourigenic properties of CAFs were initially investigated using tumour 
allograft models in immunodeficient mice. In these studies, tumour growth was 
assessed following co-injection of tumour cells with fibroblasts which had been 
isolated from tumour or surrounding tissue (Orimo et al., 2005, Olumi et al., 
1999, Hwang et al., 2008). Tumours grew faster when mixed with CAFs 
compared to co-injection with fibroblasts from surrounding tissue, owing to CAF 
secreted factors acting in a paracrine fashion to promote tumour growth. 
Specifically, CAFs were shown to secrete stromal-derived factor (SDF-1), a 
cytokine that can bind the CXCR4 receptor on the surface of cancer cells to 
Chapter 1  45 
 
stimulate their growth (Orimo et al., 2005, Ao et al., 2007). Further work has 
also demonstrated that CAFs secrete increased levels of transforming growth 
factor beta 1 (TGF-β1), which can have paracrine effects on tumour cells, 
promoting both their growth and invasion, and autocrine effects on CAFs 
themselves, promoting FMT and enabling maintenance of an activated CAF 
phenotype (San Francisco et al., 2004, Rosenthal et al., 2004). Furthermore, 
SDF-1 can also play a role in neo-angiogenesis (Orimo et al., 2005), and so in 
collaboration with additional secreted angiogenic factors, such as fibroblast 
growth factor 2 (FGF-2) and vascular endothelial growth factor (VEGF) 
(Fukumura et al., 1998), can increase the vascularisation of growing tumours. 
Tumour cell invasion can also be promoted by CAF secreted hepatocyte growth 
factor (HGF) (De Wever et al., 2004). HGF activates the receptor tyrosine kinase 
(RTK) Met, and signalling downstream of this RTK can lead to a number of pro-
tumourigenic processes including the increased motility of cancer cells (Maulik 
et al., 2002), the secretion of factors such as uPA and uPAR which are involved 
in ECM degradation (Nishimura et al., 2003), and the protection of tumours from 
apoptosis (Provencal et al., 2010). Other CAF-secreted factors such as secreted-
frizzled related protein (SFRP-1) can also have anti-apoptotic roles (Joesting et 
al., 2005). CAF-secreted soluble factors are also able to influence the immune 
response to tumour growth, with tenascin-C secretion having immunosuppressive 
functions through inhibition of monocyte migration and T lymphocyte adhesion 
(Hauzenberger et al., 1999, Loike et al., 2001), while they can also activate 
specific pro-inflammatory signatures to regulate the innate and adaptive 
immune response (reviewed in (Harper and Sainson, 2014)). CAFs can therefore 
secrete a cocktail of pro-tumourigenic soluble factors to support increased 
tumour growth and progression through a number of different mechanisms 
(Figure 1-7). 
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Figure 1-7- Tumour promoting soluble factors secreted from CAFs.  
CAFs can secrete a number of soluble components to influence tumour growth through a variety of 
different mechanisms. Pro-angiogenic factors include stromal-derived factor 1 (SDF-1), fibroblast 
growth factor 2 (FGF-2) and vascular endothelial growth factor (VEGF). Other components such as 
hepatocyte growth factor (HGF), secreted-frizzled related protein (SFRP-1) can directly induce 
increased proliferation of cancer cells, while transforming growth factor beta 1 (TGF-β1) and 
tenascin-C are among the molecules that can induce cancer cell invasion and metastasis. Factors 
such as SFRP-1 have also been shown to prevent tumour cell death. Figure adapted from 
(Shimoda et al., 2010). Image made using items from Image Bank in Servier Medical Art. 
1.8.2 Extracellular Matrix 
The ECM provides a scaffold of structural support whilst also providing a 
reservoir of molecules that act as biochemical and biomechanical cues to the 
cells around them. Fibroblasts, chondrocytes and osteoblasts all have the ability 
to secrete ECM, with each cell type producing matrix of different composition 
depending on the tissue of origin. The ECM is a dynamic structure that is subject 
to regulation at many levels including its deposition, degradation and 
remodelling (Page-McCaw et al., 2007). The ECM secreted by CAFs has been 
implicated as a major player in the tumorigenic process, and this can be 
attributed to a number of observations indicating that the tumour ECM differs 
from its normal counterpart in a number of ways; including alterations to its 
physical structure and ability to bind and present soluble growth factors, in 
addition to the composition of ECM proteins that are deposited. 
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1.8.2.1 Collagen 
Collagen is one of the most abundant fibrous protein found in the ECM, and is 
composed of a superfamily of 28 members in total, with each collagen having a 
common triple helix structural motif (Table 1-3) (Ricard-Blum, 2011, Fang et al., 
2014). 
Collagen 
Type 
α chains Molecular species Class  Distribution  
I α1(I),α2(I) [α1(I)]2 α2(I) Fibril  Widespread,  
non-cartilaginous 
II α1(II) [α1(II)]3 Fibril  Cartilage, vitreous 
III α1(III) [α1(III)]3 Fibril  Co-distributed with 
collagen I, skin, 
vessels, intestine 
IV α1(IV),α2(IV), 
α3(IV),α4(IV), 
α5(IV),α6(IV) 
[α1(IV)]2, α2(IV) 
α3(IV),α4(IV),α5(IV)  
[α5(IV)]2,α6(IV) 
Network Basement membrane 
V α1(V),α2(V), 
α3(V),α4(V) 
[α1(V)]2,α2(V) 
[α1(V)]3 
[α1(V)]2,α4(V) 
α1(V),α2(V),α3(V), 
Fibril  Co-distributed with 
collagen I, bone, 
dermis, cornea, 
placenta 
VI α1(VI),α2(VI), 
α3(VI),α4(VI), 
α5(VI),α6(V) 
α1(VI),α2(VI),α3(VI) 
α1(VI),α2(VI) α4(VI) 
Network Widespread, muscle, 
bone, cartilage, 
cornea, dermis 
VII α1(VII) [α1(VII)]3 FACIT Dermis, bladder 
VIII α1(VIIII), 
α2(VIII) 
[α1(VIIII)]2, α2(VIII) 
[α2(VIII)]2, α1(VIIII) 
[α1(VIIII)]3 
[α3(VIIII)]3 
Network Widespread, dermis, 
heart, kidney 
IX α1(IX),α2(IX), 
α3(IX) 
α1(IX),α2(IX), α3(IX) 
 
FACIT Co-distributed with 
collagen II, cartilage, 
cornea, vitreous 
X α1(X) [α1(X)]3 Network Hypertrophic 
cartilage 
XI α1(XI),α2(XI), 
α3(XI) 
α1(XI),α2(XI), α3(XI) 
α1(XI), α1(V), α3(XI) 
Fibril  Co-distributed with 
collagen II, cartilage, 
intervertebral disc 
XII α1(XII) [α1(XII)]3 FACIT Co-distributed with 
collagen I, dermis, 
tendon 
XIII α1(XIII) [α1(XIII)]3 MACIT Endothelial cells, 
dermis, eye, heart 
XIV α1(XIV) [α1(XIV)]3 FACIT Widespread & co-
distributed collagen 
I, bone, dermis, 
cartilage 
XV α1(XV) [α1(XV)]3 Multiplexin Between collagen 
fibrils close to 
basement membrane  
XVI α1(XVI) [α1(XVI)]3 FACIT Integrated into 
collagen fibrils & 
fibrillin-1 microfibrils 
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XVII α1(XVII) [α1(XVII)]3 MACIT Hemidesmosomes in 
epithelia 
XVIII α1(XVIII) [α1(XVIII)]3 Multiplexin Associated with 
basement membrane 
XIX α1(XIX) [α1(XIX)]3 FACIT Rare, localised to 
basement membrane 
XX α1(XX) [α1(XX)]3 FACIT Widespread, cornea 
XXI α1(XXI) [α1(XXI)]3 FACIT Widespread, stomach 
XXII α1(XXII) [α1(XXII)]3 FACIT Tissue junctions 
XXIII α1(XXIII) [α1(XXIII)]3 MACIT Limited distribution, 
heart, retina 
XXIV α1(XXIV) [α1(XXIV)]3 Fibril  Homology to fibril 
forming collagens, 
bone, cornea 
XXV α1(XXV) [α1(XXV)]3 MACIT Brain, heart, testis 
XXVI α1(XXVI) [α1(XXVI)]3 FACIT Testis, ovary 
XXVII α1(XXVII) [α1(XXVII)]3 Fibril  Homology to fibril 
forming collagens, 
cartilage 
XXVIII α1(XXVIII) [α1(XXVIII)]3 Network Component of 
basement membrane 
around Schwann cells 
Table 1-3- The collagen family members.  
Fibril-associated collagens with interrupted triple helices (FACIT), Membrane-associated collagens 
with interrupted triple helices (MACIT), Mutliple triple-helix domains and interruptions 
(MULTIPLEXINs). Adapted from (Ricard-Blum, 2011, Fang et al., 2014).    
Fibrillar collagens are synthesised in defined ways (Figure 1-8), starting with the 
translation of an initial pre-pro-peptide which is then post-translationally 
modified in the endoplasmic reticulum (ER). Following removal of the signal 
peptide the collagen propeptide is formed, and lysine and proline residues can 
be hydroxylated via an enzymatic reaction that requires ascorbate as a co-
factor. Consequent glycosylation of hydroxyl-lysines allows formation of an α-
chain with a left-handed polyproline II helical twist. Three α-chains can then 
wind together into a right handed triple helix, with a one residue stagger 
between adjacent α chains, to form the procollagen triple helix. The sequence 
repeats of Gly-X-Y stabilise the triple helix, where Gly is Glycine, and X and Y 
are most often proline and 4-hydroxyproline respectively. The procollagen is 
then transferred to the Golgi apparatus where it is further modified and 
packaged for secretion into the extracellular space. The large size and rigid 
structure of procollagen necessitates a requirement for specialised transport 
vesicles, and the ubiquitin ligase CUL3-KLHL12 consequently attaches ubiquitin 
to SEC31 of the SEC13-31 complex to modify COPII coated vesicles and thus 
enable encapsulation of large procollagen cargoes (Jin et al., 2012, Saito et al., 
2009). Once outside the cell, collagen-specific peptidases remove the N- and C- 
Chapter 1  49 
 
terminal peptides to produce insoluble tropocollagen, and crosslinking by 
extracellular enzymes such as lysyl oxidase (LOX) helps assemble the collagen 
into large fibrils (Figure 1-8) (Brodsky and Persikov, 2005, Ricard-Blum, 2011, 
Fang et al., 2014). 
 
Figure 1-8- Collagen biosynthesis.   
Every third residue of the collagen triple helical sequence is glycine (Gly), followed most frequently 
by proline (X) and 4-hydroxyproline (Y). Following modification in the endoplasmic reticulum, an α 
chain is formed from a left handed polyproline II helix. Three α chains form a right handed triple 
helix to generate the secondary structure of the collagen triple helix. This is further modified in the 
Golgi compartment and then packaged for secretion into the ECM. The N- and C- terminal 
propeptides are then cleaved and the fibrils cross-linked by extracellular enzymes. Image made 
using items from Image Bank in Servier Medical Art. 
The architecture of the collagen scaffold is severely altered in tumours, in ways 
that include increased deposition of fibrillar collagens and linearization, 
thickening and alignment of fibres (Zhu et al., 1995, Huijbers et al., 2010). 
These structures can provide efficient tracks to facilitate increased cell 
migration and metastasis of cancer cells (Wyckoff et al., 2007). Increased 
expression of enzymes such as LOX results in increased collagen crosslinking and 
matrix stiffness and this is also associated with increased tumour aggressiveness 
(Erler et al., 2009). Increased matrix stiffness can have a number of effects, 
including enhancing tumour cell adhesion and migration (Erler et al., 2006, Erler 
and Giaccia, 2006), and further details of how the physical properties of the 
matrix can influence tumourigenesis will be discussed later in the text (1.8.2.5). 
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However, the construction of a rigid collagen matrix is also dependent on other 
factors, including the initial deposition of fibronectin, another major ECM 
protein that plays an important role in both health and disease (Velling et al., 
2002, Shi et al., 2010). 
1.8.2.2 Fibronectin 
Fibronectin can be classified into two forms; plasma fibronectin that is secreted 
by hepatocytes and which circulates in the blood, and cellular fibronectin that is 
abundant in the fibrillar matrix of most tissues. Fibronectin is a key component 
of the ECM which is secreted as a large glycoprotein and assembled via cell-
mediated processes into fibrils (Singh et al., 2010). Although the product of a 
single gene, alternative splicing of fibronectin can generate multiple variants 
that can each contribute to protein solubility and stability (Schwarzbauer and 
DeSimone, 2011). Fibronectin is a dimer composed of two nearly identical 
subunits. Each monomer is a modular protein of three different types of 
repeating unit (Type I, II and III) which contain binding motifs to mediate 
intramolecular interactions to facilitate self-assembly, in addition to enabling 
interactions with other ECM proteins and cell surface receptors. Disulphide 
bonds between modules stabilise a folded tertiary structure, and antiparallel C-
terminal disulphide bonds enable dimer formation (Figure 1-9) (Singh et al., 
2010, Mouw et al., 2014). Fibronectin is secreted as a soluble covalent dimer 
and this structure is necessary for its subsequent fibrillogenesis (Schwarzbauer, 
1991). 
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Figure 1-9- Fibronectin structure.  
The fibronectin (FN) molecule is composed of three types of repeating unit, and the regions 
containing binding motifs to specific proteins and/or receptors are described. Domains required to 
initiate self-assemble are the RGD domain (highlighted as integrin binding domain) and the N and 
C terminal regions highlighted in orange. The FN dimer forms through C terminal disulphide bonds, 
and the folded fibronectin molecule through ionic interactions between type III domains in 
neighbouring molecules. Application of mechanical force can reveal cryptic sites for additional FN 
molecule binding and cell surface receptor interaction. Figure adapted from (Mouw et al., 2014).  
Image made using items from Image Bank in Servier Medical Art. 
Fibril assembly is mediated by interactions between the RGD sequence (Arg-Gly-
Asp) of fibronectin’s integrin-binding domain to cell surface receptors; with 
integrin α5β1 being the primary receptor for soluble fibronectin (Huveneers et 
al., 2008). Binding of fibronectin dimers to integrin α5β1 leads to receptor 
clustering and activation, which promotes further intermolecular interactions 
between additional fibronectin molecules, and exerts forces to change its 
molecular conformation to reveal cryptic sites that promote the assembly of an 
insoluble fibrillar fibronectin matrix (Mouw et al., 2014, Singh et al., 2010). 
Other members of the integrin receptor family can also contribute to matrix 
assembly, as can additional transmembrane proteins including members of the 
Syndecan family (Klass et al., 2000, Stepp et al., 2010). Syndecan-4, for 
example, can control integrin recycling (Bass et al., 2011, Morgan et al., 2013) 
and modulate cell adhesion and migration (Bass et al., 2007b, Bass et al., 2007a, 
Bass et al., 2008), all of which can influence fibril assembly. Cell contractility 
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and tension are also important in mediating fibrillogenesis and maintaining the 
fibronectin matrix architecture, and activation of focal adhesion kinase (FAK) 
and downstream Rho GTPase signalling pathways by integrin-fibronectin 
associations can be evoked to maintain cell-matrix force interactions (Ilic et al., 
2004, Yoneda et al., 2007).  
Continued deposition and end-to-end assembly can lengthen and thicken 
fibronectin fibres, and the density and rigidity of these fibrils can influence the 
deposition and structure of the collagen matrix (Egeblad et al., 2010, Velling et 
al., 2002, Shi et al., 2010). In fact, the assembly of a collagen I matrix in vivo 
actively requires fibronectin fibrillogenesis (Kadler et al., 2008, Sottile and 
Hocking, 2002) and specific binding of collagen’s α1 chain to fibronectin’s 
gelatin binding domain is necessary for deposition of collagen I into the ECM 
(Kleinman et al., 1978, McDonald et al., 1982). The initial deposition of 
fibronectin has subsequently been shown to be an early step in the formation of 
the pre-metastatic niche (Kaplan et al., 2005), whilst upregulation of fibronectin 
expression can also increase cell proliferation (Williams et al., 2008, Zheng et 
al., 2007) and induce cancer cell invasion (Tang et al., 2015b). 
1.8.2.3 Additional ECM components 
Proteoglycans are heavily glycosylated proteins composed of a core protein 
covalently linked to one or more glycosaminoglycan (GAG) chains. Primarily 
found in cartilage and the neural ECM (Bandtlow and Zimmermann, 2000, 
Knudson and Knudson, 2001), proteoglycans are classified by their relative size 
and associated GAG chains, with major GAGs including chondroitin sulphate and 
hyaluronan. In addition to being an abundant structural component of the ECM, 
they are also able to regulate the activity of other molecules, including 
facilitating the activation of matrix metalloproteinases to enhance tumour cell 
invasion and promote metastasis (Iida et al., 2007). 
Laminins are large glycoproteins that consist of globular laminin-type epidermal 
growth factor (EGF)-like repeats and α-helical domains. These heterotrimeric 
proteins are formed through association of an α, β and γ chain that come 
together through triple-helical coiled-coil domains to form cross-shaped, Y-
shaped or rod-shaped conformations (Timpl and Brown, 1994). They are a major 
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component of basal lamina, can associate with collagen IV and fibronectin 
networks, and are known to mediate cell adhesion and migration in addition to 
triggering pro-metastatic signalling pathways (Pal et al., 2014). 
Fibrinogen is a major adhesive glycoprotein that is normally converted to fibrin, 
by thrombin, in blood clot formation. However deposition of fibrinogen, without 
subsequent conversion to fibrin, is commonly found in the tumour stroma (Brown 
et al., 1988, Costantini et al., 1991, Rybarczyk and Simpson-Haidaris, 2000). The 
aberrant deposition of fibrinogen can alter the migration of cancer cells and 
directly stimulate pro-inflammatory cytokine release from surrounding stromal 
cells (Masamune et al., 2009).    
Osteopontin is a phosphorylated glycoprotein that has roles in 
biomineralisation, bone remodelling and immune modulation (Choi et al., 2008, 
Wang and Denhardt, 2008). Overexpression of osteopontin is found in a number 
of different tumour types including those originating in the breast and ovary 
(Wong et al., 2001, Brown et al., 1992) and it has also been proposed for 
biomarker use in cancer detection (Kim et al., 2002). Its chemotactic properties 
can mediate immune cell infiltration and cytokine production (Giachelli and 
Steitz, 2000), whilst its ability to interact with various cell surface receptors, 
such as αVβ3, has also been shown to mediate increased cell migration and 
invasion (Ellison et al., 1998).  
Tenascins are a family of extracellular matrix glycoproteins composed of 4 
members, namely tenascin-C, -R, -X and –W, that have important roles in 
embryonic development and tissue remodelling (Jones and Jones, 2000). 
Tenascin-C is one of the most studied family members, especially in its relation 
to cancer progression, and its expression has been found to correspond to 
metastatic niche formation (Oskarsson et al., 2011), and cancer cell invasiveness 
via regulation of EMT (Takahashi et al., 2013). Tenascin-W is also known as 
tenascin-N, and this family member has been proposed as a marker of the cancer 
stroma (Degen et al., 2008) while it has also been shown to stimulate cell 
migration (Scherberich et al., 2005). 
Thrombospondins are also involved in embryonic development and tissue 
remodelling. A family of 5 members, they have multifunctional roles in 
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mediating interactions between cells and the surrounding microenvironment 
(Ghajar et al., 2013). Thrombospondin-1 and -2 (TSP-1 and TSP-2) play important 
roles in balancing anti-angiogenic and pro-angiogenic stimuli during cancer 
progression (Naumov et al., 2006, Ren et al., 2006), while TSP-1 can also 
activate TGF-β in the tumour microenvironment (Harpel et al., 2001) to further 
contribute to the complex and interdependent pathways that promote tumour 
progression. 
1.8.2.4 Matrix degradation 
The ECM is a highly dynamic structure and in order for it to be remodelled it 
must be amenable to degradation. This can be performed by a variety of 
proteases, with two major groups being the matrix metalloproteinases (MMPs) 
and the ‘disintegrin and metalloproteinase with thrombospondin motif’ 
(ADAMTS) family.  
The MMP family is composed of 28 members, and they are able to target a wide 
range of extracellular proteins (Lu et al., 2011). MMP-1 has selectivity for 
collagen III, whereas MMP-8 and MMP-13 target collagen I and II respectively, 
while MMP-3 and -10 target proteoglycans, fibronectin and laminin. MMP-2 and 
MMP-9 can both expose a cryptic epitope within collagen IV to promote 
angiogenesis (Hangai et al., 2002, Xu et al., 2001). Cross-talk also occurs 
between MMPs and other specific pathways, with MMP-9 and VEGF expression 
being simultaneously induced by regulators such as hypoxia-inducible factor 
(HIF-1) to promote angiogenesis (Hiratsuka et al., 2002), while cleavage of the 
ECM by endopeptidases can also release embedded VEGF to further promote 
vascularity (Park et al., 1993). 
ADAMTS proteinases are also a large family, consisting of 19 members in total. In 
addition to degrading the ECM they are also able to activate proteinase 
precursors (Cawston and Young, 2010). Tumour promoting and inhibiting roles 
have been described for members of the ADAMTS family dependent upon their 
function in the TME (Kelwick et al., 2015). ADAMTS1 is commonly up-regulated in 
metastatic cancers, and its ability to increase tumour growth and metastatic 
burden in mouse models has been attributed to its capacity to cleave ECM 
proteins and inhibit tumour cell apoptosis (Ricciardelli et al., 2011).  
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Cleavage of the ECM by endopeptidases can consequently have a number of 
biological functions, from degrading matrix components to remodel the ECM and 
thus modify the cell-ECM interface, to liberating growth factors and promoting 
angiogenesis, all of which can contribute to tumour progression. 
1.8.2.5 Mechanical properties of the ECM 
The physical properties of the ECM have important ramifications for cell 
behaviour. ECM stiffening may be induced by increased collagen deposition and 
increased collagen crosslinking, which is primarily conducted by LOX and LOX-
like enzymes (Erler et al., 2006, Paszek et al., 2005). Such changes in 
architecture are often associated with increased thickness, alignment and 
linearisation of fibres (Conklin et al., 2011). In addition to tensile forces, 
increased deposition of GAGs such as hyaluronan may increase the interstitial 
pressure within the matrix due to repulsion of its negatively charged chains and 
water molecule retention (Kultti et al., 2014), and this provides another means 
to influence the mechanical properties of the matrix.  
The rigidity of the ECM can influence cell adhesion, proliferation and migration. 
Work on glioblastoma multiforme (GBM) has shown that tumour cells have 
increased rates of spreading, increased rates of proliferation and increased 
migration speeds on ECM substrates that are more rigid than those with 
similarity to normal brain tissue (Ulrich et al., 2009). The biomechanical 
properties of the matrix can also influence how cells perceive and respond to 
external forces. Increased matrix stiffness is able to enhance Rho-activated cell 
tension to promote focal adhesion (FA) assembly and increase ERK activation, 
and this can drive transformation (Paszek et al., 2005). The focal adhesion 
complex is composed of clusters of integrin receptors, adaptors and signalling 
proteins, and functions as a mechanosensor linking the cellular cytoskeleton 
with the ECM, facilitating conformational changes to apply traction force to the 
surrounding environment (del Rio et al., 2009, Sawada et al., 2006). The 
physical composition of the ECM can therefore have important ramifications for 
how cells are able to perceive and respond to their external environment, and is 
consequently another major factor that can influence cell migration.   
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1.9 Cell migration  
Cell migration is pivotal to many processes including embryonic development, 
angiogenesis and wound healing, and the ECM surrounding cells can either inhibit 
or promote cell migration depending on the cell type and its mechanism of 
movement. In general, cell migration occurs through repeated cycles of leading 
edge protrusion, adhesion, cell body translocation and retraction of the cell rear 
(Figure 1-10). However, in practice cells can migrate in a number of different 
ways, including single cell migration, multicellular streaming and collective 
migration, with the selected mode depending on the cell type and its response 
to the external microenvironment. 
 
Figure 1-10- Model of mesenchymal-like cell migration through the ECM.  
(1) Cell protrusion at the leading edge. Actin filaments grow by polymerisation and coupling with 
the ARP2/3/WASP complex. Extensions are further formed and supported through engagement of 
adaptor proteins, cell surface proteins and other molecules such as Rac, Cdc42 and Rho. (2) ECM 
interaction and focal adhesion formation. Cell surface integrin receptors bind the ECM and cluster 
at the cell membrane. Clustered integrins can recruit adaptor and signalling molecules through their 
intracellular domains, including tensin and focal adhesion kinase (FAK). This can further recruit 
other signalling and regulatory molecules, such as vinculin and Rho-family GTPases. (3) Localised 
proteolysis. Surface proteases are recruited to the binding sites to cleave ECM components to 
assist migration through the matrix and create active soluble endopeptidases to further facilitate 
degradation (4) Cell body contraction. Active myosin II binds actin filaments to generate 
actomyosin contraction.  (5) Detachment of trailing edge. Focal contact disassembly occurs by a 
number of mechanisms, including actin binding and severing proteins and cytoplasmic proteases 
that cleave focal adhesion components. Cell surface receptors can be internalised and trafficked 
for recycling or degradation. Figure adapted from (Friedl and Wolf, 2003). Image made using items 
from Image Bank in Servier Medical Art. 
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1.9.1 Single cell migration  
Cells can lose their cell-cell contacts and migrate as individual cells. This is 
particularly relevant for metastatic dissemination of cancer cells were, for 
example, local increases in TGF-β can enable breast cancer cells to switch from 
cohesive to single cell migration to promote haematogenous metastasis 
(Giampieri et al., 2009). Single cell migration can be amoeboid or mesenchymal 
in type. Mesenchymal-like cell migration follows the mechanisms outlined in 
Figure 1-10, and tends to be used by cells that have a fibroblast-like spindle-
shaped morphology that are dependent on integrin-mediated dynamics for their 
motility. Amoeboid migration, on the other-hand, uses a less adhesive gliding 
type of movement, and is supported by cortical filamentous actin and more 
short-lived weak interactions (Friedl and Wolf, 2003). 
1.9.2 Multicellular streaming 
Cells with amoeboid like morphologies can migrate in streams, as cells follow 
each other in single file without cohesive cell-cell junctions. This kind of 
migration is particularly relevant in vivo, and can occur in correlation with a 
vascularised microenvironment as blood vessels can function as pre-defined cell 
tracks (Patsialou et al., 2013). Coordinated cell streaming can enhance 
transendothelial migration and intravasation of tumour cells to promote cancer 
cell metastasis (Roussos et al., 2011) and so is a key migration mechanism used 
in invasive cancer progression. 
1.9.3 Collective migration  
Collective cell migration occurs when cells move in cohesive groups, and is 
commonly seen during embryonic development and in the sprouting of 
endothelial cells for new blood vessel formation (Davidson and Keller, 1999, 
Collen et al., 2003). Cell-cell adhesions linking groups of moving cells can cause 
assembly of cortical actin filaments along cell junctions, to essentially form a 
large multicellular contractile body (Hegerfeldt et al., 2002). Leading cells are 
able to generate a path, and migratory traction can consequently tow trailing 
cells (Friedl et al., 1995). By moving in a larger cell mass, cells are able to 
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increase local concentrations of pro-migratory factors, and more motile cells can 
promote migration and invasion of less mobile cell types. 
1.9.4 Integrin cell surface receptors 
Cells use transmembrane receptors to bind and respond to the surrounding ECM 
and facilitate their migration through it, and one of the major classes required 
for cell adhesion and migration are the integrin receptors (Hynes, 1987). 
Integrins are a diverse family of heterodimeric receptors that are generally 
composed of a non-covalently linked α and β subunit, with each subunit having a 
large extracellular domain, a single membrane spanning domain, and a short 
cytoplasmic tail (Hynes, 2002). Heterodimerisation generates 24 known types of 
receptor that can engage and respond to various and overlapping ECM 
components (Table 1-4). 
Ligand Receptor  Common distribution 
Collagen α10β1 
α2β1 
α1β1 
α11β1 
Chondrocytes 
Chondrocytes, endothelial cells, fibroblasts 
Chondrocytes, epithelial cells 
Mesenchymal non-muscle cells 
Fibronectin  α5β1 
α8β1 
αVβ1 
αVβ6 
αVβ3 
αIIbβ3 
Fibroblasts, chondrocytes, endothelial cells 
Smooth muscle cells 
Fibroblasts, osteoclasts, smooth muscle cells 
Epithelial cells 
Endothelial cells, epithelial cells 
Platelets 
Laminin α10β1 
α2β1 
α1β1 
α7β1 
α6β4 
α6β1 
α3β1 
Chondrocytes 
Keratinocytes, chondrocytes, endothelial cells 
Chondrocytes, epithelial cells 
Differentiated muscle cells 
Endothelial cells 
Chondrocytes, endothelial cells 
Keratinocytes 
Fibrinogen αVβ3 
αVβ5 
αVβ6 
αIIbβ3 
Endothelial cells, epithelial cells 
Endothelial cells, epithelial cells, platelets 
Epithelial cells 
Platelets 
Osteopontin αVβ1 
αVβ3 
αVβ5 
Fibroblasts, osteoclasts, smooth muscle cells 
Endothelial cells, fibroblasts, epithelial cells 
Endothelial cells, epithelial cells, platelets 
Tenascin αVβ3 
αVβ6 
α2β1 
α9β1 
Endothelial cells, epithelial cells 
Endothelial cells 
Keratinocytes, chondrocytes, endothelial cells 
Keratinocytes, endothelial cells 
Thrombospondin αVβ3 
αVβ5 
Endothelial cells, epithelial cells 
Endothelial cells, epithelial cells, platelets 
Vitronectin αVβ1 
αVβ3 
αVβ5 
Fibroblasts, osteoclasts, smooth muscle cells 
Endothelial cells, epithelial cells 
Endothelial cells, epithelial cells, platelets 
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αVβ6 
αVβ8 
α1β1 
Epithelial cells 
Uterus, kidney, brain, ovary, placenta 
Chondrocytes, epithelial cells  
Table 1-4- Integrin heterodimers and their ligands.  
Integrin-ligand interactions for some of the most common components of the ECM (Humphries et 
al., 2006, Niu and Chen, 2011). 
Integrins provide a link between the ECM and the cell’s cytoskeleton, and hence 
are important for most types of cell migration. Integrins can exist in three 
different conformational states; an inactive bent conformation with a low 
affinity for ECM ligands, a primed extended conformation which still has a closed 
head-piece and low ligand affinity, and an active extended head-piece with high 
ligand affinity (Luo et al., 2007). Despite lacking enzymatic activity, they are 
able to initiate ‘outside in’ signalling through ligand binding to the external 
domain and consequent recruitment of signalling molecules such as FAK, or by 
influencing how growth factors such as EGFR or FGFR can respond to their 
ligands (Walker et al., 2005). Alternatively, cells can also trigger ‘inside-out’ 
signalling, where the integrin receptors are switched from low-affinity inactive 
states to high-affinity active conformations through association of β-integrin 
cytoplasmic tails with FERM-domain containing proteins such as talin and kindlin 
(Moser et al., 2009, Wegener et al., 2007). Integrin signalling is highly regulated 
at a number of different levels, including ligand binding, intracellular signalling 
and receptor trafficking, all of which can affect how cells migrate (Caswell and 
Norman, 2006).  
1.9.4.1 Integrin trafficking 
Integrins can be endocytosed from the cell surface into early endosomes via a 
number of different mechanisms; these can be clathrin-dependent or 
independent, caveolin-mediated, or macropinocytosic (Gu et al., 2011, De 
Franceschi et al., 2015). Once internalised, integrins are sorted for degradation 
or recycled back to the cell surface by a number of distinct mechanisms that are 
controlled by small GTPases, and the pathway that they take can influence cell 
migration. Members of the Ras superfamily of small GTPases which are involved 
in integrin trafficking include those of the Rho, Rab and Arf groups. The Rho 
GTPases include Rho, Rac and Cdc42, and these members tend to influence 
integrin trafficking and cell motility through regulation of actin cytoskeleton 
dynamics (Ridley, 2006). The role played by the Rab and Arf GTPases in integrin 
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trafficking are more direct than those played by the Rho subfamily, and involve 
the dynamic recycling and trafficking of internalised receptors to the plasma 
membrane. Recycling through a Rab-4 dependent pathway can promote rapid 
delivery of integrins back to the plasma membrane, while longer recycling routes 
include recycling to Rab-11-positive perinuclear recycling compartments prior to 
returning to the cell surface (Caswell and Norman, 2006, Morgan et al., 2009, 
Scita and Di Fiore, 2010, De Franceschi et al., 2015). For example, integrin αvβ3 
can be trafficked through the Rab-4 dependent short loop pathway, as the 
receptor is rapidly trafficked from early endosomes back to the plasma 
membrane through a mechanism dependent on growth factor induced 
autophosphorylation of PKD1 and its recruitment to the cytoplasmic tail of β3 
(Roberts et al., 2001, Roberts et al., 2004, White et al., 2007). Integrin α5β1 on 
the other-hand can be sorted from early endosomes into recycling endosomes via 
the Rab-11 dependent long loop (Roberts et al., 2004). In this case receptors are 
trafficked to the Rab-11 positive perinuclear recycling compartment (PNRC) 
before being returned to the plasma membrane, and this can be regulated by a 
number of different kinases including PKB/Akt (Roberts et al., 2004) and PKCε 
(Ivaska et al., 2005), in addition to actin related proteins such as Arp2/3 (Actin-
related protein 2/3) and WASH (WASP and SCAR homologue) (Duleh and Welch, 
2012, Zech et al., 2011)  (Figure 1-11). 
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Figure 1-11- Rab GTPase control of integrin trafficking.  
Integrins can be internalised into early endosomes (EE) by a number of different mechanisms, 
which can be regulated by Rab-21. Following internalisation they can then be trafficked by a 
number of different pathways. The short-loop pathway is mediated by Rab-4 to traffick integrins 
back to the cell surface, and the long loop pathway by Rab-11 and RCP mediated processes 
through the perinuclear recycling compartment (PNRC). Integrins can also be trafficked to the late 
endosome (LE), where they can be transported back to the plasma membrane in a Rab-25 
dependent process, sorted and secreted in microvesicles (MV) via the multivesicular body (MVB), 
or are targeted for lysosomal degradation by ubiquitination. Image made using items from Image 
Bank in Servier Medical Art.     
These recycling pathways enable adhesion turnover and replenishment of cell 
surface integrins, and they have important influences on the control of cell 
migration and invasion. The Rab-11 effector RCP (Rab-coupling protein) controls 
the recycling of integrin α5β1 and receptor RTKs. RCP-driven recycling of α5β1 to 
leading edge protrusions increases the fibronectin-dependent migration of 
cancer cells, with increased invasive behaviour not owing to differences in 
adhesive function but to α5β1 and RCP’s effect on the trafficking of RTKs such as 
EGFR1 and activation of the pro-invasive PKB/Akt pathway (Caswell et al., 
2008). Mutant p53 can also activate RCP-dependent trafficking of integrins and 
RTKs to promote invasion (Muller et al., 2009, Muller et al., 2013), and RCP-
dependent trafficking can also influence Rho GTPase function to regulate 
invasion, by suppressing Rac and promoting RhoA activity through 
phosphorylation of RacGAP1 (Jacquemet et al., 2013). 
Differential receptor trafficking can also occur, where distinct heterodimers for 
the same ligand are trafficked through different pathways to regulate the 
activity of each other. In the case of the fibronectin receptors, the activity of 
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αvβ3 suppresses α5β1 recycling (White et al., 2007, Morgan et al., 2009), and this 
can also influence cell migration. Recycling of αvβ3 is associated with directional 
migration and invasion into ECM containing low fibronectin concentrations 
through pathways that are dependent on Rac activation, whereas α5β1 recycling 
can induce random migration through the Rho-ROCK-Cofilin pathway in matrices 
with high fibronectin abundance (White et al., 2007, De Franceschi et al., 2015, 
Morgan et al., 2013, Danen et al., 2005). Control of integrin trafficking is 
therefore an integral regulator of cell migration, and aberrant activity of such 
pathways can result in the increased migratory effect seen in metastatic cancers 
(Table 1-5). 
Integrin 
Receptor 
Associated 
Molecule 
Trafficking 
Step 
Biological 
Process 
Disease 
Association 
α5β1 Rab25 Recycling Invasion Ovarian cancer, breast 
cancer, colon cancer, 
intestinal neoplasia  
α5β1 RCP Recycling Invasion 
Metastasis 
Breast cancer, mutant p53 
carcinomas, head and neck 
squamous carcinoma  
α5β1 CLIC3 Recycling Invasion Ovarian cancer, pancreatic 
cancer, breast cancer 
α5β1, α6 GIPC1 Endocytosis Invasion 
Metastasis 
Vascular-
development 
Breast cancer, ovarian 
cancer, gastric cancer, 
pancreatic cancer 
α5β1, αVβ3 PRKD1 Recycling Proliferation 
Invasion 
Breast cancer, prostate 
cancer, gastrointestinal 
cancer, skin cancer 
α3β1, α5β1, STX6 
VAMP3 
Recycling Proliferation Breast, colon, liver, 
pancreatic, prostate, 
bladder, skin, testicular, 
tongue, cervical, lung and 
gastric cancers 
α5β1, α2β1 
αVβ3, α6β4 
Rab11 Recycling Invasion 
Metastasis 
Skin carcinogenesis, 
Barrett’s dysplasia, mutant 
p53 carcinomas 
αVβ6 HAX1 Endocytosis Transformation 
Invasion 
Metastasis 
Breast cancer, colon 
cancer, oral cancer 
α9β1 Arf6 Recycling Tissue repair Axonal development, 
regeneration peripheral 
nervous system 
α1, α2, α5 
α6, β1 
Rab21 Endocytosis Migration 
Cytokinesis  
Prostate cancer, lung 
cancer  
Table 1-5- Integrin trafficking pathways associated with human disease processes. 
A summary of some of the known associations between human pathophysiological conditions and 
integrin receptor trafficking pathways. GAIP interacting protein C1 (GIPC1), Rab coupling protein 
(RCP), Chloride intracellular channel protein 3 (CLIC3), Protein Kinase D1 (PRKD1), 
Synaptophysin 6 (STX6), Vesicle-associated membrane protein 3 (VAMP3), HS1 associated 
protein (HAX1). Table adapted from (De Franceschi et al., 2015). 
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1.9.4.2 ECM and trafficking   
Integrin trafficking plays a pivotal role in the dynamic formation and disassembly 
of adhesions that mediate cell migration, however ECM components can also be 
internalised into the cells during transmembrane receptor endocytosis. 
Endopeptidases can co-localise with integrins and adhesion complexes to cleave 
ECM components and enable co-uptake of the matrix upon receptor 
internalisation (Galvez et al., 2002, Shi and Sottile, 2011). Ligand-bound 
receptors can be targeted to lysosomes for degradation, however in cancers that 
have increased expression of the lysosomal protein CLIC3, ligand-bound integrins 
were found not to be degraded but recycled to the plasma membrane to 
promote increased levels of cell invasion and metastasis (Dozynkiewicz et al., 
2012). In environments with low fibronectin levels, internalised fibronectin can 
be re-secreted from late endosomes and lysosomes to further promote cell 
migration by providing an autocrine substrate to enable cells to increase their 
own motility (Sung and Weaver, 2011). Recent data has also shown that ligand-
bound integrins can be trafficked to late endosomes to support mTOR signalling 
(Rainero et al., 2015). The interaction between mTORC1 and integrin trafficking 
is particularly interesting, and suggests a link between ECM internalisation, 
nutrient signalling and cell migration. Furthermore, given mTORC1’s key role in 
controlling selectivity of protein synthesis, in particular translation initiation and 
elongation, this observation may indicate a potential mechanistic connection 
between the turnover and internalisation of the ECM and the synthesis of 
cellular and secreted proteins. All of these factors can contribute to increased 
cancer cell invasion and metastasis, and so further understanding the role of the 
ECM in cell migration and tumour growth is an important area of research that 
could have a major impact on the development of future cancer therapies.  
1.10 PhD Objectives 
Understanding how cells can sense, respond, influence and migrate through their 
microenvironments is fundamental to understanding how cancer cells can grow, 
disseminate and metastasise. It is metastasis rather than primary tumour growth 
that causes the majority of human cancer deaths, and so unravelling the 
molecular basis of this process is essential to provide the necessary knowledge 
required to generate targeted and effective therapies. 
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Control of gene expression is pivotal to a large range of cell processes from cell 
migration to ECM secretion, and as a consequence is subject to regulation by a 
number of highly complex and complicated mechanisms. The translation of 
mRNA into protein can be regulated at a number of different levels including 
global upregulation/downregulation of the total amount of protein produced, to 
more subtle shifts in the translational efficiency of particular transcripts. 
Transfer RNAs are key adaptor molecules which are required to read codons of 
the mRNA and bring the appropriate amino acid to the translation machinery. 
Moreover, it is clear that the tRNA repertoire differs markedly between cells 
that are rapidly proliferating and those that are terminally differentiated or 
quiescent. Whilst cells express a large number of different tRNAs, the initiator 
methionine tRNA (tRNAiMet) is of particular interest, as only this tRNA can 
recognise and bind the start codon to initiate translation. Increased levels of 
tRNAs are found across a variety of cancer types, however it is currently 
unknown whether this is a cause or a consequence of tumourigenesis, or what 
role, if any, this might play in tumour progression. The objective of this work is 
therefore to understand whether increased expression of one particular tRNA, 
tRNAiMet, could influence cell behaviour, with a specific interest in understanding 
whether tRNAiMet expression could affect cell migration and tumour growth.  
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Chapter 2 Materials and methods 
2.1 Materials 
2.1.1  Reagents 
Reagent Supplier 
0.45μm filter Gilson 
1.5mL microcentrifuge tubes Eppendorf 
1.5mL RNAse free microcentrifuge tubes Life Technologies 
1Kb Plus DNA Ladder Life Technologies 
1mL syringe  Becton Dickinson 
2% gelatin Sigma 
25G needle Becton Dickinson 
AEBSF Melford Laboratories 
Agarose  Sigma 
Ampicillin Sigma 
Aprotinin Sigma 
Ascorbic Acid Sigma 
BglII New England Biolabs 
BSA First link 
Casyton Roche 
Cell lifter  Corning 
Chloroform Sigma 
Citric acid Sigma 
ClaI New England Biolabs 
Coomassie gel stain  Expedeon 
Dialysed foetal calf serum  PAA 
DMEM minus methionine and cysteine Life Technologies 
DMEM/F12 media Life Technologies 
DMSO Fisher Scientific  
DNAse1 Roche 
DTT Melford Laboratories 
Dulbecco’s Modified Eagle Medium (DMEM) Life Technologies 
Dynabeads anti-mouse Life Technologies 
EasyTag Express Protein Labelling Max 35S PerkinElmer 
ECL Western blotting substrate Pierce 
EcoRI New England Biolabs 
EDTA Sigma 
EGTA Sigma 
Ethanol VWR 
Falcon tissue culture 6 well plates  BD Biosciences 
Falcon tissue culture dishes (10 & 15cm2) BD Biosciences 
Fibronectin  Sigma 
Foetal Calf Serum PAA 
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Full-Range Rainbow Ladder Amersham 
Fungizone Life Technologies 
Glass bottom 3cm dishes Maktek 
Glutaraldehyde Sigma 
Glycerol Fisher Scientific 
Glycine Sigma 
HpaI New England Biolabs 
Hybond-P PVDF membrane GE Healthcare 
Hydrogen peroxide Sigma 
Hygromycin Life Technologies 
Igepal CA-630 Fluka 
Iodoacetamide (IAA) Sigma 
Leupeptin Melford 
L-Glutamine Life Technologies 
Maxisorp 96 well microtiter plates Life Technologies 
MesNa Fluka 
Milk powder Marvel 
Na2CO3 Fisher Scientific 
Na2HPO4 Fisher Scientific 
Na3V04 Fisher Scientific 
NaCl Fisher Scientific 
NaF Sigma 
NaHCO3 Fisher Scientific 
NaN3 Sigma 
NaOH Fisher Scientific 
NH4OH Sigma 
Nunc tissue culture plates TCS biologicals 
NuPAGE MES SDS running buffer Life Technologies 
NuPAGE MOPS SDS running buffer Life Technologies 
NuPAGE pre-cast gels (4-12% & 10%) Life Technologies 
NuPAGE sample buffer Life Technologies 
NuPAGE transfer buffer Life Technologies 
Odyssey blocking buffer Licor 
Ortho-phenylenediamine Sigma 
Parafilm wrap Fisher Scientific 
Paraformaldehyde (PFA) Electron Microscopy Sciences 
PBS containing calcium and magnesium Sigma 
Penicillin/Streptomycin Life Technologies 
PerfeCTa SYBR Green Fast Mix Quanta 
Propan-2-ol Fisher Scientific 
Propidium Iodide Sigma 
RNase free water  Sigma 
Salubrinal  Calbiochem 
Scintillation fluid National Diagnostics  
SDS Fisher Scientific 
SILAC DMEM Lonza 
SILAC labelled amino acids Cambridge Isotope Laboratories 
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siRNA Dharmacon 
SnaBI New England Biolabs 
Strataclean beads Agilent 
Streptavadin-conjugated HRP GE Healthcare 
Sulfo-NHS-SS-Biotin Pierce 
Super RX medical x-ray film Fuji 
TOP10 OneShot chemically competent cells Life Technologies 
TransIT-LT1 transfection reagent  Mirus 
Trichloroacetic acid (TCA) Sigma 
Tris HCl Melford 
Triton-X100 Sigma 
Trizol Life Technologies 
Trypsin  Life Technologies 
Tween-20 Sigma 
Vectashield mounting media + DAPI Vector laboratories 
Whatman GF/C 2.5cm filter paper GE Healthcare 
XF base medium  Seahorse Biosciences 
β-mercaptoethanol Sigma 
Table 2-1- Reagents and suppliers 
 
2.1.2 Solutions 
Solution  Recipe  
1% SDS lysis buffer  1% SDS (v/v), 50mM Tris-HCl pH7.0, 0.1M DTT 
4% SDS lysis buffer 4% SDS (v/v), 0.1M Tris-HCl pH7.4, 0.1M DTT 
Biotin reduction 
buffer  
50mM Tris-HCl pH7.4, 10mM NaCl, pH8.6 at 4°C 
ELISA coating buffer  0.05M Na2CO3, pH9.6 at 4°C 
ELISA development 
reagent  
0.56 mg/mL ortho-phenylenediamine , 25.4mM Na2HPO4, 12.3mM 
citric acid, pH5.4 with 0.003% H2O2 
Extraction buffer 10mM NH4OH, 0.5% Triton-X100 (v/v) in PBS with calcium and 
magnesium  
FACS buffer  PBS, 1% BSA (v/v), 0.5μg/mL propidium iodide 
LB Broth  85mM NaCl, 1% bacto-trypton (w/v), 0.5% yeast extract (w/v) 
NDLB 50mM Tris-HCl pH7.0, 150mM NaCl, 10mM NaF, 1mM Na3V04, 5mM 
EDTA, 5mM EGTA, 1.5% Triton-X100 (v/v), 0.75% Igepal CA-630 
(v/v) 
PBS-T PBS, 0.1% Tween-20 (v/v) 
TBS 10mM Tris-HCl pH7.4, 150mM NaCl 
TBS-T TBS, 0.1% Tween-20 (v/v) 
Table 2-2- Recipes of solutions  
 
2.1.3 Kits 
Kit  Supplier  
Agilent RNA 6000 Pico Kit Agilent  
Amaxa Nucleofector Kit R Lonza 
GeneArt CRISPR Nuclease Vector with OFP Reporter Kit Life Technologies 
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Mini Elute Gel Extraction Kit Qiagen  
Quantitech Reverse Transcription Kit Qiagen  
Qubit Protein Assay Life Technologies 
Rapid Ligation Kit  Roche 
RiboZero Magnetic Kit Illumina 
RNeasy MinElute Cleanup Kit Qiagen  
XF Cell Mitochondrial Stress Test Seahorse Bioscience 
Table 2-3- Kits and suppliers 
 
2.1.4 Primers 
Primer Sequence 
5S rRNA Forward CAGCACCCGGTATTCCCAGG 
5S rRNA Reverse  GGCATACCACCCTGAACGC 
ARPP P0 Forward GCACTGGAAGTCCAACTACTTC 
ARPP P0 Reverse TGAGGTCCTCCTTGGTGAACAC 
Collagen II Forward  GGGTCACAGAGGTTACCCAG 
Collagen II Reverse  ACCAGGGGAACCACTCTCAC 
tRNAIle Forward GGCGGCCGGTTAGCTCAG 
tRNAIle Reverse CCCGTACGGGGATCGAAC 
tRNAiMet Forward AGAGTGGCGCAGCGGAAG 
tRNAiMet Reverse AGCAGAGGATGGTTTCGATCC 
Table 2-4- qRT-PCR primer sequences 
 
2.1.5 Plasmids 
Plasmid Supplier 
pGEM easy T Promega 
pLPCX Clontech 
pLHCX Clontech 
Table 2-5- Expression vectors 
 
2.1.6 siRNA 
Target  siRNA Supplier  
Collagen II  ON-TARGET plus Col2a1 siRNA L-043139-01-0005 Dharmacon  
Integrin alpha 5 ON-TARGET plus Itga5 siRNA L-060502-01-0005 Dharmacon  
Non-targeting(NT) siGENOME control pool NT #1 D-001206-13-50 Dharmacon  
Table 2-6- siRNA used for siRNA knock-down experiments 
 
2.1.7 Primary antibodies  
Protein  Host  Antibody  Technique (dilution)   Supplier  
Collagen II  Rabbit  AB21291 Western blot (1:1000), 
Immunostaining ECM 
Abcam 
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(1:100), IHC of TMA 
(1:300)  
Integrin α5 Rat 553319 ELISA (1:100), IF (1:100)  BD Pharmingem 
Integrin α5 Rabbit  AB1921 Western blot (1:5000) Chemicon 
Integrin β1 Rat 550531 ELISA (1:100) BD Pharmingen  
P-eIF2α Rabbit  44728G Western blot (1:1000) Life Technologies 
TfR Rat 553264 ELISA (1:100) BD Pharmingem 
β-actin  Mouse A1978 Western blot (1:10,000) Sigma 
Table 2-7- Primary antibodies 
 
2.1.8 Secondary antibodies 
Antibody Host  Technique (dilution)   Supplier  
Alexa-fluor 488 α-
rat 
Goat IF (1:200) Life 
Technologies 
HRP α-mouse Goat Western blot (1:1000) Sigma 
HRP α-rabbit  Goat Western blot (1:1000) Sigma 
IRDye 680CW α-
rabbit 
Donkey Western blot (1:10,000) LI-COR 
IRDye 800CW α-
mouse 
Donkey Western blot (1:10,000) LI-COR 
IRDye 800CW α-
rabbit 
Donkey Immunostaining ECM  (1:10,000) 
Western blot (1:10,000) 
LI-COR 
Table 2-8- Secondary antibodies  
 
2.2 Methods 
2.2.1 2+tRNAiMet mice  
The 2+tRNAiMet mouse was generated by the Transgenic Technology group at the 
CR-UK Beatson Institute, Glasgow. Briefly, two copies of the murine tRNAiMet 
gene (tRNA78), including ~140bp of flanking sequence, were targeted to the 
HPRT locus of HM1 embryonic stem cells, and used to generate chimeric mice. 
2+tRNAiMet transgenic offspring were derived by crosses to C57Bl/6 mice. 
2.2.2 Allograft models 
2.2.2.1 Melanocyte allograft  
1x106 transformed melanocytes (Tyr::NrasQ61K;INK4a−/−) were injected 
subcutaneously into littermatched WT or 2+tRNAiMet transgenic male mice and 
tumour size monitored 3 times per week. Mice were culled once tumours 
reached 15x15mm size, and survival plotted by Kaplan-Meier analysis.    
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2.2.2.2 Lewis lung carcinoma allograft   
This experiment was conducted by the Reynolds lab, Institute of Cancer 
Research, London. 1x106 lewis lung carcinoma cells were injected 
subcutaneously into the right flank of littermatched WT or 2+tRNAiMet transgenic 
male mice.  All tumours were harvested 21 days post injection and final tumour 
volume was measured as (LxWxW)/2, where L is the longest dimension and W is 
the shortest dimension. Tumours were paraformaldehyde (PFA) fixed and 
immunohistochemistry (IHC) performed for endomucin to enable blood vessel 
identification. Vessels were counted across the entire tumour section and are 
reported as vessels per mm2.  
2.2.2.3 B16 melanoma allograft 
This experiment was conducted by the Reynolds lab, Institute of Cancer 
Research, London. 0.5x106 B16 F0 mouse melanoma cells were injected 
subcutaneously into the right flank of littermatched WT or 2+tRNAiMet transgenic 
male mice.  Mice were culled and tumours harvested 22 days from the day the 
tumour was a measurable 3x3mm size.  Tumours were skinned, and final tumour 
volume was measured as (LxWxW)/2, where L is the longest dimension and W is 
the shortest dimension. Tumours were PFA fixed and IHC performed for 
endomucin to enable blood vessel identification. Vessels were counted across 
the entire tumour section and are reported as vessels per mm2. 
2.2.2.4 Lewis lung carcinoma allograft with ethyl-3,4-dihydroxybenzoate 
treatment 
This experiment was conducted by the Reynolds lab, Institute of Cancer 
Research, London. 1x106 lewis lung carcinoma cells were injected 
subcutaneously into littermatched WT or 2+tRNAiMet transgenic male mice, 
followed by daily dosing with 40mg/kg ethyl-3,4-dihydroxybenzoate (DHB). 
Tumours were harvested 21 days post injection and final tumour volume 
measured as (LxWxW)/2, where L is the longest dimension and W is the shortest 
dimension. Tumours were PFA fixed and IHC performed for endomucin to enable 
blood vessel identification. Vessels were counted across the entire tumour 
section and are reported as vessels per mm2. 
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2.2.3 Cloning  
2.2.3.1 tRNAiMet expression vector 
A construct containing tRNAiMet (pGEM.tRNAiMet) was kindly provided by the White 
lab (formerly CR-UK Beatson Institute, now University of York, UK). As the pGEM 
easy T vector provided was a bacterial expression vector, tRNAiMet was subcloned 
into a mammalian expression vector in which the cytomegalovirus (CMV) 
promoter was removed to allow Pol III transcription of the tRNA from its own 
internal promoters without interference from Pol II at the upstream CMV 
promoter.  
Fragments containing tRNAiMet were digested out of the pGEM.tRNAiMet construct 
using EcoRI and ligated into the multiple cloning site (MCS) of the EcoRI digested 
pLPCX vector. Briefly, 1μg of DNA was digested with EcoRI and the fragments 
separated by gel electrophoresis (1.5% agarose gel at 90V for 75 minutes). The 
digested vector and insert were then purified from the gel using a Mini Elute Gel 
Extraction Kit and ligated using a 1:2 molar ratio of vector to insert and a Rapid 
Ligation Kit, all exactly as per manufacturer’s instructions.    
The pLPCX.tRNAiMet construct and pLHCX final destination vector were digested 
using BglII and ClaI, and then gel purified and ligated as described above to 
produce the pLHCX.tRNAiMet containing vector. To make the corresponding 
pLHCX empty vector control minus the Pol II CMV promoter, the pLHCX vector 
was digested with HpaI and SnaBI, gel purified, and then religated. 
Transformation of TOP10 chemically competent E.coli was conducted to 
propagate the constructs. In short, 2uL of the ligation reaction was added to a 
vial of TOP10 cells and incubated on ice for 15 minutes. Vials were heat-shocked 
for 30 seconds at 42°C and then placed back on ice for 2 minutes. 250μL pre-
warmed LB broth was added to each vial, followed by horizontal shaking at 37°C 
for 1 hour at 225rpm. 50μL and 200μL of each transformation was then spread 
onto pre-warmed agar selective plates (containing 100μg/mL ampicillin) and 
incubated at 37°C overnight. Individual colonies were picked and propagated in 
5mL LB broth + 100μg/mL ampicillin by incubating at 37°C with shaking at 
225rpm for 6 hours. This culture was then diluted 1:500 into 200mL LB broth + 
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100μg/mL ampicillin, and incubated at 37°C with shaking at 225rpm overnight. 
Bacterial cells were harvested by centrifugation at 4000rpm for 20 minutes at 
4°C. Pellets were maxiprepped and sequenced by the Molecular Technology 
Service, CR-UK Beatson Institute, Glasgow.   
2.2.3.2 Collagen II CRISPR expression vector 
Single-stranded oligonucleotides were designed to exon 1 of collagen II (Top 
strand oligo 5’-3’: CCTCGGGGCTCCCCAGTCGCGTTTT, Bottom strand oligo 5’-3’: 
GCGACTGGGGAGCCCCGAGGCGGTG), annealed to make double stranded oligos 
and ligated into the linearised GeneArt CRISPR Nuclease Vector exactly as per 
manufacturer’s instructions. The construct was then transformed, propagated 
and sequenced as described in 2.2.3.1.  
2.2.4 Cell culture  
2.2.4.1 Immortalised cell lines  
Immortalised mouse embryonic fibroblasts (iMEFs) previously made using the 3T3 
method were kindly provided by the White lab (formerly CR-UK Beatson 
Institute, now University of York, UK) and cultured in DMEM supplemented with 
10% FBS, 200μM L-Glutamine, 100U/mL penicillin streptomycin, 0.25μg/mL 
fungizone. Stable cell lines expressing pLHCX.tRNAiMet and corresponding empty 
vector control where made by transfection using 1x105 cells per well in a 6 well 
plate with 2.5μg construct and TransIT-LT1 transfection reagent, exactly as per 
manufacturer’s instructions. Selection of stable pools was performed in full 
growth media supplemented with 250μg/mL hygromycin. Stable pLHCX.tRNAiMet 
iMEFs were also transfected with the collagen II CRISPR construct, or 
corresponding empty GeneArt vector control, using 1x106 cells per 10cm2 dish 
with 15μg construct and TransIT-LT1 transfection reagent exactly as per 
manufacturer’s instructions. Transfected cells were selected using fluorescence 
activated cell sorting (FACS) of orange fluorescent protein (OFP) expressing 
cells. 
For continued culture, cells were grown at 37°C/5%CO2 and passaged every 2 – 3 
days. To passage cells, media was removed, cells were washed in PBS, and 
incubated in 0.25% trypsin for 5 minutes at 37°C/5%CO2. After visualising cell 
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detachment by light microscopy, cells were resuspended in full growth media 
and plated at the required density in new tissue culture dishes.  
Cryofreezing was conducted for long term storage. Cells were trypsinised and 
resuspended as described above, and then centrifuged at 1000rpm for 5 minutes 
at room temperature (RT). Pelleted cells were then resuspended in freezing 
media (Complete growth media minus selective antibiotics + 10% FBS + 10% 
DMSO). Four 1mL freezing vials were obtained per 80 – 90% confluent 15cm2 
tissue culture dish. Vials were initially frozen at -80oC using a Mr Frosty Freezing 
Container, as per manufacturer’s instructions, and then transferred to liquid 
nitrogen for long term storage.  
2.2.4.2 Primary cell lines 
Primary breast fibroblasts derived from human breast tumour or surrounding 
tissue were kindly gifted by the Reynolds Lab (Institute of Cancer Research, 
London, UK). Cells were cultured in DMEM/F12 media supplemented with 10% 
FBS, 200μM L-Glutamine, 100U/mL penicillin streptomycin and 0.25μg/mL 
fungizone. Cells were passaged and cryopreserved as described for immortalised 
cell lines for a maximum of 2 passages (2.2.4.1).  
Primary mouse embryonic fibroblasts (MEFs) were isolated from E13 – E15 
littermatched WT or 2+tRNAiMet embryos. After sterile dissection from the yolk 
sac and removal of the foetal liver and head, the embryo was disaggregated by 
forceful pipetting, cells pelleted by centrifugation, and resuspended in DMEM 
supplemented with 10% FBS, 200μM L-Glutamine, 100U/mL penicillin 
streptomycin, 0.25μg/mL fungizone and 50μM β-mercaptoethanol. Cells were 
plated on 0.1% gelatin coated dishes and incubated at 37°C/5%CO2 until 80% 
confluent. Cells were passaged once as described for immortalised cells at a 1:3 
splitting ratio (2.2.4.1), with 1 plate being used for cryopreservation and the 
remaining cells used as described in the results chapters.   
2.2.4.3 Transient transfection 
iMEFs were transiently transfected with a GADD34 containing construct (kindly 
gifted from the Willis lab, MRC toxicology unit, Leicester, UK) in a 6 well plate 
using 2.5μg construct and TransIT-LT1 reagent as per manufacturer’s 
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instructions, with one  exception. Cells were plated at 1x105 cells per well and 
left to adhere for 4 hours prior to transfection, as opposed to an overnight 
incubation.  
2.2.4.4 siRNA transfection  
iMEFs were transfected with 5nM integrin α5 siRNA, 10nM collagen II siRNA, or 
corresponding concentration of non-targeting (NT) siRNA, using the Amaxa 
Nucleofector system with solution R and programme T-20 exactly as per 
manufacturer’s instructions. One nucleofection reaction was conducted per 80 – 
90% confluent 15cm2 dish, with each reaction being replated into a new 10cm2 
dish. Cells were then used experimentally as described in the results chapters. 
2.2.4.5 Drug treatments 
iMEF cells were plated at 1x105 cells per well in a 6 well tissue culture plate and 
incubated at 37°C/5%CO2 for 2 hours to adhere. Cells were then treated with 
75μM salubrinal, or 0.35% DMSO as control. For migration experiments, cells 
were incubated at 37°C/5%CO2 in the presence of drug or control for 2 further 
hours prior to 17 hours of timelapse microscopy. In the case of western blot, 
cells were incubated at 37°C/5%CO2 overnight prior to lysis.  
2.2.5 Cell proliferation assay  
iMEFs were plated at 1x105 cells per well in a 6 well tissue culture plate and 
incubated at 37°C/5%CO2. Media was refreshed every other day and total cell 
number was counted every day for 4 days, at which time the cells had reached 
90% confluence. To count cell number, cells were trypsinised and resuspended in 
growth media as described in 2.2.4.1 and then total cell number measured using 
a Casy Cell Counter (Innovatis), as per manufacturer’s instructions 
2.2.6 Flow cytometry  
iMEF cells were trypsinised and resuspended as described in 2.2.4.1, counted 
using a Casy Cell Counter and 1x106 cells centrifuged at 1000rpm for 5 minutes at 
RT. Pelleted cells were resuspended in FACS buffer, transferred to FACS tubes 
and placed on ice until analysis by flow cytometry using FACSCalibur (BD 
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Biosciences) and FlowJo Single Cell Analysis Software as per manufacturer’s 
instructions.  
2.2.7 Cell metabolism assay 
An XF Cell Mitochondrial Stress Test was conducted using the XFp Extracellular 
Flux Analyser as per manufacturer’s instructions. Briefly, cells were plated at 
5000, 10,000 and 20,000 cells per well in a 96 well plate, and incubated at  
37°C/5%CO2 overnight. Assay medium was made by supplementing XF base 
medium with 1nM pyruvate, 2mM glutamine and 25mM glucose, and adjusting 
the media to pH7.4. Oligomycin and FCCP were prepared at 100μM and 
Rotenone/Antimycin A at 50μM, all three drugs were prepared in assay media, 
and then loaded into the supplied cartridge ports. The cell culture media was 
removed from cells, and the cells washed twice with PBS. Assay media was then 
added and the cells incubated at 37°C (No CO2) for 30 minutes prior to running 
the XF Cell Mitochondrial Stress Test in the XF Extracellular Flux Analyser 
(Seahorse Bioscience) as per manufacturer’s instructions.  
2.2.8 RNA extraction 
Cells at 80 – 90% confluence were washed twice with PBS, scraped into Trizol 
(1mL per 10cm2 tissue culture dish), snap frozen on dry ice and stored at -80°C 
until use. Prior to use, samples were thawed and incubated at RT for 5 minutes 
to allow dissociation of nucleoprotein complexes. 200μL chloroform was added 
per 1mL Trizol used, samples were vortexed for 15 seconds, and centrifuged at 
13,000rpm for 15 minutes at 4°C. The upper aqueous layer was then transferred 
to a fresh tube and an equal volume of isopropanol added. The tubes were then 
vortexed for 10 seconds and incubated at RT for 10 minutes. The samples were 
then centrifuged at 13,000rpm for 10 minutes at 4°C. The RNA pellet was then 
washed by adding 1mL 75% ethanol and centrifuging the samples at 13,000rpm 
for 5 minutes at 4°C. The supernatant was removed, and the pellet left to air 
dry for 15 minutes. The pellet was then resuspended in 20μL RNase-free water, 
pre-warmed to 50°C, and samples incubated at 50°C for 15 minutes. After brief 
vortexing, samples were incubated at 50°C for a further 5 minutes, and then 
transferred to ice. The RNA concentration was determined by measurement of 
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the A260:A280 ratio using a NanoDrop spectrophotometer (Thermo Scientific), and 
the RNA stored at -80°C.  
2.2.9 RNA-Sequencing 
For the RNA-Sequencing (RNA-Seq) of iMEF.Vector and iMEF.tRNAiMet cells, 1x106 
cells were plated in 10cm2 tissue culture dishes and incubated at 37°C/5%CO2 for 
48 hours. For the RNA-Seq of iMEF.Vector cells treated with iMEF.Vector and 
iMEF.tRNAiMet conditioned media, 1x106 iMEF.Vector cells were plated in 10cm2 
tissue culture dishes and incubated at 37°C/5%CO2 for 2 hours to adhere. Media 
was then removed and replaced with conditioned media from iMEF.Vector and 
iMEF.tRNAiMet cells. The conditioned media was prepared by filtration through a 
0.45μm filter and 1:1 dilution with full growth media before being added to the 
iMEF.Vector cells. The iMEF.Vector cells were incubated with the conditioned 
media for 48 hours at 37°C/5%CO2. 
2.2.9.1 Sample preparation  
RNA was extracted from the above cells as described in 2.2.8. Samples were 
then ribodepleted using the RiboZero Magnetic Kit as per manufacturer’s 
instructions. Briefly, the magnetic beads of the RiboZero kit were washed with 
RNase-free water and resuspended in Resuspension Solution with RiboGuard 
RNase Inhibitor. 4μg RNA was added to the Ribo-Zero rRNA Reaction Buffer and 
Removal Solution and incubated at 68°C for 10 minutes, followed by RT 
incubation for 5 minutes. The probe-hybridised RNA samples were then added to 
the washed magnetic beads, vortexed for 10 seconds, and incubated at RT for 5 
minutes. Tubes were incubated at 50°C for 5 minutes and then transferred to a 
magnetic stand. The supernatant, containing the RNA sample depleted of rRNA, 
was transferred to a new RNase-free microcentrifuge tube and the RNA purified 
using the following modified protocol of the RNeasy MinElute Cleanup Kit. The 
RNA sample volume was adjusted to 100μL with RNase-free water and 350μL 
Buffer RLT added. Following mixing, 550μL 100% ethanol was added and the 
samples mixed gently by pipetting. The samples were transferred to an RNeasy 
MinElute spin column and centrifuged at 10,000rpm for 15 seconds. The flow 
through was discarded and the process repeated. The spin column was then 
transferred to a new collection tube, 500μL Buffer RPE was added to the spin 
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column followed by centrifugation at 10,000rpm for 15 seconds, to wash the 
column membrane. The flow through was discarded and 500μL 80% ethanol 
added to the spin column and the samples centrifuged at 10,000 rpm for 2 
minutes. The spin column was then transferred to a new collection tube, with 
the lid of the spin column open, and centrifuged at 13,000 rpm for 5 minutes. 
The spin column was then placed in a new RNase-free microcentrifuge tube and 
12μL RNase-free water added directly to the spin column. Samples were 
centrifuged at 13,000rpm for 1 minute to elute the RNA. The removal of 
ribosomal RNA was determined by showing the lack of 18S and 28S rRNA peaks on 
the RNA quality trace using the RNA 6000 Pico Kit and Bioanalyzer (Agilent 
Technologies) exactly as per manufacturer’s instructions.  
2.2.9.2 Sequencing and data analysis 
RNA-Seq was performed by Billy Clark, Molecular Technology Service, CR-UK 
Beatson Institute, Glasgow. Briefly, an Illumia TruSeq RNA Sample Prep Kit was 
used to prepare the samples, and sequencing was performed on the NextSeq500 
platform using a High Output 75 cycle kit. Data was analysed by Ann Hedley, 
Bioinformatics, CR-UK Beatson Institute, Glasgow.  
2.2.10 cDNA synthesis 
cDNA was prepared using a Quantitech Reverse Transcription Kit as per 
manufacturer’s instructions. In cases where the cDNA was being used to assess 
the expression of tRNAs, cDNA was prepared using 5, 10 and 20ng of RNA as 
template, to ensure the reaction was quantitative. In cases where the cDNA was 
being used to assess the expression of Pol II transcribed genes, 1μg of RNA was 
used as template. In each case, 2μL genomic DNA wipeout buffer was added to 
the RNA in a total volume of 14μL, samples were incubated at 42°C for 2 
minutes and then transferred to ice. A reverse transcription mix of 1μL 
Quantiscript reverse transcriptase + 4μL Quantiscript RT buffer +  1μL RT primer 
mix was then added to each sample, followed by incubation for 15 minutes at 
42°C and then 3 minutes at 95°C to inactivate the reverse transcriptase. 
Controls containing no reverse transcriptase were included to ensure there was 
no genomic DNA contamination. cDNA was stored at -20°C. 
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2.2.11 qRT-PCR 
Gene expression analysis (qRT-PCR) was conducted using SyBr green and the 
BioRad CFX platform in a 96 well plate set-up. A total reaction volume of 10μL 
per well was used, containing a 1:20 dilution of cDNA template + 1x PerfeCTa 
SYBR Green Fast Mix + 0.5μM forward primer + 0.5μM reverse primer (primer 
details provided in 2.1.4). Samples were plated in duplicate. In order to 
calculate reaction efficiency and enable quantification, standard curves were 
generated using serially diluted cDNA from combined samples. A no template 
control was also included to test for primer dimer formation. Reactions were 
conducted using a 3 step protocol, corresponding to 95°C for 3 mins, followed by 
40 cycles of 95°C for 20 seconds, 60°C for 20 seconds and 72°C for 20 seconds, 
with a final extension step of 72°C for 5 minutes and a melt curve from 65°C to 
95°C in 0.5°C increments. Data was collected and analysed in CFX Manager 
Software (BioRad).  
2.2.12 Western blotting   
After cells had reached 80 – 90% confluence, media was aspirated, the cells were 
placed on ice and washed in ice-cold PBS. Cells were lysed into either 1% SDS 
buffer or NDLB supplemented with protease inhibitors (50μg/mL leupeptin + 
50μg/mL aprotinin + 1mM AEBSF), as specified in the figure legends. For cell 
lysis, 150uL buffer was added per 10cm2 dish, the cells were scraped from the 
dish using a cell lifter, transferred into a 1.5mL microcentrifuge tube, passed 
through a 25G needle 5 times and centrifuged at 13,000rpm for 10 minutes, 4°C. 
The supernatant was removed and used immediately or stored at -20°C (in cases 
were phospho-proteins were being detected samples were always used 
immediately). 
SDS-PAGE electrophoresis was used to resolve protein samples. Samples were 
reduced in 1x NuPAGE sample buffer + 0.1M DTT at 95°C for 5 minutes and then 
loaded onto 4-12% or 10% pre-cast Novex Bis-Tris gels with MES or MOPs running 
buffer. The gel type and buffer used was dependent on the protein size and 
separation needed. Electrophoresis was performed at 120V until required 
separation was reached, as determined by visual separation of the full-range 
rainbow ladder.  
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The proteins were transferred from the gel to PVDF membrane by wet transfer 
using the NuPage transfer system and NuPage transfer buffer, at 40V for 2 hours. 
The membrane was blocked in 4% milk, or 4% BSA for phospho-antibodies, with 
gentle rocking at RT for 1 hour. The membrane was then incubated with the 
appropriate primary antibody diluted in 1% milk or 1% BSA (dependent on 
blocking solution used), at 4°C overnight with gentle shaking. The membrane 
was then washed three times with TBS-T, with gentle rocking for 10 minutes per 
wash. Following this, the membrane was incubated with the appropriate 
secondary antibody for 1 hour at RT with gentle shaking. The membranes were 
then washed three times for 10 minutes with TBS-T, and the blots then 
developed. In the case of integrin α5 detection, the secondary antibody was HRP 
conjugated and the membranes were incubated in ECL solution for 3 minutes 
followed by transfer to a film cassette and detection by autoradiography using x-
ray film and a Kodak X-Omat 488 x-ray processor. For the phospho-eIF2α blots, 
IRDye secondary antibodies and the LI-COR Aerius infrared imaging system was 
used for visualisation.         
2.2.13 Immunoprecipitation 
Magnetic dynabeads were coupled with the primary antibody of interest by one 
wash in PBS + 0.1% BSA, followed by incubation with antibody diluted in ice-cold 
PBS + 0.1% BSA. 1.5μg of antibody was used for each lysate undergoing 
immunoprecipitation. The dynabeads and antibody were then mixed for 1 hour 
at 4°C on a rotating wheel. Cells at 80-90% confluency were surface labelled 
with Sulfo-NHS-SS-Biotin, by aspirating their media, placing them on ice, 
washing them twice with ice-cold PBS, adding 0.13mg/mL Sulfo-NHS-SS-Biotin 
and rocking the cells gently for 1 hour at 4°C. Cells were then placed back on 
ice, washed twice with ice-cold PBS, PBS removed, and cells scraped into NDLB 
supplemented with protease inhibitors (50μg/mL leupeptin + 50μg/mL aprotinin 
+ 1mM AEBSF) using 100μL buffer per 10cm2 plate. The lysate was passed 
through a 25G needle 5 times, centrifuged at 13,000rpm for 10 minutes at 4°C, 
the supernatant removed and protein concentration determined using a Qubit 
Protein Assay and Qubit Fluorometer exactly as per manufacturer’s instructions 
(Life Technologies). The antibody-incubated dynabeads were then washed once 
in PBS and incubated with 500μg of each protein lysate. The dynabeads and 
lysates were mixed for 2 hours at 4°C on a rotating wheel. The bead slurry was 
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then washed four times in NDLB and the beads resuspended in 1x non-reducing 
NuPAGE loading buffer. The proteins were removed from the beads by 
incubating at 95°C for 10 minutes, resolved by SDS-PAGE electrophoresis, and 
visualised by western blot with streptavidin-conjugated HRP detection, as 
described in 2.2.12.    
2.2.14 Capture-ELISA 
Maxisorp 96 well microtiter plates were incubated with 50μL/well of primary 
antibody, diluted in ELISA coating buffer, overnight at 4°C with gentle shaking. 
Plates were washed once with PBS-T and blocked in 0.1% PBS-T + 5% BSA for 1 
hour at RT with gentle shaking.  Cells at 80-90% confluency were surface 
labelled with Sulfo-NHS-SS-Biotin, by aspirating their media, placing them on 
ice, washing them twice with ice-cold PBS, adding 0.13mg/mL Sulfo-NHS-SS-
Biotin and rocking the cells gently for 1 hour at 4°C. Cells were then placed back 
on ice, washed twice with ice-cold PBS, PBS removed, and the cells scraped into 
NDLB supplemented with protease inhibitors (50μg/mL leupeptin + 50μg/mL 
aprotinin + 1mM AEBSF) using 100μL buffer per 10cm2 plate. The lysate was 
passed through a 25G needle 5 times, centrifuged at 13,000rpm for 10 minutes 
at 4°C the supernatant removed and serial dilutions of the protein lysate made 
in NDLB. The BSA blocking solution was removed from the plate, the plate was 
washed twice with PBS-T, and incubated with the protein lysate overnight at 4°C 
with gentle shaking. Unbound protein was removed by washing three times in 
PBS-T and streptavidin-conjugated HRP was added (1:1000 dilution in PBS-T 0.1% 
BSA) for 1 hour at 4°C with gently shaking. Plates were extensively washed, 
three times with PBS-T and three times with PBS. ELISA development reagent 
was added and the plate incubated at room temperature for approximately 15 
minutes. The reaction was then stopped with 8M H2SO4 and the absorbance read 
at 490nm on a plate reader (Tecan).  
2.2.15 Internalisation assays 
1x106 cells per 10cm2 dish were incubated at 37°C/5%CO2 for 48 hours. Maxisorp 
96 well microtiter plates were incubated with 50μL/well of primary antibody 
diluted in ELISA coating buffer overnight at 4°C with gentle shaking. Cells were 
surface labelled with Sulfo-NHS-SS-Biotin by aspirating their media, placing them 
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on ice, washing them twice with ice-cold PBS, adding 0.13mg/mL Sulfo-NHS-SS-
Biotin and rocking the cells gently for 45 minutes at 4°C. Cells were washed 
twice with ice-cold PBS to remove excess biotin. At this point, plates of cells 
required for total protein measurement were kept on ice until cell lysis, whilst 
plates of cells required for the blank measurement were kept on ice until MesNa 
treatment. The remaining plates were used to measure internalisation of surface 
proteins. Cells were incubated with pre-warmed growth media at 37°C for the 
described time, followed by media aspiration plates were incubated on ice as 
cells were washed once with ice-cold PBS and once with biotin reduction buffer. 
To remove cell surface biotin, cells were incubated with 20mM MesNa in biotin 
reduction buffer for 1 hour at 4°C with gentle rocking. The reaction was 
quenched by adding 20mM IAA and incubating the cells at 4°C with gentle 
rocking for 10 minutes. The cells were then lysed at described in 2.2.14 and the 
levels of internalised biotinylated proteins determined by capture-ELISA as 
described in 2.2.14.      
2.2.16 Recycling assays  
The internalisation assay described in 2.2.15 was repeated with the following 
modifications to enable measurement of the amount of internalised biotinylated 
surface protein recycled to the cell surface. Following the removal of cell 
surface biotin by MesNa treatment, cells were incubated on ice and washed 
twice with ice-cold PBS. Pre-warmed growth media was then added to the cells 
and plates incubated at 37°C for the described recycling time. Media was then 
aspirated, and plates returned to ice, the cell surface biotin reduction step was 
repeated and the protocol continues as described in 2.2.15.  
2.2.17 Immunofluorescence  
Glass bottomed 3cm2 dishes were coated with 1μg/mL fibronectin at 
37°C/5%CO2 for 4 hours, washed once with PBS, and 7.5x104 cells were seeded 
into the dishes in full growth media and incubated overnight at 37°C/5%CO2. 
Media was removed, and cells fixed with 4% PFA at RT for 15 minutes. Cells were 
permeablised in PBS + 0.2% Triton-X100 at RT for 5 minutes, washed twice with 
PBS, and blocked in PBS + 1% BSA for 1 hour at RT. Following one PBS wash, 
primary antibody was added in blocking solution for 1 hour at RT. Following 
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three PBS washes, secondary antibody was added in blocking solution for 1 hour 
at RT. After two PBS washes, the cells were incubated with phalloidin stain, 
1:200 dilution in PBS, for 10 minutes at RT, then washed twice with PBS and 
mounted using Vectashield + DAPI. Cells were visualised by confocal microscopy 
using an Olympus FV-1000 microscope.    
2.2.18 Metabolic labelling  
Cells were grown to 80 - 90% confluence, washed twice with PBS and incubated 
for 30 minutes at 37°C/5% CO2 with DMEM minus methionine and cysteine, but 
supplemented with 10% dialysed FBS and 200μM L-Glutamine. Cells were 
trypsinised as described in 2.2.4.1, resuspended in the media described above 
supplemented with 0.07mCi EasyTag Express Protein Labelling Max 35S, and then 
incubated for 2 hours at 37°C/5% CO2. Cells were washed with, and scraped into, 
ice-cold PBS. 25μL of cell suspension was aliquoted for total label measurement, 
and 25μL of cell suspension was then added to BSA/NaN3 (1mg/mL BSA in 0.02% 
sodium azide) and precipitated by adding ice-cold 10% TCA solution, vortexing 
and then incubating the samples on ice for 30 minutes. The precipitated 
material was filtered onto Whatman GF/C 2.5cm filter paper, and the filters 
washed twice in ice-cold 10% TCA, twice in ice-cold 100% ethanol, and air dried 
for 30 minutes. The total count cell suspension was also spotted onto filter 
paper and dried. Scintillation fluid was added and filters analysed using a 
Microbeta Trilux scintillation counter (PerkinElmer). 
2.2.19 SILAC based mass spectrometry  
iMEF.Vector and iMEF.tRNAiMet cells were labelled with light (Arg0/Lys0) and 
heavy amino acids (Arg10/Lys8). Briefly, cells were passaged (as described in 
2.2.4.1) in SILAC DMEM containing light or heavy amino acids supplemented with 
10% FBS for 3 passages, and then transferred to media containing light or heavy 
amino acids supplemented with 10% dialysed FBS for 3 passages. Following full 
SILAC amino acid incorporation (as tested by David Sumpton, Proteomics, CR-UK 
Beatson Institute, Glasgow), cells were used in SILAC based mass spectrometry 
to assess quantitative changes in the secretome and cellular proteome.  
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2.2.19.1 Secretome 
1x106 cells were plated into a 10cm2 dish and cultured for 48 hours at 37°C/5% 
CO2, washed twice in PBS and transferred into serum-free media for 6 hours at 
37°C/5% CO2. Media was then collected and combined. In the case of the 
forward experiment iMEF.Vector cells labelled with light amino acids were 
combined with iMEF.tRNAiMet cells labelled with heavy amino acids, and in the 
reverse experiment iMEF.Vector cells labelled with heavy amino acids were 
combined with iMEF.tRNAiMet cells labelled with light amino acids. Media was 
centrifuged at 300g for 10 minutes at 4°C, supernatant was collected and 
centrifuged at 2000g for 10 minutes at 4°C, the supernatant was collected again 
and centrifuged at 10,000g for 30 minutes at 4°C. The collected media was then 
acidified to pH5 with 10% TFA and 10uL strataclean beads added per 1mL media. 
The media/bead slurry was then vortexed for 1 minute and incubated overnight 
on a rotor wheel at 4°C. Beads were collected by brief centrifugation and 
resuspended in NuPAGE loading buffer + 0.1M DTT, and boiled for 5 minutes at 
95°C. The supernatant was then loaded onto a 10% NuPAGE Bis-Tris gel and 
proteins separated by electrophoresis. The gel was coomassie stained and 
proteins analysed by quantitative mass spectrometry. Mass spectrometry was 
conducted by David Sumpton, Proteomics, CR-UK Beatson Institute, Glasgow. In 
short, gel slices were excised and destained before digestion. Proteins were 
reduced in 10mM DTT and alkylated with 50mM IAA, washed with 50% ACN/50mM 
ABC, dried in speedvac and digested with 0.05μg/mL trypsin in 50mM ABC 
overnight. Extracted digests were stage tipped and analysed on Orbitrap Elite. 
Data was searched and quantified against swissprot MOUSE using MaxQuant. 
2.2.19.2 Cellular proteome 
1x106 of each of the SILAC labelled cell lines described above were plated into 
10cm2 dishes and cultured for 48 hours at 37°C/5% CO2. Cells were then washed 
twice in PBS and lysed into 4% SDS lysis buffer. Samples were sonicated and 
centrifuged at 13,000rpm for 5 minutes at RT. Protein supernatant was collected 
and the concentration measured using Qubit fluorometric quantitation (Life 
Technologies). Protein samples were then subjected to quantitative mass 
spectrometry by David Sumpton, Proteomics, CR-UK Beatson Institute, Glasgow. 
Briefly, lysates from heavy and light SILAC labelled cells were mixed 1:1. In the 
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case of the forward experiment iMEF.Vector cells labelled with light amino acids 
were combined with iMEF.tRNAiMet cells labelled with heavy amino acids, and in 
the reverse experiment iMEF.Vector cells labelled with heavy amino acids were 
combined with iMEF.tRNAiMet cells labelled with light amino acids. A total of 
500μg of protein per experiment was reduced, alkylated and digested using the 
small FASP method. The digests were separated on a high pH reverse phase 
column and 22 fractions were collected. Each fraction was dried down, re-
dissolved in 5% acetonitrile/0.25% formic acid and analysed on Orbitrap Velos 
(LC-MS). Data was searched and Quantified against swissprot MOUSE using 
MaxQuant. 
2.2.20 ECM generation 
2.2.20.1 ECM derived from control and tRNAiMet overexpressing cells 
Cell derived matrix was generated from primary MEFs and iMEFs. For timelapse 
microscopy and immunostaining experiments ECM was derived in 6-well tissue 
culture plastic plates, and for AFM measurements ECM was generated in glass 
bottom 3cm2 dishes. In each case, plates/dishes were coated in 0.2% gelatin and 
incubated at 37°C/5% CO2 for 1 hour. Following two PBS washes, they were then 
cross-linked with 1% glutaraldehyde at RT for 30 minutes. After two PBS washes, 
plates were quenched in 1M glycine at RT for 20 minutes, washed twice with 
PBS, and incubated in full growth media at 37°C/5%CO2 for 30 minutes. 2x105 
cells per well were seeded and cells incubated at 37°C/5%CO2 overnight (or until 
cells fully confluent). Once cells reached confluence, the media was changed to 
full growth media containing 50μg/mL ascorbic acid, and the ascorbate 
containing media refreshed every other day for seven days. Media was then 
aspirated, cells washed once with PBS containing calcium and magnesium (D-
PBS), and then incubated with extraction buffer for 2 minutes at RT. Following 
two D-PBS washes, residual DNA was digested with 10μg/mL DNase I in D-PBS at 
37°C/5%CO2 for 30 minutes. Following two D-PBS washes, cell derived matrices 
were stored at 4°C in D-PBS containing 100U/mL penicillin streptomycin and 
0.25μg/mL fungizone. Prior to use, cell derived matrices were washed twice 
with D-PBS and incubated in full growth media for 30 minutes at 37°C/5%CO2.   
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2.2.20.2 ECM derived from conditioned media treated cells 
In cases where conditioned media from control or tRNAiMet overexpressing cells 
was used to generate the ECM, the above protocol was used on iMEF.Vector 
cells, but the media used to refresh the cells upon confluence, and every other 
day thereafter, was conditioned media. The conditioned media was obtained 
from 1x106 cells per 10cm2 dish that were plated for 48hrs, filtered through a 
0.45μm filter, diluted 1:1 with fresh growth media and supplemented with 
50μg/mL ascorbic acid. In each case, the cells providing the conditioned media 
were also cultured in the presence of 50μg/mL ascorbic acid for 48 hours. 
2.2.20.3 ECM derived from microvesicle free conditioned media 
In cases where microvesicle depleted conditioned media was used to generate 
ECM, cell derived matrices were made as described in 2.2.20.2, however the 
conditioned media used was depleted of microvesicles by sequential 
centrifugation as follows: conditioned media collected and centrifuged at 300g 
for 10 minutes at 4°C, supernatant collected and centrifuged at 2000g for 10 
minutes at 4°C, supernatant collected and centrifuged at 10,000g for 30 minutes 
at 4°C, supernatant collected and centrifuged at 100,000g for 70 minutes at 
4°C. The supernatant collected from the final centrifugation step corresponded 
to microvesicle free conditioned media.    
2.2.20.4 ECM derived from conditioned media from siRNA treated cells 
In cases where conditioned media collected from siRNA treated cells was used to 
generate ECM, cell derived matrices were made as described in 2.2.20.2, 
however the conditioned media was collected from cells 48 hours post-
nucleofection with siRNA as described in 2.2.4.4, with 50μg/mL ascorbic acid 
included in the post-transfection growth media.  
2.2.21 Immunostaining 
ECM was generated as described in 2.2.20 and washed twice with D-PBS. 
Matrices were then fixed with 4% PFA for 15 minutes at RT and then washed five 
times in PBS + 0.1% Tween-20 for 5 minutes at RT with gentle shaking. The ECM 
was blocked with Odyssey blocking buffer for 90 minutes at RT with gentle 
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shaking, and then incubated overnight with primary antibody diluted in blocking 
buffer at 4°C with gentle shaking. The matrices were then washed five times in 
PBS + 0.1% Tween-20 for 5 minutes at RT with gentle shaking, and incubated 
with a fluorescently labelled secondary antibody, 1:10,000 dilution in blocking 
buffer for 1 hour at RT with gentle shaking and protected from light. The ECM 
was washed five times in PBS + 0.1% Tween-20 for 5 minutes at RT with gentle 
shaking. The final wash was aspirated and fluorescence quantified using the 
Aerius infrared imaging system (LI-COR). 
2.2.22 Atomic force microscopy  
ECM was generated as described in 2.2.20, and atomic force microscopy (AFM) 
conducted by Ellie Pulleine, School of Engineering, University of Glasgow. 
Briefly, to measure the thickness of ECMs following a wound scratch, AFM force 
spectroscopy and contact imaging were performed using a JPK NanoWizard II Bio 
AFM in combination with a Bruker MLCT cantilever. A Nanoworld Arrow TL-1 
cantilever with bead attached was used for force spectroscopy. 
2.2.23 Migration assays 
2.2.23.1 Directional migration  
2x105 cells were plated in 6 well tissue culture plates and incubated at 
37°C/5%CO2 until they reached confluence. A vertical wound was then scratched 
down the centre of each well using a 200μL pipette tip. Cells were washed twice 
with full growth media, and incubated with 4mL media per well. Cell migration 
was visualised by timelapse microscopy (Nikon microscope), images were taken 
at 10 minute intervals for 17 hours, at 4 different positions per well. Single cell 
tracking was used to quantify the speed of cell migration using the manual 
tracking plugin of Image J.    
2.2.23.2 Random migration  
Cells were plated at a density of 1x105 cells per well in 6 well tissue culture 
plates and incubated at 37°C/5%CO2 for a minimum of 2 hours to adhere. Cell 
migration was visualised by timelapse microscopy (Nikon microscope), images 
were taken at 10 minute intervals for 17 hours, at a minimum of 4 different 
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positions per well. Single cell tracking was used to quantify the speed of cell 
migration using the manual tracking plugin of Image J.  
2.2.24 Breast cancer tissue microarray & 
immunohistochemistry 
The breast cancer TMA was produced by Clare Orange (TMA and Image Analysis 
Unit Manager, University Department of Pathology, Southern General Hospital), 
from a cohort of 544 breast cancer patients presenting with invasive breast 
cancer in the West of Scotland between 1995 and 1998. Full clinico-pathological 
analysis and 10 year follow-up data was available for the TMA. The slides were 
stained for collagen II by Colin Nixon and the histology service, CR-UK Beatson 
Institute, Glasgow. Briefly, slides were dewaxed in xylene and passed through 
ethanol for rehydration (2 × 100% ethanol and 1 × 70% ethanol). Heat-induced 
epitope retrieval was conducted in pH6 sodium citrate retrieval buffer. 
Endogenous peroxidases were blocked, and a collagen II specific antibody was 
applied at a 1:300 dilution for 35 minutes at RT. Slides were then incubated with 
Mouse EnVision for 30 minutes, and the staining was visualized with DAB and 
counterstained with Haematoxylin. Slides were scanned at 20x magnification 
using NanoZoomer NDP scanner (Hamamatsu) and were then stored on a 
dedicated server and available for viewing using Slidepath Digital Image Hub. 
Collagen II expression was scored as low, medium or high depending on the 
predominant intensity of stromal staining. 10% of the TMA was double scored by 
Iain MacPherson, CR-UK Beatson Institute, Glasgow. Kaplan Meier survival 
analysis was performed to estimate differences in disease-free survival according 
to collagen II expression levels.  Statistical analysis was performed using SPSS 
statistical package (version 19 for Windows), with assistance from Joanne 
Edwards, University of Glasgow, and Liane McGlynn and Iain MacPherson, CR-UK 
Beatson Institute, Glasgow.  
2.2.25 Statistics 
Statistical analysis was performed on all relevant experiments. To compare two 
data-sets unpaired t-tests were performed if the data was normally distributed, 
or a Mann-Whitney test if the data was not normally distributed. To compare 
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more than two data sets, ANOVA tests were used if the data was normally 
distributed, and a Kruskal-Wallis test if the data was not normally distributed. In 
the case of survival data a Log-rank Mantel-Cox test was used. Statistical 
significance is annotated within the figures and the associated p-values are 
indicated in each figure legend, with p<0.05 considered as significant.  
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Chapter 3 The influence of tRNAiMet levels on 
fibroblast behaviour 
3.1 Introduction 
Fibroblasts play a key role in the progression of malignant disease, and 
understanding how CAFs differ from their normal counterparts could provide new 
opportunities to target the tumour stroma and develop cancer therapies. 
Compared to normal fibroblasts (NFs), CAFs have a higher capacity for cell 
proliferation, migration and invasion, and a number of studies have used gene 
expression analysis to investigate the mechanisms behind these functional 
differences (Finak et al., 2008, Singer et al., 2008, Bauer et al., 2010). Increased 
CAF proliferation can be ascribed to activation of signalling pathways that 
converge to regulate expression of oncogenes, such as c-Myc (Peng et al., 2013, 
Tang et al., 2015a). c-Myc has been widely implicated in tumourigenesis through 
its pathological activation in cancer cells (reviewed recently in (Gabay et al., 
2014)), but the impact of c-Myc overexpression on fibroblast behaviour, and how 
that can influence tumour growth, tends to be overlooked. Indeed, oncogene 
and tumour suppressor pathways, including c-Myc, directly regulate Pol III 
transcription and can increase tRNA expression levels (Felton-Edkins et al., 
2003). Changes in a cells tRNAome can influence its proliferation or 
differentiation state and this property can be exploited by cancer cells (Gingold 
et al., 2014), and so it is possible that altered tRNA expression in stromal cells 
could also provide a mechanism to enable CAFs to support tumour progression.  
We therefore sought to characterise the effects of tRNAiMet overexpression on 
fibroblast behaviour, and understand whether any differences that we identified 
could be ascribed to the canonical or non-canonical functions of tRNAs. The 
primary role of tRNAiMet is in the initiation of protein synthesis, where it 
associates with eIF2·GTP to form the ternary complex (TC). Upon binding to the 
40S ribosomal subunit to form the 43S pre-initiation complex, it can then 
associate with additional initiation factors and scan through the 5’ UTR to find 
the correct start codon and initiate translation (Kapp and Lorsch, 2004). 
However, numerous non-canonical functions of tRNAs have also been described, 
raising the possibility that phenotypic effects of tRNA overexpression may not be 
due to direct influences on the protein synthesis machinery. tRNAs have been 
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implicated in apoptosis through their ability to associate directly with 
cytochrome c to inhibit caspase activation (Mei et al., 2010b), and the discovery 
of functional tRNA derived fragments (tRFs) also provides additional mechanisms 
by which tRNAs can affect cell function. Processing of tRNAs can generate tRFs, 
resulting in one of the most abundant categories of small RNAs. Interestingly, 
these tRFs also have increased expression in a variety of cancer cell lines (Lee et 
al., 2009a). Moreover, overexpression of tRF-1001, a tRF derived from the 3’ end 
of Ser-TGA pre-tRNA was shown to induce proliferation in prostate cancer cells, 
while other work has shown that tRNA fragments can modulate the DNA damage 
response and cell proliferation in lymphoma (Lee et al., 2009a, Maute et al., 
2013).  
This chapter will therefore characterise the cellular effects of tRNAiMet 
overexpression, and specifically describe how increased tRNAiMet levels can 
affect the motile behaviour of fibroblasts, addressing some aspects of the 
cellular mechanisms through which tRNAiMet may exert these effects.
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3.2 Results 
3.2.1 Generation of tRNAiMet overexpressing immortalised 
fibroblast cell lines  
To characterise the influence of tRNAiMet expression on fibroblast behaviour we 
generated pools of immortalised mouse embryonic fibroblasts (iMEFs) which 
overexpressed tRNAiMet (iMEF.tRNAiMet) or an empty vector as control 
(iMEF.Vector), and used qPCR to quantify the level of  tRNAiMet overexpression 
(Figure 3-1). Two pairs of iMEF pools were used throughout the subsequent 
experiments, with pools 1 and 2 having approximately 15 and 5-fold increases in 
tRNAiMet expression respectively, corresponding to the range of increased tRNA 
expression seen in human breast tumours compared to normal tissue (Pavon-
Eternod et al., 2009). 
 
Figure 3-1- Overexpression of tRNAiMet in immortalised mouse embryonic fibroblasts. 
qPCR of tRNAiMet expression in pools of iMEFs, all samples are normalised to ARPP P0 and are 
presented relative to iMEF.Vector control, n=3, +/- SEM, unpaired t-test, *** p <0.0005. 
3.2.2 Overexpression of tRNAiMet does not affect cellular protein 
synthesis 
Owing to the essential role of tRNAiMet in initiating translation, we sought to 
understand how increasing the levels of tRNAiMet might affect the rate of cellular 
protein synthesis. 35S-methionine incorporation was used to compare the 
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biosynthesis of proteins between iMEF.tRNAiMet and iMEF.Vector cells, and 
showed that increased levels of tRNAiMet did not significantly change the amount 
of radiolabel incorporated into newly synthesised TCA-precipitatable proteins 
(Figure 3-2). Increasing the amount of tRNAiMet available for TC formation is 
therefore not sufficient to affect the overall rate of cellular protein synthesis in 
immortalised fibroblast cell lines.   
 
Figure 3-2- tRNAiMet does not affect the rate of cellular protein synthesis. 
35S-methionine incorporation was used to assess changes the synthesis of new proteins. Cells 
were depleted of methionine and cysteine for 30 minutes at 37°C/5% CO2, then trypsinised and 
resuspended in media containing 0.07mCi EasyTag Express Protein Labelling Max 35S and 
incubated at 37°C/5% CO2 for 2 hours. TCA precipitation was used to stop and concentrate the 
reaction, and the ratio of TCA precipitated radiolabel to total radiolabel calculated, n=5, +/- SEM, 
unpaired t-test, ns = not significant.   
3.2.3 Overexpression of tRNAiMet does not affect cell proliferation 
Previous publications have not only highlighted the ability of CAFs to proliferate 
faster than  NFs (Peng et al., 2013, Tang et al., 2015a), but have also shown that 
increased levels of tRFs can drive increased cancer cell proliferation (Lee et al., 
2009a).  Furthermore, others have found that increased levels of tRNAiMet itself is 
able to drive an increase in proliferation of human epithelial cells (Pavon-
Eternod et al., 2013). We therefore assessed the effects of tRNAiMet 
overexpression on the proliferation of iMEFs, and found that overexpression of 
tRNAiMet did not affect the rate at which they proliferated (Figure 3-3).  
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Figure 3-3- tRNAiMet does not affect the rate of cell proliferation. 
1x105 iMEF.Vector and iMEF.tRNAiMet cells were plated in 6 well tissue culture plates and cell 
number counted every day for 4 days, corresponding to the cells reaching 80 – 90% confluence, 
n=3, +/- SEM. 
In addition to counting total cell number, we also used FACS analysis to visualise 
propidium iodide (PI) uptake to ensure that tRNAiMet overexpression was not 
affecting cell viability. PI is a membrane impermeant dye that binds double 
stranded DNA and so is excluded from viable cells. FACS analysis showed that 
tRNAiMet overexpression did not affect the viability of iMEFs (Figure 3-4). These 
FACS-based analyses also indicated that side scatter from iMEF.tRNAiMet and 
iMEF.Vector cells was not significantly different, suggesting no difference in 
ribosome content between the two cell lines and reinforcing the lack of effect 
on total protein synthesis. This analysis also showed no differences in forward 
scatter between iMEF.tRNAiMet and iMEF.Vector cells, indicating that tRNAiMet 
levels do not necessarily influence cell size (Figure 3-4). Cell size is intrinsically 
linked to growth and proliferation, and so these data again reinforce the view 
that tRNAiMet levels do not influence these processes. 
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Figure 3-4- tRNAiMet does not affect cell viability, granularity or size. 
(A) Representative FACS plots. Duplicate suspensions of 1x106 iMEF.Vector and iMEF.tRNAiMet 
pool 1 cells were prepared in FACS buffer (PBS + 1% BSA + 0.5μg/mL propidium iodide) and 
FACS used to assess cell viability via PI uptake, cell granularity by side scatter reading, and cell 
size by forward scatter reading. (B) Quantification of FACS analysis, n=3, +/- SEM, unpaired t-test, 
ns = not significant. 
3.2.4 Overexpression of tRNAiMet does not affect energy 
metabolism 
Published data have shown that tRNAs are able to regulate apoptosis by binding 
to cytochrome c and inhibiting caspase activation (Mei et al., 2010b). 
Cytochrome c, however, is also a component of the mitochondrial electron 
transport chain, and so plays an important role in generating mitochondrial 
membrane potential to drive ATP formation. It is therefore possible that tRNAs 
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may play a role in regulating electron transport and oxidative phosphorylation 
(Mei et al., 2010a). We used the XFp Extracellular Flux Analyser (Seahorse 
Bioscience) to determine whether tRNAiMet overexpression had any effect on 
energy metabolism in iMEFs. An XF Cell Mitochondrial Stress Test was conducted 
on iMEF.Vector and iMEF.tRNAiMet cells using modulators of respiration to target 
electron transport chain components to test for differences in metabolic 
capacity following tRNAiMet overexpression. Oligomycin inhibits the ATP synthase 
(Complex V) to decrease oxygen consumption rate (OCR), FCCP affects the inner 
mitochondrial membrane to disrupt the electron gradient and increase the OCR, 
and Rotenone and Antimycin A target Complex I and III respectively to inhibit 
electron transport and electron transfer (Figure 3-5A). Sequential addition of 
these compounds to iMEF.Vector and iMEF.tRNAiMet cells, and measurement of 
the resulting changes in OCR, showed that across multiple pools of cells there 
was no significant difference in the levels of basal respiration, ATP production, 
proton leak, maximal respiration, spare respiration capacity or non-
mitochondrial respiration following tRNAiMet overexpression (Figure 3-5B), and so 
increased levels of this one particular tRNA in fibroblasts did not detectably 
affect their capacity for energy metabolism. 
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Figure 3-5- tRNAiMet does not affect energy metabolism. 
(A) A schematic representation of the parameters measured by the XFp Extracellular Flux Analyser 
(Schematic adapted from www.seahorsebio.com). The XF Cell Mitochondrial Stress Test uses 
Oligomycin to inhibit ATP synthase, FCCP to disrupt the electron gradient, and Rotenone and 
Animycin A to inhibit electron transport and electron transfer. The measured oxygen consumption 
rate then indicates the parameters described in the figure. (B) Graphical representation of the 
results of the XF Mitochondrial Stress Test in iMEF.Vector and iMEF.tRNAiMet pool 1 and 2 cells, no 
significant difference consistent with tRNAiMet overexpression, n=1, +/- standard deviation of 
technical replicates.  
3.2.5 Overexpression of tRNAiMet does not affect cell spreading 
Secretion and remodelling of ECM proteins by fibroblasts plays a key role in 
defining the tumour microenvironment. However, the adhesive and migratory 
properties of fibroblasts also contribute to the establishment of a 
microenvironment that supports tumour growth. The way in which a cell is able 
to adhere and spread on a substrate is an important property, and in the case of 
cancer cells it can reflect their metastatic potential. With respect to stromal 
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cells, the adherence of fibroblasts can influence their ability to establish a niche 
to promote tumour growth, and so with this in mind we assessed the ability of 
the iMEFs to adhere and spread following tRNAiMet overexpression. By measuring 
the cell area at various times following adherence to plastic, we found that 
there was no significant difference in the rate of cell spreading, or the final area 
of fully spread cells, between iMEF.Vector and iMEF.tRNAiMet cells (Figure 3-6) 
suggesting that tRNAiMet overexpression did not exert any influence on the 
adhesive properties of fibroblasts. 
 
Figure 3-6- tRNAiMet does not affect cell spreading. 
1x105 iMEF.Vector and iMEF.tRNAiMet cells were plated on plastic and imaged immediately for 2 
minute intervals over the course of 2 hours by timelapse microscopy. Area of cell spreading was 
measured in Image J, data represents area of 40 cells over n=3 independent experiments, +/- 
SEM. 
3.2.6 Overexpression of tRNAiMet increases cell migration  
Cell migration plays a pivotal role in tumour progression, and although a key 
determinant of metastatic dissemination is the increased migration of cancer 
cells themselves, an increase in the migratory ability of associated stromal cells 
is also essential to overcome a number of rate-limiting factors in tumour 
progression (Joyce and Pollard, 2009). We therefore used timelapse microscopy 
to study migration of iMEF.Vector and iMEF.tRNAiMet cells to determine whether 
increasing the expression of tRNAiMet could influence fibroblast migration. 
Wound-scratch assays of cells directionally migrating into a wound on plastic 
showed that iMEF.tRNAiMet cells had an increased cell speed compared to 
iMEF.Vector control cells (Figure 3-7A). This tRNAiMet–driven increase in cell 
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migration was also observed when sub-confluent cells were migrating randomly 
on plastic (Figure 3-7B).  
 
Figure 3-7- Overexpression of tRNAiMet increases speed of cell migration. 
Cell migration was recorded by timelapse microscopy over a 17 hour time course for (A) confluent 
iMEF.Vector and iMEF.tRNAiMet cells migrating into a wound on plastic, and (B) subconfluent 
iMEF.Vector and iMEF.tRNAiMet cells randomly migrating on plastic. In each case the data 
represent the speed of 30 – 40 cells per experiment calculated using manual tracking in Image J 
over the first 200 minutes period (were 200 minutes corresponds to the time taken for the wound to 
close in iMEF.tRNAiMet cells), n=3, box and whisker plot represents 5-95 percentile,  Kruskal-Wallis 
test, **** p < 0.0001, **p<0.01.   
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3.2.7 Overexpression of tRNAiMet increases cell migration through 
a mechanism that does not involve synthesis of collagen II 
In the following chapter the ability of tRNAiMet to influence cell migration 
through non-cell autonomous mechanisms will be discussed. This work found 
that overexpression of tRNAiMet influences the ECM secreted by fibroblasts, 
specifically through generation of a collagen II-rich matrix that supports 
increased cell migration. Because we found that tRNAiMet overexpressing cells 
were able to increase secretion of soluble ECM components to produce a matrix 
that supports increased cell migration, we tested the ability of conditioned 
media from tRNAiMet overexpressing cells to influence the migration of control 
iMEFs on plastic. Pre-treatment and continued incubation of iMEF.Vector cells 
with conditioned media from iMEF.tRNAiMet cells did not increase the speed of 
cells migrating on plastic (Figure 3-8).  
 
Figure 3-8- Conditioned media from tRNAiMet overexpressing cells does not affect cell 
migration. 
iMEF.Vector cells were plated at 1x105 cells/well and incubated at 37°C/5% CO2 for 2 hours to 
adhere on plastic. Cells were then incubated with conditioned media from iMEF.Vector and 
iMEF.tRNAiMet cells for a further two hours, and random migration in the presence of the 
conditioned media recorded by timelapse microscopy over a 17 hour time course and analysed in 
ImageJ. Data represents the speed of 30 – 40 cells per experiment calculated using manual 
tracking in Image J over the 17 hour time course, n=3, box and whisker plot represents 5-95 
percentile,  Kruskal-Wallis test, ns = not significant. 
As data presented in Chapter 4 specifically suggests that increased collagen II 
secretion is responsible for the tRNAiMet-driven non-cell autonomous effects on 
cell migration, we also proceeded to use siRNA to knockdown collagen II 
expression in iMEF.tRNAiMet cells and assessed its effect on their migration. 
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Knockdown of collagen II in iMEF.tRNAiMet cells had no effect on their migration 
speed (Figure 3-9), indicating that the way in which tRNAiMet levels influence 
fibroblast migration is mechanistically distinct from the non-cell autonomous 
control of cell migration described in the next chapter. 
 
Figure 3-9- siRNA of collagen II does not affect tRNAiMet-driven fibroblast migration.  
(A) qPCR was used to quantify collagen II levels in iMEF.tRNAiMet cells transfected with a NT or 
collagen II specific siRNA, all data normalised to ARPP P0 and presented relative to expression in 
the NT siRNA iMEF.tRNAiMet treated cells. Data presented is representative of one of the n=3 
biological repeats, +/- standard deviation of technical replicates, 2 way ANOVA, *p<0.05. (B) 
iMEF.tRNAiMet cells transfected with NT or collagen II specific siRNA were trypsinised 24 and 48 
hours post transfection, plated at 1x105 cells/well and incubated at 37°C/5% CO2 for 2 hours to 
adhere on plastic. Random migration was recorded by timelapse microscopy over a 17 hour time 
course and analysed in ImageJ. Data represents the speed of 30 – 40 cells per experiment 
calculated using manual tracking over the 17 hour time course, n=3, box and whisker plot 
represents 5-95 percentile, Kruskal-Wallis test, ns = not significant. 
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3.2.8 tRNAiMet–driven fibroblast migration is dependent on ternary 
complex formation 
We wanted to consider whether the mechanism which enables tRNAiMet to drive 
increased cell migration is associated with its canonical function in protein 
synthesis. The role of tRNAiMet in translation initiation is dependent on its ability 
to associate with eIF2 and GTP to form the ternary complex (TC) (Sonenberg and 
Hinnebusch, 2009). Regulation of translation initiation can be controlled by the 
phosphorylation status of initiation factors. Phosphorylation of eIF2α reduces TC 
formation and inhibits global translation initiation, and this phosphorylation 
event can be activated by exposure to cell stresses. Whilst reduced TC formation 
decreases levels of global protein synthesis, it increases the translation of 
specific mRNAs including stress-related mRNAs and other transcripts that have 
upstream open reading frames (uORFs). To determine whether differential TC 
formation was involved in tRNAiMet-driven cell migration we assessed the levels 
of phospho-eIF2α in the iMEF.Vector and iMEF.tRNAiMet cell lines. Western blots 
showed no significant difference in phospho-eIF2α levels following tRNAiMet 
overexpression, indicating that the increase in migration driven by tRNAiMet was 
not dependent on absolute differences in phospho-eIF2α expression (Figure 
3-10). 
 
Figure 3-10- Endogenous levels of phospho-eIF2α are unchanged by overexpression of 
tRNAiMet.  
iMEF.Vector and iMEF.tRNAiMet cells were plated at 1x105cells/well overnight at 37°C/5% CO2, 
lysed into 1% SDS lysis buffer and levels of phospho-eIF2α determined by western blot.   
Despite detecting no difference in the endogenous levels of phospho-eIF2α 
following tRNAiMet overexpression, it is possible that cells may have different 
phospho-eIF2α requirements following shifts in TC availability. Therefore, to 
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further investigate the dependency of tRNAiMet-driven cell migration on TC 
levels, two additional methods were used to manipulate eIF2α phosphorylation. 
The phosphatase inhibitor, salubrinal, can increase the levels of phospho-eIF2α 
(by inhibiting phospho-eIF2α dephosphorylation). Conversely, overexpression of 
the protein phosphatase regulatory subunit, GADD34, can decrease the levels of 
phospho-eIF2α (by recruiting protein phosphatase 1 to dephosphorylate phospho-
eIF2α). We found that salubrinal treatment specifically increased the migration 
speed of iMEF.Vector cells, but did not influence migration of tRNAiMet 
overexpressing cells (Figure 3-11), while transient transfection of a GADD34-
expressing construct into fibroblasts decreased the ability of tRNAiMet to promote 
the migration of iMEF.tRNAiMet cells (Figure 3-12). Taken together these data 
indicate that the TC influences cell migration, and that overexpression of 
tRNAiMet modifies the way in which the migratory machinery responds to 
alterations in TC levels. 
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Figure 3-11- The tRNAiMet driven increase in cell speed can be recapitulated by increasing 
levels of phospho-eIF2α in control cells.  
(A) Western blot to determine the concentration of salubrinal that increases phospho-eIF2α levels. 
iMEF.tRNAiMet cells were plated at 1x105 cells/well and incubated at 37°C/5% CO2 for 2 hours to 
adhere to plastic. Media was then replaced to contain salubrinal or corresponding DMSO control, 
and cells incubated overnight. Lysates were made using 1% SDS lysis buffer, and levels of 
phospho-eIF2α determined by western blot. (B) iMEF.Vector cells and iMEF.tRNAiMet were plated 
at 1x105 cells/well and incubated at 37°C/5% CO2 for 2 hours to adhere to plastic. Cells were then 
incubated with media containing 75μM salubrinal, or corresponding DMSO control for 2 hours 
before using timelapse microscopy to record random migration over a 17 hour time course in media 
containing salubrinal or corresponding DMSO control. Data represents the speed of 30 – 40 cells 
per experiment calculated using manual tracking over the 17 hour time course, n=3, box and 
whisker plot represents 5-95 percentile,  Kruskal-Wallis test, **** p < 0.0001, ns = not significant.  
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Figure 3-12- The tRNAiMet-driven increase in cell speed is influenced by manipulating levels 
of the ternary complex. 
iMEF.Vector and iMEF.tRNAiMet cells were transfected with a GADD34 containing construct 48 
hours prior to (A) lysis into 1% SDS lysis buffer, were levels of phospho-eIF2α were then 
determined by western blot. (B) 1x105 cells/well were incubated at 37°C/5% CO2 for 2 hours to 
adhere to plastic and random migration then recorded by timelapse microscopy over a 17 hour time 
course. Data represents the speed of 30 – 40 cells per experiment calculated using manual 
tracking over the 17 hour time course, n=3, box and whisker plot represents 5-95 percentile, 
Kruskal-Wallis test, **** p < 0.0001. 
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Although total levels of protein synthesis are not increased following tRNAiMet 
overexpression (Figure 3-2) the results of the salubrinal and GADD34 experiments 
indicate that the effects of tRNAiMet on cell migration may be due to the role of 
the TC in translation of a small subset of mRNAs. To investigate this we used 
cycloheximide, an inhibitor of protein synthesis, to determine whether synthesis 
of new protein was required for the increase in migration driven by tRNAiMet. 
Although addition of cycloheximide inhibited protein biosynthesis (Figure 3-13A), 
it was unable to inhibit the increase in migration induced by tRNAiMet 
overexpression (Figure 3-13B&C). Cycloheximide exerts its effects through 
blocking the translocation step of elongation, and so does not affect the actual 
formation of the TC. Collectively this data therefore indicates that the effect of 
tRNAiMet on cell migration is influenced by the TC, but is not dependent on 
translational elongation and the synthesis of new proteins. 
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Figure 3-13- Cycloheximide does not inhibit tRNAiMet-driven cell migration.  
(A) 35S-methionine incorporation was used to ensure the cycloheximide concentrations used were 
inhibiting the synthesis of new proteins. Cells were pretreated with 0, 0.5 and 5μg/mL 
cycloheximide for 1 hour and then depleted of methionine and cysteine for 30 minutes at 37°C/5% 
CO2 in media containing the described cycloheximide concentrations. Cells were then trypsinised 
and resuspended in media containing 0.07mCi EasyTag Express Protein Labelling Max 35S 
including the described cycloheximide concentrations and incubated at 37°C/5% CO2 for 2 hours. 
TCA precipitation was used to stop and concentrate the reaction, and the ratio of TCA precipitated 
radiolabel to total radiolabel calculated, n=2, +/- SEM of biological replicates, ANOVA, **** p < 
0.0001. (B)  iMEF pool 1 cells were pretreated with 0, 0.5 and 5μg/mL cycloheximide for 1 hour and 
then trypsinised, replated at 1x105 cells/well in media containing the cycloheximide concentrations 
described and incubated at 37°C/5%CO2 for 2 hours to adhere to plastic. Random migration was 
then recorded by timelapse microscopy over a 17 hour time course. The data represents the speed 
of 30 – 40 cells per experiment, calculated using manual tracking in Image J over the first 200 
minute period, n=3, box and whisker plot represents 5-95 percentile, Kruskal-Wallis test, **** p < 
0.0001. (C) iMEF pool 2 cell migration as described in (B).  
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3.2.9 tRNAiMet–driven cell migration is dependent on integrin α5β1 
-fibronectin association 
To provide further insight into the mechanism by which tRNAiMet promotes 
increased cell migration, we determined the integrin-dependence of tRNAiMet-
driven cell motility.  We assessed the ability of iMEF.Vector and iMEF.tRNAiMet 
cells to migrate on surfaces coated with increasing concentrations of 
fibronectin. From this it was clear that the difference in migration speed 
between control and tRNAiMet overexpressing fibroblasts was abrogated when 
cells were plated onto fibronectin-coated surfaces (Figure 3-14).  At a low 
coating concentration (0.25μg/mL) this was owing to the ability of this ECM 
protein to increase the migration speed of control cells, whereas higher 
fibronectin concentrations tended to inhibit cell movement so that there was no 
discernible difference between the migration speed of iMEF.Vector and 
iMEF.tRNAiMet cells. 
 
Figure 3-14- Fibronectin negates the increase in cell migration driven by tRNAiMet. 
Plates were coated with the described concentration of fibronectin for 2 hours prior to cell plating. 
iMEF.Vector and iMEF.tRNAiMet cells were plated at 1x105 cells/well and incubated at 37°C/5%CO2 
for 2 hours to adhere. Timelapse microscopy was used to record random migration over a 17 hour 
time course. The speed of 30 – 40 cells was calculated using manual tracking in Image J over the 
first 200 minute period, n=3, box and whisker plot represents 5-95 percentile,  Kruskal-Wallis test, 
**** p < 0.0001, ns = not significant. 
Integrin α5β1 is the primary receptor for fibronectin, and so we assessed the 
ability of integrin α5β1 to influence tRNAiMet–driven cell migration. An antibody 
that binds and blocks the fibronectin binding site of integrin α5β1 (mAb16) 
inhibited the migration of tRNAiMet overexpressing fibroblasts while not affecting 
the movement of iMEF.Vector cells (Figure 3-15). The involvement of α5β1 in 
Chapter 3  108 
 
tRNAiMet-driven cell migration was further investigated by using siRNA to 
knockdown integrin α5 levels, and also by using an antibody (16G3) which binds 
to the RGD sequence in fibronectin to oppose its interaction with the α5β1 
receptor. siRNA of integrin α5 (Figure 3-16) and addition of 16G3 (Figure 3-17) 
both inhibited migration of tRNAiMet overexpressing cells, but had no effect on 
the movement of control fibroblasts.  Taken together, these data indicate that 
association of integrin α5β1 with fibronectin is a prerequisite for tRNAiMet-driven 
cell migration. 
 
Figure 3-15- tRNAiMet-driven cell migration is opposed by an integrin α5 blocking antibody.  
iMEF.Vector and iMEF.tRNAiMet cells were plated at 1x105 cells/well and incubated at 37°C/5%CO2 
for 2 hours to adhere to plastic. Cells were then incubated for a further 2 hours with either 2µg/mL 
control IgG antibody, or 2µg/mL mAb16 antibody. Random migration of cells was then recorded by 
timelapse microscopy for 17 hours. In each case the velocity of 30 – 40 cells per experiment was 
calculated using manual tracking in Image J over the 17 hour time course for (A) Pool 1 cells, n=3, 
box and whisker plot represents 5-95 percentile, (B) Pool 2 cells, n=2, box and whisker plot 
represents 5-95 percentile, Kruskal-Wallis test, **** p < 0.0001, ns = not significant. 
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Figure 3-16- tRNAiMet-driven cell migration is opposed by siRNA of integrin α5.  
(A) iMEF.Vector and iMEF.tRNAiMet cells were transfected with a NT or an integrin α5 specific 
siRNA. Cells were lysed 24 hours post transfection into NDLB, and subjected to western blot to 
determine knockdown of integrin α5 levels. (B) iMEF.Vector and iMEF.tRNAiMet cells treated with NT 
and integrin α5 siRNA were trypsinised 24 hours post transfection and plated at 1x105 cells/well. 
After a 2 hour incubation at 37°C/5%CO2 to adhere to plastic, the random migration of cells was 
recorded for 17 hours by timelapse microscopy. In each case the velocity of 30 – 40 cells per 
experiment was calculated using manual tracking in Image J over the 17 hour time course, n=3, 
box and whisker plot represents 5-95 percentile, Kruskal-Wallis test, **** p < 0.0001, *p<0.05. 
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Figure 3-17- tRNAiMet-driven cell migration is opposed by blockade of the RGD site in 
fibronectin. 
iMEF.Vector and iMEF.tRNAiMet cells were plated at 1x105 cells/well and incubated at 37°C/5%CO2 
for 2 hours to adhere to plastic. Cells were then incubated for a further 2 hours with either 2µg/mL 
control IgG antibody, or 2µg/mL 16G3 antibody. Random migration of cells was then recorded by 
timelapse microscopy for 17 hours. In each case the velocity of 30 – 40 cells per experiment was 
calculated using manual tracking in Image J over the 17 hour time course, n=3, box and whisker 
plot represents 5-95 percentile, Kruskal-Wallis test, **** p < 0.0001, *** p < 0.001. 
The dependency of tRNAiMet-driven cell migration on the integrin α5β1–fibronectin 
interaction led us to examine the expression and localisation of α5β1 in iMEFs. 
qPCR showed that there was no significant difference in the levels of mRNA 
encoding integrin α5β1 following tRNAiMet overexpression (Figure 3-18A), and 
Western blot showed no consistent differences in total α5 protein levels between 
iMEF.tRNAiMet and iMEF.Vector cells (Figure 3-18B). Surface expression of integrin 
α5 was also measured, and while immunoprecipitation and ELISA showed that 
there was slightly less integrin α5 at the surface of iMEF.tRNAiMet pool 1 cells 
compared to control (Figure 3-18C&D), analysis in iMEF.tRNAiMet pool 2 cells 
showed no significant difference in integrin α5 surface expression (Figure 3-18E), 
suggesting that this was not a consistent consequence of tRNAiMet overexpression. 
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Figure 3-18- tRNAiMet overexpression does not influence integrin α5β1 expression. 
(A) qPCR was used to quantify expression of integrin α5β1 in iMEF.Vector and iMEF.tRNAiMet cells. 
All data are normalised to ARPP P0 and are presented relative to expression in iMEF.Vector pool 
1, n=3, +/- SEM, ANOVA, ns = not significant. (B) iMEF.Vector and iMEF.tRNAiMet cells were plated 
to 80 – 90 % confluence, lysed into NDLB, and subjected to western blot to determine total protein 
integrin α5 levels. (C) Surface expression of integrin α5, and transferrin receptor (TfR) as a control, 
were assessed in pool 1 iMEF.Vector and iMEF.tRNAiMet cells by immunoprecipitation. Cells were 
surface-labelled with NHS-S-S-Biotin at 4°C, then lysed and incubated with beads coated in 
monoclonal antibodies specific for integrin α5 or TfR. Lysates were separated by gel 
electrophoresis and surface expression of integrin α5 or TfR determined by binding and detection of 
streptavidin-HRP complex. (D) Surface expression of integrin α5, and TfR were assessed in pool 1 
iMEF.Vector and iMEF.tRNAiMet cells by ELISA. Briefly, cells were surface-labelled with NHS-S-S-
Biotin at 4°C, lysed and levels of biotinylated integrin α5 determined by ELISA, using microtiter 
plates coated with monoclonal antibodies specific for integrin α5 or TfR and a dilution of iMEF 
lysate to ensure the detection was within the linear dynamic range of the assay, n=3, +/- SEM. (E) 
Surface expression of integrin α5 in pool 2 iMEF.Vector and iMEF.tRNAiMet cells was assessed by 
ELISA as described in (C).  
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Although there was no significant difference in mRNA, protein levels, or surface 
expression of integrin α5, we wanted to determine whether overexpression of 
tRNAiMet could influence integrin α5 distribution and function. We used 
immunofluorescence to examine the localisation of integrin α5, and were unable 
to detect any discernible difference in distribution of α5 following tRNAiMet 
overexpression (Figure 3-19).  
 
Figure 3-19- No significant difference in integrin α5β1 localisation following tRNAiMet 
overexpression. 
Immunofluorescence was used to assess the localisation of integrin α5. iMEF.Vector and 
iMEF.tRNAiMet pool 1 cells were plated onto glass coated with 1μg/mL fibronectin for 24 hours and 
then fixed and stained for integrin α5, and counterstained with phalloidin and DAPI to visualise F-
actin and nuclei respectively, scale bar represents 20μm.  
The internalisation and recycling of integrins is an important process that can 
influence cell migration, and the Rab GTPase dependent recycling of integrin 
α5β1 to cell protrusions is a mechanism that can increase migration of cancer 
cells (Muller et al., 2009, Rainero et al., 2012). We therefore investigated rates 
of integrin α5β1 internalisation and recycling in iMEF.Vector and iMEF.tRNAiMet 
cells. The rate of internalisation of integrin α5 was unchanged between 
iMEF.Vector and iMEF.tRNAiMet cells, and an antibody to active integrin β1 (9EG7) 
showed that there was also no difference in internalisation of the active 
conformation of the integrin (Figure 3-20A). There was no significant difference 
in recycling of internalised integrin α5 back to the cell membrane, however there 
was less active integrin β1 recycled back to the cell surface in tRNAiMet 
overexpressing cells (Figure 3-20B). Whilst keeping ligand engaged integrins 
within the cell may be a mechanism to promote increased cell migration, these 
internalisation and recycling experiments were conducted on pool 1 of tRNAiMet 
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overexpressing iMEFs, and are therefore most likely a reflection of the lower 
surface expression of integrin α5 in pool 1 iMEFs detected by both ELISA and IP 
that was not reflected in pool 2 (Figure 3-18). And so, although the consistent 
increase in cell migration driven by tRNAiMet is dependent on the ability of 
integrin α5β1 to bind fibronectin, the actual mechanism by which it exerts its 
effects, and the link to its role in the TC, still remains to be identified. 
 
Figure 3-20- Investigation of integrin α5 internalisation and recycling following tRNAiMet 
overexpression. 
(A) iMEF.Vector and iMEF.tRNAiMet pool 1 cells were surface labelled with NHS-S-S-Biotin at 4°C, 
warmed to 37°C for indicated times, and the proportion of integrin α5 and active β1 (9EG7) 
internalisation determined by ELISA, n=1, +/- standard deviation of technical replicates. (B) 
iMEF.Vector and iMEF.tRNAiMet pool 1 cells were surface labelled with NHS-S-S-Biotin at 4°C, 
warmed to 37°C for 30 minutes to allow internalisation of cell surface receptor, and the remaining 
label at the cell surface reduced. Cells were then warmed to 37°C for the indicated times and the 
proportion of integrin α5 and active β1 (9EG7) recycled to the cell surface determined by ELISA 
n=1, +/- standard deviation of technical replicates.………………………………………………………
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3.3 Discussion 
The canonical function of tRNAs is their role in protein synthesis, and increased 
translation is necessary to implement many of the steps that are considered to 
be the hallmarks of cancer (Hanahan and Weinberg, 2000). High levels of tRNAs 
are seen across a variety of cancer types (Pavon-Eternod et al., 2009, Zhou et 
al., 2009, Mahlab et al., 2012). In malignant myeloma, increased tRNA 
abundance is associated with high translational activity, and treatment with a 
proteasome inhibitor decreases the charging of tRNAs, consequently increasing 
the accumulation of misfolded proteins, leading to apoptosis of myeloma cells 
(Zhou et al., 2009). The specificity of these effects have been attributed to 
tRNAs charged with hydrophobic amino acids, of which methionine is one, and so 
again provides evidence that specific tRNAs can be altered in cancer to 
accommodate the increased need for protein translation.   
Translation initiation is generally considered to be the rate limiting step in 
eukaryotic protein synthesis (Sonenberg and Hinnebusch, 2009), however we 
found that increased levels of the initiator methionine tRNA did not affect the 
overall rate of cellular protein synthesis in fibroblasts (Figure 3-2). Thus, despite 
the fact that increased tRNAiMet has a profound influence on cell migration, this 
tRNA is not likely to be a limiting factor in translation initiation in general.  
Furthermore, tRNAiMet levels do not seem to be linked to cell size, energy 
metabolism, cell spreading, or rate of proliferation. 
The contribution of tRNA expression to cell proliferation is a contested 
phenomenon, with opposing opinions in the literature. Distinct changes in the 
repertoires of tRNAs expressed in proliferating and differentiating cells results in 
increased translational efficiency of proliferative genes in actively dividing cells 
(Gingold et al., 2014). Thus, these workers classified tRNAiMet as a “proliferative 
tRNA” owing to the fact that its transcription was increased in proliferating cells 
compared to differentiating cells. However, a causal link between tRNAiMet levels 
and increased cell proliferation was not demonstrated. Other studies have 
claimed that overexpression of tRNAiMet may increase the proliferation of human 
epithelial cells (Pavon-Eternod et al., 2013). However, this work used the 
intensity of Hoechst staining to quantify the increase in cell proliferation and it 
is worth noting that although Hoechst stain binds to all nucleic acids, its 
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fluorescence is dramatically increased upon binding to AT-rich double stranded 
DNA (Portugal and Waring, 1988). The work of Gingold and colleagues showed 
that changes in tRNA expression profiles correlate with an increase in activating 
epigenetic modifications, consequently changing the chromatin landscape in 
such cells. Analysis of codon usage in genes highly expressed in proliferative 
cells also described a tendency for proliferative-associated genes to be AT rich 
(Gingold et al., 2014). It is therefore possible that the tRNAiMet induced increase 
in cell proliferation detected in human epithelial cells was owing to an increase 
in the accessibility of AT rich genes, and genes that are annotated as 
proliferative may also have other functions, including roles in cell migration. 
Indeed other publications have shown that although overexpression of 
components of the Pol III machinery can drive transformation, this effect is 
uncoupled from cellular proliferation (Johnson et al., 2008), and so our data sits 
in line with this view, as we find that increased expression of a single Pol III 
product, tRNAiMet, cannot drive an increase in cell proliferation. Furthermore, 
recent studies have also shown that the level of tRNA modification regulates cell 
growth, and not altered total tRNA expression levels (Rojas-Benitez et al., 
2015). Therefore, although initial studies suggested that additional copies of the 
tRNAiMet gene in Drosophila larvae could increase their growth rate (Rideout et 
al., 2012), this recent study showed that extra copies of tRNAiMet alone do not 
influence growth, and it is an increase in levels of an N6-threonylcarbamoyl-
adenosine modification of tRNAiMet that is limiting for Drosophila growth in vivo 
(Rojas-Benitez et al., 2015). It would therefore be interesting to investigate 
differences in modification of tRNAiMet within our fibroblast model, to 
understand whether the effects we see are a consequence of absolute increased 
tRNAiMet expression or are related changes in tRNAiMet modification. 
Increased expression of tRNAiMet increased the migration speed of fibroblasts 
(Figure 3-7). The opposing effects of salubrinal and GADD34 on cell migration 
suggest that TC levels are critical, and to some extent drive, the tRNAiMet 
induced increase in cell speed (Figure 3-11 & Figure 3-12). If phospho-eIF2α 
levels were increased by tRNAiMet overexpression, the explanation for this 
phenomenon would be simple.  However, this is not the case as phospho-eIF2α 
levels are identical in iMEF.tRNAiMet and iMEF.Vector cells (Figure 3-10). 
However, it may also be possible for local phosphorylation of eIF2α to be 
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changed in the cell without affecting total phospho-protein levels, and so it 
would be interesting to use immunofluorescence to visualise the distribution of 
phospho-eIF2α in the iMEF.tRNAiMet overexpressing cells and thus determine 
whether there are any changes in localisation of the protein synthesis machinery 
which could contribute to the increased cell migration driven by tRNAiMet levels.   
Observations that cycloheximide treatment did not inhibit tRNAiMet-driven cell 
migration indicate that although increased cell speed is dependent on the 
formation of the TC, it is not necessarily reliant on active synthesis of new 
proteins (Figure 3-13). That is not to say that these effects could not be owing to 
expression of a highly stable protein whose levels would not be affected by 
these relatively brief cycloheximide treatments. Furthermore, although the 
concentrations of cycloheximide that we have used are effective in reducing 
protein synthesis, they do not completely abrogate it, and so it may still be 
possible for the cell to translate specific proteins at the sacrifice of others. 
However, it is also important to consider the possibility that the role of tRNAiMet 
and the TC in driving cell migration may not be owing to a direct role of the TC 
in selective translation. A well-established consequence of increased 
phosphorylation of eIF2α is the inhibition of global translation and increase in 
selective protein synthesis. This causes an increase in the accumulation of 
untranslated mRNAs (Srivastava et al., 1998). Untranslated mRNAs are recruited 
to stress granules (SGs) which in addition to being in a dynamic equilibrium with 
polysomes, also contain many components of the cap-dependent pre-initiation 
complex (Kedersha et al., 2002). The formation of SGs re-localises cellular 
proteins and untranslated RNAs, and it has been shown that scaffold proteins 
such as Vinexin can be re-distributed from focal adhesions (FAs) to SG through 
association with CPEB4 (Chang and Huang, 2014). Promotion of the CPEB4-
Vinexin interaction, and consequent Vinexin-Vinculin disassociation, through 
phospho-eIF2α induced SG formation could affect cell migration through 
alterations in the dynamics of FAs. Therefore, although the tRNAiMet effect on 
cell migration is dependent on the TC, whether it exerts its effects directly, or 
indirectly, is yet to be determined.  
In addition to its dependency on TC formation, iMEF.tRNAiMet-driven cell 
migration was also dependent on the ability of integrin α5β1 to bind fibronectin 
(Figure 3-15, Figure 3-16 & Figure 3-17). When iMEF.Vector cells were plated 
Chapter 3  117 
 
onto substrates containing fibronectin it rendered their migration more 
iMEF.tRNAiMet-like (Figure 3-14), while blocking the ability of integrin α5β1 to bind 
fibronectin inhibited the increase in migration induced by tRNAiMet expression 
(Figure 3-15, Figure 3-16, Figure 3-17). Previous work has shown that cells are 
able to endocytose fibronectin and re-secrete it from a late 
endosomal/lysosomal compartment (LE/Lys) to provide an autocrine ECM to 
promote increased cell migration (Sung et al., 2011, Sung and Weaver, 2011). 
However, there was no consistent significant difference detected in transcript, 
total protein level, surface expression, rate of internalisation or recycling of the 
fibronectin receptor integrin α5β1 (Figure 3-18, Figure 3-19 & Figure 3-20), nor 
was there any difference in the secretion of fibronectin from the fibroblasts 
themselves (as will be discussed in the next chapter). Nevertheless, tRNAiMet 
overexpressing cells are more dependent on integrin α5β1-fibronectin interaction 
than iMEF.Vector control cells for their cell movement. It could therefore be 
possible that there are differences in intracellular signalling downstream of 
ligand activation of the integrin, and so despite the integrin α5β1 expression 
being similar, if subsequent connections to the actin cytoskeleton are altered, or 
there are differences in the downstream interactome, then changes in these 
pathways could affect cell migration. Indeed, integrin α5β1 can signal to Rho 
subfamily GTPases, such as RacGAP1, to control the levels of Rac and RhoA 
activity to drive invasion into fibronectin-containing matrices (Timpson et al., 
2011, Jacquemet et al., 2013, Machacek et al., 2009). Furthermore, local 
degradation and translation of RhoA has also been shown to have important roles 
in Sema3A-induced growth cone collapse during axonal outgrowth (Deglincerti et 
al., 2015), thus connecting translational control with regulation of cell 
protrusions through RhoA-mediated signalling pathways. It would therefore be 
interesting to consider whether there are changes in localisation and/or switches 
in activation of such molecules following tRNAiMet overexpression. 
In this chapter we have described how increased levels of tRNAiMet can have 
profound impacts on fibroblast behaviour. Despite not affecting the total level 
of protein synthesis, cell size, metabolism, proliferation, or rate of spreading, 
overexpression of tRNAiMet increases the migration speed of fibroblasts, and this 
increase in cell speed is dependent on TC formation and on the ability of 
integrin α5β1 to bind fibronectin (Figure 3-21).  
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Figure 3-21- Model of the effect of tRNAiMet overexpression on fibroblast behaviour.  
Increased levels of tRNAiMet increase the migration of fibroblasts through a mechanism that is 
dependent on the association of tRNAiMet with the ternary complex, and the ability of integrin α5β1 to 
bind fibronectin. It is currently unknown whether this is due to the effects of the ternary complex on 
protein synthesis, and/or whether this is directly related to integrin α5β1 binding and responding to 
fibronectin. Image made using items from Image Bank in Servier Medical Art. 
Although the mechanistic link between these two processes and increased 
tRNAiMet expression still remains to be determined, taken together these data 
show that increased levels of specific tRNAs can influence fibroblast behaviour. 
These effects on cell migration are reminiscent of phenotypic effects seen in 
CAFs, and whilst CAFs can influence carcinogenesis through a number of 
mechanisms, their major influence is attributed to generation of a 
microenvironment that facilitates increased tumour growth. The next chapter 
will therefore explore the non-cell autonomous effects of tRNAiMet 
overexpression, to understand whether small changes in the stromal cell 
tRNAome can influence the ECM secreted by fibroblasts to produce an 
environment that can support an increase in tumourigenicity. 
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Chapter 4 Increased tRNAiMet drives cell migration 
and tumour growth via non-cell 
autonomous mechanisms 
4.1 Introduction  
The microenvironment which surrounds tumour cells plays a key role in 
determining how they are able to grow and develop, and a key component of the 
tumour microenvironment (TME) is the fibroblasts and the ECM they secrete. 
Whilst the initial work of the Tlsty and Cunha groups highlighted the role of CAFs 
in cancer progression (Olumi et al., 1999), subsequent work has started to 
characterise how CAFs differ from their normal counterparts, and how these 
differences can account for the ability of CAFs to drive an increase in 
tumourigenicity (Orimo et al., 2005, Mitra et al., 2012). 
In the previous chapter we found that increased expression of one particular 
tRNA, tRNAiMet, could influence distinct aspects of fibroblast behaviour. 
Published work has also described tissue-specific differences in tRNA expression 
across a variety of human tissues, with changes in relative expression levels 
correlating to the codon use of highly expressed genes in those tissues (Dittmar 
et al., 2006). Recent data has highlighted the coordination between tRNA supply 
and demand, demonstrating that cells can overexpress defined cohorts of tRNAs 
to increase the efficiency of translation of particular pathways (Gingold et al., 
2014). In this study, proliferating cells were found to actively increase the 
transcription of tRNAs specific for codons overrepresented in pathways required 
for proliferation, essentially locking themselves into a proliferative state by 
optimising the translation of the components of these particular pathways. 
Additional work has also shown differential requirements for other components 
of the translation initiation machinery in normal development and cancer (Truitt 
et al., 2015), demonstrating that cancer cells can hijack excess levels of eIF4E 
to drive translation of oncogenic pathways. This dependency on components of 
the protein synthesis machinery is an effective mechanism to control 
translational efficiency in health, but can be exploited by cancer cells to drive 
specific gene expression programmes to support increased tumourigenicity in 
disease. 
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A number of publications have demonstrated that tRNAs are increased in 
different cancer types (Pavon-Eternod et al., 2009, Zhou et al., 2009, Mahlab et 
al., 2012). Although it was previously unknown whether this was a cause or 
consequence of carcinogenesis, understanding that expression of the 
components of the translation machinery can affect the efficiency of specific 
pathways highlights the possibility that tRNA levels could indeed play a role in 
cancer progression. 
By focussing on the roles of specific tRNAs, a previous publication indicated that 
overexpression of tRNAiMet was able to essentially reprogramme global tRNA 
expression levels and increase proliferation of human epithelial cells (Pavon-
Eternod et al., 2013). Other work also showed that increased levels of tRNAiMet 
could increase Drosophila larval growth owing to indirect effects involving 
increased mRNA translation and secretion of insulin-related peptides (Rideout et 
al., 2012). This in vivo effect on translation and protein secretion is particularly 
interesting, and again alludes to the fact that tRNA levels could function in 
regulating gene expression. Control of the CAF secretome through the mTOR/4E-
BP1 pathway has been found to increase tumour growth and promote the 
chemoresistance of tumour cells, and selective inhibition of this pathway within 
CAFs can increase the sensitivity of cancer cells to chemotherapy (Duluc et al., 
2015). Translational regulation therefore has a key role in cancer progression, 
not only within cancer cells themselves, but also in the stromal cells that 
support carcinogenesis (Gao and Roux, 2014, Loreni et al., 2014).  
In this chapter we therefore sought to understand whether expression of tRNAiMet 
was differentially regulated in CAFs compared to NFs, and whether modulating 
the expression of tRNAiMet in fibroblasts could affect their role in the tumour 
microenvironment.…………………………………………………………………
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4.2 Results 
4.2.1 Expression of tRNAiMet in cancer-associated fibroblasts   
With an interest in understanding whether tRNA expression could help drive the 
pro-carcinogenic properties of CAFs, we used qPCR to quantify expression of 
tRNAs in immortalised human mammary cancer-associated fibroblasts (iCAFs) 
compared to immortalised patient-matched normal fibroblast controls (iNFs). 
These iCAFs have a greater capacity than iNFs to promote tumour growth and 
angiogenesis when co-injected with Ras transformed MCF7 cells as subcutaneous 
allografts, and are established to maintain their phenotype when grown in 
culture (Orimo et al., 2005). Increased expression of tRNAiMet and tRNAIle was 
seen in iCAFs compared to iNFs, whilst no change was detected in the expression 
of 5S rRNA, another non-coding RNA transcribed by RNA Polymerase III (Pol III) 
(Figure 4-1A). The expression of tRNAs in primary fibroblasts isolated from 
tumour-associated or surrounding tissue in breast cancer patients was also 
assessed. From the 4 matched pairs of tumour-associated and ‘normal’ 
fibroblasts that were available, one displayed increased tRNAiMet expression in 
tumour-associated fibroblasts compared to those isolated from surrounding 
tissue (Figure 4-1B). Unfortunately no further clinical information was available 
on these particular patients, and so any correlation of increased tRNAiMet 
expression with breast cancer vascularity, subtype or stage could not be 
determined.  
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Figure 4-1- Changes in expression of specific tRNAs in cancer-associated fibroblasts and 
normal fibroblasts. 
(A) qPCR was used to quantify the expression of tRNAiMet, tRNAIle, and 5S rRNA in immortalised 
normal fibroblasts (iNF) and immortalised cancer associated fibroblasts (iCAF). All samples are 
normalised to ARPP P0 and are presented relative to iNF, n=minimum of 3, +/- SEM, ANOVA, * p 
<0.05. (B) qPCR was used to quantify the expression of tRNAiMet and tRNAIle in fibroblasts derived 
from breast tumour, or surrounding tissue, in four different breast cancer patients. All samples are 
normalised to ARPP P0 and are presented relative to expression of tRNAiMet in patient 1 
surrounding fibroblasts, where 1 corresponds to patient number 1255, 2 is patient number 1764, 3 
is patient number 1902 and 4 is patient number 1997, n=2, +/- SEM of the 2 biological replicates, 
ANOVA, * p<0.05, ** p < 0.005, ns = not significant. 
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4.2.2 Increased expression of tRNAiMet in the host animal 
promotes growth and angiogenesis of allografted tumours 
To further investigate the consequences of tRNAiMet overexpression in the 
stroma, we utilised a transgenic mouse expressing two additional copies of the 
tRNAiMet gene (2+tRNAiMet mouse) (Figure 4-2A). This resulted in a ubiquitous 
increase in tRNAiMet expression throughout the animal, including a 1.3 – 1.5 fold 
increase in expression in fibroblasts isolated from both the lungs and embryos of 
2+tRNAiMet mice (Figure 4-2B), which was similar to increases previously seen in 
immortalised human CAFs (Figure 4-1A&B). To determine whether increased 
levels of tRNAiMet in the host animal could influence tumour progression, we 
introduced tumour cells into the 2+tRNAiMet mice as syngeneic subcutaneous 
allografts and recorded their growth. We initially used transformed melanoblasts 
derived from mice that were null for INK4a, and which expressed mutant NRas 
under a melanoblast specific promoter (Tyr:NrasQ61K;INK4a−/−). These 
transformed melanoblasts grew more rapidly and reached their clinical end-point 
significantly faster in 2+tRNAiMet mice than they did in wild-type littermate 
controls (Figure 4-3A). To pursue this observation, we then introduced lewis lung 
carcinoma (LLC) or B16 F0 melanoma cells as subcutaneous syngeneic allografts 
into 2+tRNAiMet mice. When introduced into 2+tRNAiMet mice, both LLC (Figure 
4-3B) and B16 F0 (Figure 4-3C) cells formed significantly larger and more 
vascularised tumours than when grown in wild-type littermate control animals, 
indicating that increased tRNAiMet expression in the host animal can promote 
increased angiogenesis and tumour growth. 
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Figure 4-2- The 2+tRNAiMet transgenic mouse model. 
(A) The HPRT-tRNAiMet targeted allele used to generate the 2+tRNAiMet transgenic mouse. Two 
additional copies of the tRNAiMet transgene were targeted to the HPRT locus on the X 
chromosome, with the targeted allele containing the human HPRT promoter sequence and exon 1 
(box 1), and mouse HPRT exon 2 and 3 (box 2 and 3) (B) qPCR of tRNAiMet expression in various 
tissues and primary fibroblasts isolated from the lungs and embryos of the 2+tRNAiMet mouse, all 
samples normalised to ARPP P0, n=4 lung and n=2 embryonic fibroblasts, +/- SEM of biological 
replicates, unpaired t-test, ** p < 0.005, * p <0.05. Tissue data provided by Dritan Liko, Kirsteen 
Campbell & Louise Mitchell, CR-UK Beatson Institute, Glasgow. Lung fibroblast data provided by 
Tracy Berg, Institute of Cancer Research, London. 
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Figure 4-3- Increased expression of tRNAiMet in the host animal promotes angiogenesis and 
growth of allografted tumours. 
(A) 1x106 transformed melanocytes (Tyr:NRasQ61K;Ink4a-/-) were injected subcutaneously into 
littermatched WT or 2+tRNAiMet transgenic male mice and tumour size monitored. Mice were culled 
once tumours reached 15x15mm, and survival plotted by Kaplan-Meier, n = 14 WT mice, n = 14 
2+tRNAiMet transgenic mice, Log-rank (Mantel-Cox) test, * p < 0.05. (B) 1x106 Lewis Lung 
Carcinoma cells were injected subcutaneously into littermatched WT or 2+tRNAiMet transgenic male 
mice. Tumours were harvested at 21 days and final tumour volume measured. Tumours were PFA 
fixed, stained with endomucin for blood vessel identification, and vessels counted across the entire 
tumour section, n = 10 WT mice, n = 9 2+tRNAiMet transgenic mice, +/- SEM, unpaired t-test, * p < 
0.05. Experiment conducted by the Reynolds Lab, Institute of Cancer Research, London. (C) 
0.5x106 B16 F0 mouse melanoma cells were injected subcutaneously into littermatched WT or 
2+tRNAiMet transgenic male mice. Tumours were harvested 22 days from tumour establishment 
(classed as minimum 3x3mm measurable tumour), n = 20 WT mice, n = 14 2+tRNAiMet transgenic 
mice, +/- SEM, unpaired t-test, * p < 0.05, ** p < 0.005. Experiment conducted by the Reynolds 
Lab, Institute of Cancer Research, London.   
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4.2.3 Fibroblasts isolated from 2+tRNAiMet transgenic mice 
deposit a pro-migratory ECM 
A key component of the tumour microenvironment that can influence cancer cell 
behaviour is the ECM deposited by stromal fibroblasts. To determine whether 
tRNA levels influence the characteristics of fibroblast-derived ECM we isolated 
fibroblasts from the lungs and embryos of 2+tRNAiMet mice, used them to prepare 
cell-derived matrices by previously established methods (Caswell et al., 2008, 
Cukierman et al., 2001, Vlodavsky, 1999), and assessed the ability of this cell-
free ECM to support the migration of other cells. When used as a substrate for 
cell migration, the ECM derived from primary cells from 2+tRNAiMet mice was 
able to promote an increase in the migration speed of both endothelial cells and 
fibroblasts (Figure 4-4A&B). This suggested a role for tRNAiMet in driving changes 
in the ECM secreted by fibroblasts to promote endothelial cell migration that 
could contribute to angiogenesis and increase the migration of fibroblasts to 
further remodel the ECM. 
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Figure 4-4- Fibroblasts isolated from 2+tRNAiMet transgenic mice deposit a pro-migratory 
ECM. 
(A) ECM was generated from primary lung fibroblasts isolated from either WT or 2+tRNAiMet 
transgenic mice. Migration of human umbilical vein endothelial cells (HUVEC) on the ECM was 
recorded by timelapse microscopy and analysed in ImageJ. Data represents ECM generated from 
7 independent isolations of primary fibroblasts from pools of 3 x WT and 3 x 2+tRNAiMet transgenic 
mice, tracking the migration of at least 28 HUVECs in each replicate. Box and whisker plot 
represents 5-95 percentile, Mann-Whitney test, **** p < 0.0001. Data provided by Tracy Berg, 
Institute of Cancer Research, London. (B) ECM was generated from primary fibroblasts isolated 
from littermatched WT or 2+tRNAiMet primary mouse embryonic fibroblasts (MEFs). Migration of 
immortalised MEFs (iMEFs) on the ECM was recorded by timelapse microscopy over a 17 hour 
time course, and analysed in ImageJ. Data represents ECM generated from 1 independent 
isolation of primary fibroblasts from two pairs of littermatched WT and 2+tRNAiMet transgenic mice, 
tracking the migration of at least 60 iMEFs in each replicate, n=3 for pair 1, n= 2 for pair 2. Box and 
whisker plot represents 5-95 percentile, Mann-Whitney test, **** p < 0.0001.  
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4.2.4 tRNAiMet supports deposition of pro-migratory ECM via 
release of secreted factors 
Many ECM components are secreted from fibroblasts as soluble proteins, and are 
then subsequently incorporated into the insoluble ECM. To determine the stage 
at which increased tRNAiMet expression influenced ECM deposition we went on to 
generate cell derived matrices from iMEF.tRNAiMet and iMEF.Vector cell lines. 
ECM generated from iMEF.tRNAiMet cells was also able to support increased 
migration speed of fibroblasts compared to ECM derived from iMEF.Vector 
control cells (Figure 4-5A). Furthermore, conditioned media from iMEF.tRNAiMet 
cells, when incubated with control fibroblasts, also enabled iMEFs to generate an 
ECM that could support increased cell migration (Figure 4-5B&C), indicating that 
tRNA expression levels can influence the synthesis and secretion of soluble ECM 
components. 
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Figure 4-5- tRNAiMet supports deposition of pro-migratory ECM via release of secreted 
factor(s). 
(A) Migration of iMEFs on ECM was recorded by timelapse microscopy over a 17 hour time course 
and analysed in ImageJ for ECM generated from immortalised fibroblasts (iMEFs) stably 
overexpressing either empty vector (iMEF.Vector) or tRNAiMet (iMEF.tRNAiMet). (B) Schematic 
representation of ECM derived from conditioned media treated cells. iMEF vector cells were plated 
to confluence on gelatin coated plated, and then cultured for 7 days in the presence of filter-
sterilised conditioned media from iMEF.Vector or iMEF.tRNAiMet cells, which was diluted 1:1 with 
fresh media and refreshed every other day for 7 days. Cells were then removed used a triton 
containing buffer, and the ECM used as a substrate for cell migration (C) Migration of iMEFs on 
ECM generated from iMEFs in the presence of conditioned media from iMEF.Vector or 
iMEF.tRNAiMet cells was recorded by timelapse microscopy over a 17 hour time course and 
analysed in ImageJ. All data represents ECM generated from at least 3 independent ECM 
isolations, tracking the migration of at least 40 iMEFs in each replicate. Box and whisker plot 
represents 5-95 percentile, Mann-Whitney test, **** p < 0.0001.  
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Cell migration can be influenced by the mechanical properties of the ECM, and 
secreted enzymes such as lysyl oxidases and transglutaminases, have been shown 
to increase ECM stiffness to promote cell migration (Baker et al., 2013). 
Importantly, atomic force microscopy (AFM) showed that the ECM generated in 
the presence of conditioned media from iMEF.tRNAiMet cells was not thicker, nor 
was it consistently different in stiffness, than the ECM deposited in the presence 
of conditioned media from iMEF.Vector control cells (Figure 4-6). This therefore 
indicates that tRNAiMet overexpression supports deposition of a pro-migratory ECM 
via release of a secreted factor(s), and is not due to any physical changes in 
stiffness of the matrix. 
 
Figure 4-6- No consistent difference in the thickness or stiffness of the pro-migratory ECM 
generated in the presence of conditioned media from tRNAiMet overexpressing cells.  
Atomic force microscopy and contact imaging were performed using a JPK NanoWizard II Bio AFM 
in combination with a Bruker MLCT cantilever and to measure the thickness the ECMs following 
wound scratch, or a Nanoworld Arrow TL-1 cantilever with bead attached for force spectroscopy, 
n=3 independent ECM generations, +/- SEM, **** p < 0.0001, ns = not significant, ANOVA test. 
Experiment conducted in collaboration with Ellie Pulleine, University of Glasgow. 
Previously published work has highlighted the ability of microvesicles (MVs) 
released by fibroblasts to mediate tumour-stroma communication and influence 
cancer cell motility (Luga and Wrana, 2013). To assess whether any of the 
secreted factors that mediate tRNAiMet’s ability to generate pro-migratory ECM 
might be MV-associated, we centrifuged the conditioned media collected from 
iMEF.Vector and iMEF.tRNAiMet cells to deplete it of MVs and assessed its 
subsequent ability to influence the ECM deposited by iMEFs. Centrifugation of 
iMEF.tRNAiMet conditioned media did not affect its ability to support the 
deposition of a pro-migratory ECM (Figure 4-7), indicating that tRNAiMet-driven 
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MV release is not a key mediator of this tRNA’s ability to influence ECM 
generation. 
 
Figure 4-7- Microvesicles are not the secreted factor required for tRNAiMet to support 
deposition of pro-migratory ECM. 
ECM was generated from iMEFs in the presence of microvesicle depleted conditioned media from 
iMEF.Vector or iMEF.tRNAiMet cell lines. Migration of iMEFs on the ECM was recorded by timelapse 
microscopy over a 17 hour time course and analysed in ImageJ. Data represents ECM generated 
from at least 3 independent ECM isolations, tracking the migration of at least 40 iMEFs in each 
replicate. Box and whisker plot represents 5-95 percentile, Mann-Whitney test, **** p < 0.0001. 
Other published work has shown that secreted factors can modify the ECM in a 
way that does not necessarily depend on the presence of the matrix-depositing 
cells.  For example, enzymes such as lysyl oxidase and tissue transglutaminase 
are capable of catalysing the formation of inter-chain cross-bridges and this can 
occur after matrix deposition (Cox et al., 2013, Forsprecher et al., 2009). 
Furthermore, if the conditioned media from tRNAiMet overexpressing cells were 
to be particularly rich in motogens possessing heparin-binding domains (such as 
fibroblast growth factors), these could potentially associate with the heparin 
sulphate groups of a pre-assembled ECM. We were therefore interested in 
understanding whether conditioned media from tRNAiMet overexpressing cells 
required the presence of cells to generate a pro-migratory ECM, or whether 
addition of conditioned media to cell-free ECM was sufficient to influence the 
matrix and increase cell migration. When conditioned media from either 
iMEF.Vector or iMEF.tRNAiMet cells was incubated with control, cell-free ECM for 
24hr, and fibroblasts were then plated onto these matrices, no consistent 
difference in cell speed was observed between the two conditions. These data 
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indicate that factors released from tRNAiMet overexpressing cells influence the 
way in which matrix proteins are deposited by fibroblasts, but they are not able 
to modify a pre-assembled ECM (Figure 4-8). 
 
Figure 4-8- Conditioned media from tRNAiMet overexpressing cells is not able to influence 
the migratory characteristics of pre-assembled ECM. 
ECM was generated from iMEF.Vector cells and the cell free ECM was then incubated with 
conditioned media from iMEF.Vector or iMEF.tRNAiMet cell lines for 24 hours. Migration of iMEFs on 
the ECM was recorded by timelapse microscopy over a 17 hour time course and analysed in 
ImageJ. Data represents ECM generated from 2 independent ECM isolations, tracking the 
migration of at least 40 iMEFs in each replicate. Box and whisker plot represents 5-95 percentile, 
Kruskal-Wallis test, * p < 0.05, ns = not significant. 
Cell migration can be affected by a number of different parameters, and our 
previous data indicated that the tRNAiMet effect on generation of a pro-migratory 
ECM was not owing to a change in the physical properties of the matrix, nor was 
it recapitulated by simply incubating the secreted factors with ECM alone. It 
therefore seemed likely to be due to a change in the composition of the ECM 
secreted by the tRNAiMet overexpressing cells. A major component of the ECM 
secreted by fibroblasts is fibronectin, and initial fibronectin deposition and 
fibrillogenesis by integrin α5β1 is an early and integral part of ECM generation. 
Data presented in the previous chapter indicate that when cells are plated onto 
plastic surfaces iMEF.tRNAiMet-driven migration is dependent on the integrin α5β1–
fibronectin interaction. We therefore proceeded to assess the migration of 
iMEF.Vector and iMEF.tRNAiMet cells using their own pre-derived matrices as ECM 
substrates. When iMEF.Vector and iMEF.tRNAiMet cells were plated onto their own 
cell-derived matrices, the ECM derived from iMEF.tRNAiMet cells was able to 
promote increased cell migration, however the difference in migration speed 
between iMEF.Vector and iMEF.tRNAiMet cell lines evident when these cells 
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migrate on plastic surfaces (as described in the previous chapter) was no longer 
apparent (Figure 4-9). Next, we determined the α5β1 and fibronectin-
dependence of tRNAiMet-driven cell migration using the blocking antibodies 
described in the previous chapter.  Blockade of integrin α5β1 (using mAb16) or 
fibronectin’s RGD site (with the 16G3 antibody) did not influence the migration 
speed of fibroblasts on ECM deposited by either iMEF.Vector or iMEF.tRNAiMet 
overexpressing cells (Figure 4-10). These data indicate that the integrin α5β1-
fibronectin interaction is not required for cell movement on cell-derived matrix, 
nor is α5β1 required for fibroblasts to sense the pro-migratory properties of ECM 
derived from tRNAiMet overexpressing cells.  
 
Figure 4-9- ECM derived from tRNAiMet-overexpressing cells promotes increased migration 
of fibroblasts but negates the difference in migration between iMEF.Vector and 
iMEF.tRNAiMet. 
iMEF.Vector and iMEF.tRNAiMet cells were plated at 1x105 cells/well on ECM derived from 
iMEF.Vector or iMEF.tRNAiMet cells and incubated at 37°C/5%CO2 for 2 hours to adhere. Random 
migration was then recorded by timelapse microscopy over a 17 hour time course. The data 
represents the speed of 30 – 40 cells per experiment, calculated using manual tracking in Image J 
over the 17 hour time course, n=3, box and whisker plot represents 5-95 percentile, Kruskal-Wallis 
test, **** p < 0.0001, ns = not significant. 
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Figure 4-10- Integrin α5β1–fibronectin interaction does not influence fibroblast migration on 
ECM derived from control or tRNAiMet overexpressing cells. 
ECM was generated from iMEF.Vector and iMEF.tRNAiMet cell lines, and iMEFs then incubated at 
37°C/5%CO2 on the ECM for 2 hours to adhere. Media was changed to contain 2μg/mL blocking 
antibody and incubated for a further 2 hours. Migration of iMEFs on the ECM was then recorded by 
timelapse microscopy over a 17 hour time course and analysed in ImageJ. Data represents ECM 
generated from 2 independent ECM isolations, tracking the migration of at least 40 iMEFs in each 
replicate. Box and whisker plot represents 5-95 percentile, Kruskal-Wallis test, **** p < 0.0001. 
4.2.5 tRNAiMet drives a secretome that is enriched in collagen II 
and collagen-modifying enzymes 
We used SILAC based mass spectrometry to quantitatively analyse the 
complement of soluble proteins secreted from control and tRNAiMet 
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overexpressing iMEFs (pool 1). Briefly, iMEF.tRNAiMet and iMEF.Vector cells were 
labelled with light and heavy amino acids respectively and combined for the 
forward experiment (FWD), with corresponding heavy and light amino acid 
labelling in the reverse experiment (REV). We used an affinity bead-based 
approach to extract the proteins secreted into serum-free conditioned media, 
and also prepared cell extracts for cellular proteome analysis. Analysis of the 
secretome showed that the most upregulated protein secreted following tRNAiMet 
overexpression was collagen II, while there was also an increase in secretion of 
additional collagens and collagen processing enzymes in the iMEF.tRNAiMet cell-
exposed media  (Figure 4-11A&C and Appendix I). The increase in secretion of 
ECM components was particularly striking, as over half of the significant changes 
in proteins secreted following tRNAiMet overexpression were associated with the 
ECM (highlighted in red, Figure 4-11A&C). Proteomic analysis on the cells 
themselves indicated that tRNAiMet expression also disproportionately increased 
cellular synthesis of secretory proteins, with 88% of the proteomic hits following 
tRNAiMet overexpression being secretory, while the production of other cellular 
components was not greatly affected (Figure 4-11B and Appendix II). 
Furthermore, specificity towards increased secretion of particular proteins was 
also apparent. Despite fibronectin being one of the most abundant proteins in 
the iMEF secretome, its levels were not changed following tRNAiMet 
overexpression, while expression of the normally less abundant collagen II was 
increased almost 70 fold (Figure 4-11D). Immunostaining of the ECM derived 
from iMEF.Vector and iMEF.tRNAiMet cells further confirmed that the collagen II 
secreted into the media was also incorporated into the ECM itself, with the level 
of collagen II incorporation correlating to the extent of tRNAiMet overexpression 
in the iMEF cell lines (Figure 4-11E and Figure 3-1). 
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Figure 4-11- tRNAiMet drives a secretome that is enriched in collagen II and collagen-
modifying enzymes. 
(A) The secretome was analysed following tRNAiMet overexpression using quantitative SILAC mass 
spectrometry. iMEF.Vector and iMEF.tRNAiMet cells were labelled with heavy and light amino acids, 
secreted proteins isolated from the conditioned media, separated by gel electrophoresis, and then 
analysed by mass spectrometry. Forward experiment (FWD) corresponds to iMEF.tRNAiMet cells 
labelled with heavy amino acids combined with iMEF.Vector cells labelled with light amino acids, 
and the reverse experiment (REV) corresponds to iMEF.Vector cells labelled with heavy amino 
acids combined with iMEF.tRNAiMet cells labelled with light amino acids. ECM associated proteins 
are highlighted in red. (B) The total cellular proteome of iMEF.Vector and iMEF.tRNAiMet cells, ECM 
proteins are highlighted in red. (C) A table of some of the top upregulated secreted proteins 
identified in the media in the secretome following tRNAiMet overexpression. (D) Data from (A) 
replotted to show the total abundance of proteins identified in the media of iMEF.tRNAiMet cells 
against the fold change in expression of proteins in the iMEF.tRNAiMet cells compared to 
iMEF.Vector. (E) ECM was generated from iMEF.Vector and iMEF.tRNAiMet cells. Incorporation of 
collagen II into the ECM was assessed by immunostaining using collagen II specific antibodies, 
and quantified using the Aerius infrared imaging system (LI-COR® Biosciences), unpaired t-test, 
**p<0.005 (A-D data generated in collaboration with David Sumpton, CR-UK Beatson Institute, 
Glasgow). 
Chapter 4  137 
 
After discovering the striking effects of tRNAiMet on the synthesis and secretion of 
collagen II and ECM components at the proteomic level, we were also interested 
in understanding whether these effects were reflected at the level of 
transcription. We used RNA sequencing (RNA-Seq) to analyse the transcriptome 
of iMEF.Vector and iMEF.tRNAiMet (pool 1) cells. Distance heatmaps by biological 
sample showed that iMEF.tRNAiMet cells did indeed cluster separately from 
iMEF.Vector cells on the basis of their transcriptome (N.B., the third biological 
repeat of iMEF.tRNAiMet clustered with control cells, the reason for this 
experimental variability was unknown, and so the data set was still included in 
all analysis) (Figure 4-12A and Appendix III). Pathway enrichment analysis of 
genes differentially expressed following tRNAiMet overexpression showed that 
stellate cell activation, liver fibrosis, and ECM remodelling were among the top 
pathways enriched at the transcriptomic level following tRNAiMet overexpression 
(Figure 4-12B). Whilst our previous data had already highlighted the role of 
tRNAiMet in ECM remodelling, the pathway enrichment analysis provided 
additional support for this, as activated stellate cells are also responsible for 
secreting collagen scar tissue and inducing fibrogenic activity (Mannaerts et al., 
2013). Moreover, it also raised the possibility that tRNAiMet overexpression may 
also be affecting cellular differentiation and so could essentially be acting to 
reprogramme fibroblast cell fates.  
A large proportion of the most upregulated proteins previously identified 
following tRNAiMet overexpression were also upregulated in this RNA-Seq analysis 
of the transcriptome, including collagen II (Figure 4-12C). We used qPCR to 
validate the increase in collagen II mRNA levels identified following tRNAiMet 
overexpression, and found that this was indeed the case for iMEF pool 1 (the 
same pool used for the RNA-Seq experiments). However, there was no change in 
collagen II mRNA levels in iMEF pool 2 following tRNAiMet overexpression (Figure 
4-12D) despite these cells still increasing the incorporation of collagen II protein 
into the ECM and being able to deposit a highly pro-migratory matrix (Figure 
4-11E & Figure 4-5A&B). As previously shown in Figure 3-1, the increase in 
tRNAiMet expression in pool 1 is much greater than that of pool 2. It may 
therefore be possible for there to be a threshold required to see the effects of 
tRNAiMet overexpression, and larger increases in tRNAiMet are able to drive changes 
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at the level of both transcription and translation, whereas smaller increases in 
tRNAiMet expression result only in regulation at the post-transcriptional level. 
As conditioned media from tRNAiMet overexpressing cells was sufficient to enable 
fibroblasts to generate a pro-migratory ECM, we wanted to understand whether 
factors in the media were affecting gene expression pathways in the cells 
forming the ECM, or whether the conditioned media was simply providing extra 
soluble components to be incorporated into the matrix by the cells. We 
therefore treated iMEF.Vector cells with conditioned media from either 
iMEF.tRNAiMet or iMEF.Vector cells and used RNA-Seq to analyse any changes in 
gene expression. The transcriptome of iMEF.Vector cells remained largely 
unchanged regardless of whether they were treated with conditioned media 
from control or tRNAiMet overexpressing cells (N.B., the third biological repeat of 
cells treated with iMEF.tRNAiMet conditioned media clustered separately from all 
the other samples, but the data set was still included in all analysis) (Figure 
4-12E). In fact, only five genes in the iMEF.Vector cells were significantly 
differentially regulated following treatment with iMEF.tRNAiMet or iMEF.Vector 
cell conditioned media (Figure 4-12F). Considering over 400 genes were 
differentially regulated between iMEF.tRNAiMet and iMEF.Vector cells, it seems 
that alterations to the secretome following tRNAiMet overexpression do not affect 
gene expression in neighbouring cells, but simply provide increased levels of 
soluble ECM components which these cells can then incorporate into the 
surrounding microenvironment. 
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Figure 4-12- RNA sequencing following tRNAiMet overexpression. 
(A) Heatmap cluster analysis representing differences in gene expression between iMEF.tRNAiMet 
and iMEF.Vector cells. Red represents similarity, with progression to yellow representing 
increasing differences. Number represents the number of biological replicate. (B) Pathway 
enrichment analysis of genes differentially expressed in iMEF.tRNAiMet compared to iMEF.Vector 
cells. (C) The top 10 upregulated genes expressed in iMEF.tRNAiMet compared to iMEF.Vector 
cells, with red text highlighting those genes that were also upregulated at the level of the 
secretome. (D) qPCR to quantify the levels of collagen II expression in pools of MEF.tRNAiMet and 
iMEF.Vector cells, presented relative to iMEF.Vector pool 1, and normalised to ARPP P0, n=3, +/- 
SEM, ANOVA, **** p < 0.0001, ns = not significant. (E) Heatmap cluster analysis representing 
differences in gene expression between iMEF.Vector cells treated with conditioned media from 
iMEF.tRNAiMet or iMEF.Vector cells. Red represents similarity, with progression to yellow 
representing increasing differences. (F) The only differentially expressed genes in iMEF.Vector 
cells following treatment with iMEF.tRNAiMet conditioned media compared to iMEF.Vector 
conditioned media. 
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4.2.6 Collagen II secretion is required for tRNAiMet to drive 
production of pro-tumourigenic ECM  
To assess whether collagen II secretion was responsible for the ability of tRNAiMet 
overexpression to drive deposition of pro-migratory ECM, cell-derived matrices 
were generated from iMEFs cultured with conditioned media from iMEF.tRNAiMet 
cells which had previously been transfected with non-targeting (NT) or collagen 
II specific siRNA (Figure 4-13A). Knockdown of collagen II in iMEF.tRNAiMet cells 
resulted in conditioned media that had a decreased ability to enable iMEFs to 
generate an ECM that supported increased fibroblast migration (Figure 4-13B-D). 
Furthermore, knockdown of collagen II in primary lung fibroblasts isolated from 
2+tRNAiMet mice also compromised the ability of the ECM derived from these cells 
to support increased migration of endothelial cells (Figure 4-13E). 
We also studied ECM that had been deposited by iMEFs in which we had used a 
CRISPR gene editing approach to stably knockdown collagen II levels 
(MEF.tRNAiMet Collagen II CRISPR) (Figure 4-14A&B). Immunostaining of the ECM 
showed that CRISPR-mediated collagen II knockdown led to a significant 
decrease in the incorporation of collagen II into the matrix (Figure 4-14C), and 
this correlated with a decreased ability of this ECM to support increased cell 
migration (Figure 4-14D&E), reinforcing the conclusion that increased collagen II 
secretion following tRNAiMet overexpression is responsible for generation of a pro-
migratory ECM. 
To investigate the role of collagen deposition supporting tumourigenicity in vivo, 
we introduced lewis lung carcinoma cells as syngeneic allografts into WT and 
2+tRNAiMet mice in the presence and absence of ethyl-3,4-dihydroxybenzoate 
(DHB), a prolyl hydroxylase inhibitor that is well established to compromise 
collagen synthesis in vivo (Gilkes et al., 2013). While DHB administration did not 
affect the vascularity or growth of tumours in WT mice, it did inhibit increased 
vascularity and growth of tumours in 2+tRNAiMet mice, indicating that collagen 
secretion is also required for tRNAiMet to drive production of a pro-tumourigenic 
ECM in vivo (Figure 4-15). 
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Figure 4-13- Collagen II secretion is required for tRNAiMet to drive production of a pro-
migratory ECM. 
(A) Schematic representation of method used to generate siRNA conditioned media derived ECM. 
iMEF cells were plated to confluence on gelatin coated plates, and then grown for a further 7 days 
in ascorbate containing media that was diluted 1:1 with filter sterilised conditioned media from 
iMEF.tRNAiMet cells treated with either NT or collagen II specific siRNA. The ascorbate 
media/conditioned media mix was refreshed and replaced every 2 days over the 7 day time course. 
Cells were then removed using a triton containing buffer, leaving the ECM of interest coating the 
culture dish. (B) qPCR was used to quantify collagen II knockdown in the cells providing 
conditioned media to generate the iMEF siRNA conditioned media derived ECM, all data 
normalised to ARPP P0 and presented relative to expression in the iMEF.tRNAiMet non-targeting 
siRNA treated cells. Data presented is representative of n=3 independent experiments, +/- 
standard deviation of technical replicates, ANOVA, *p<0.05. (C) Single cell traces and spiderplots 
representative of the data quantified in (D). Migration of iMEFs, or HUVECs were indicated, on 
ECM was recorded by timelapse microscopy over a 17 hour time course and analysed in ImageJ 
for (D) ECM generated from iMEFs in the presence of conditioned media from iMEF.tRNAiMet cells 
treated with NT or collagen II specific siRNA. (E) ECM generated from primary lung fibroblasts 
treated with NT or collagen II specific siRNA. HUVEC data provided by Tracy Berg, Institute of 
Cancer Research, London. Data represents ECM generated from at least 3 independent ECM 
isolations, tracking the migration of at least 40 iMEFs in each replicate. Box and whisker plot 
represents 5-95 percentile, Kruskal-Wallis test, **** p < 0.0001, ns = not significant.  
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Figure 4-14- CRISPR gene editing methods indicate that collagen II secretion is required for 
tRNAiMet to drive production of a pro-migratory ECM. 
(A) qPCR was used to quantify collagen II levels in iMEF.Vector and iMEF.tRNAiMet cells 
transfected with an empty CRISPR vector, and in iMEF.tRNAiMet cells transfected with a CRISPR 
vector specific for collagen II, all data normalised to ARPP P0 and presented relative to expression 
in the iMEF.Vector cells, n=3, +/- SEM, ANOVA, ****p<0.0001 (B) Schematic representation of 
method used to generate ECM from iMEF pools. iMEF cells were plated to confluence on gelatin 
coated plates, and then grown for a further 7 days in ascorbate containing media. The ascorbate 
containing media was refreshed and replaced every 2 days over the 7 day time course. Cells were 
then removed using a triton containing buffer, leaving the ECM of interest coating the culture dish. 
(C) ECM generated from iMEF.Vector, iMEF.tRNAiMet and iMEF.tRNAiMet Collagen II CRISPR cells. 
Incorporation of collagen II into the ECM was assessed by immunostaining using collagen II 
specific antibodies, quantified using the Aerius infrared imaging system (LI-COR® Biosciences), 
ANOVA, ** p <0.005. (D) Single cell traces and spiderplots representative of the data quantified in 
(E). (E) Migration of iMEFs was recorded by timelapse microscopy over a 17 hour time course and 
analysed in ImageJ. Data represents ECM generated from at least 3 independent ECM isolations, 
tracking the migration of at least 40 iMEFs in each replicate. Box and whisker plot represents 5-95 
percentile, Kruskal-Wallis test, **** p < 0.0001. 
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Figure 4-15- The prolyl hydroxylase inhibitor, DHB, opposes the ability of tRNAiMet to drive 
production of a pro-tumourigenic ECM. 
1x106 lewis lung carcinoma cells were injected subcutaneously into littermatched WT or 2+tRNAiMet 
transgenic male mice, followed by daily dosing 40mg/kg DHB. Tumours were harvested at 21 days 
and final tumour volume measured. Tumours were PFA fixed and subjected to IHC against 
endomucin for vessel counts across the entire tumour section, ANOVA, ** p < 0.005, * p < 0.05, ns 
= not significant. Experiment conducted by the Reynolds Lab, Institute of Cancer Research, 
London. 
4.2.7 Collagen II expression in human cancer 
After establishing the role of collagen II in supporting increased tumourigenicity 
following tRNAiMet overexpression in mouse models, we were interested in 
understanding how this might relate to tumour progression in human disease. A 
tissue microarray (TMA) of primary operable breast cancer was available to us, 
established from a cohort of 544 breast cancer patients diagnosed with invasive 
breast cancer in the West of Scotland from 1995 to 1998, containing three 
replicate tumour cores from each patient (1800-Bre-TMA, Dr Joanne Edwards, 
University of Glasgow). This TMA was associated with a full clinico-pathological 
characterisation of the patients involved and a 10 year follow-up of breast 
cancer specific survival, and so provided a powerful tool to determine whether 
increased collagen II expression correlated with decreased survival in human 
breast cancer patients. 
The TMA was stained for collagen II and scored based on the intensity of collagen 
II staining in the tumour stroma. We categorised the tumour cores into those 
that had predominantly low, medium or high collagen II expression (Figure 
4-16A), separating the samples into estrogen receptor (ER) positive and negative 
breast cancers in-case of hormone dependency, and compared these with overall 
patient survival. Data collected was specific to breast cancer survival, which 
tends to have a clinical association with death due to metastases from a primary 
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breast cancer source. It should be noted however that scoring of TMAs for 
stromal staining can complicated by the heterogeneity of staining and 
differences in stromal percentage, but in this instance the TMA cores had also 
been pre-selected for tumour rich areas, and so were not necessarily 
representative of the total tumour stroma. 
When considering the whole dataset, low collagen II expression correlated with 
decreased survival, with the effects being more pronounced in ER negative 
breast cancer (Figure 4-16B). It is therefore possible that whilst increased 
stromal expression of collagen II can increase the tumourigenicity of lung cancer 
and melanoma cell lines in mouse models, it may not necessarily be responsible 
for progression in human breast cancer patients. However, because collagen II 
expression was scored regardless of tumour stroma percentage (TSP), we also 
separately analysed the datasets comparing patient survival and collagen II 
expression in patients with high TSP and low TSP (which had been previously 
determined by scoring TSP on full sections of the patient derived material, Fadia 
Gujam, University of Glasgow, unpublished data). In ER negative breast cancer, 
patients with high TSP did seem to have a trend of decreased survival with 
increased collagen II expression up to the 40 month mark, however this did not 
extend beyond this time point, nor did it reach statistical significance (Figure 
4-16B). However, it should be noted that as the survival described is time from 
diagnosis to death due to breast cancer, the number of events plotted (N of 
events) is actually much lower that the number of patients monitored (Total N), 
especially when the patient population is separated on TSP and ER status. The 
reduced N numbers are not only due to survival, but also due to censored 
patients that died from causes other than breast cancer. There was therefore 
little statistical power in the analysis of ER negative breast cancer patients with 
high TSP, which was unfortunate as this may have been the most appropriate 
population to study within this patient cohort with respect to stromal collagen II 
expression and its contribution to tumour progression.  
When considering all patients with high TSP, having either low or high collagen II 
expression correlated with decreased survival and this did reach statistical 
significance due to the improved patient number (p value = 0.046 using a Log 
Rank (Mantel-Cox) testing equality of survival distributions for the different 
levels of collagen II score). This suggests a bell-shaped association of collagen II 
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expression with survival, and so having an optimum medium amount of stromal 
collagen II could be protective from breast cancer progression, whilst having 
either low or high amounts are detrimental. Low concentrations of collagen II 
could result in the organisation of a stroma with larger pore sizes and an 
architecture that is easily amenable to cell invasion and metastases, whilst high 
concentrations of collagen could also be supportive of increased cell migration 
and metastases, but through different mechanisms, including engagement of 
transmembrane receptors on the surface of cancer cells and consequent 
activation of signalling pathways that support increased dissemination.  
The relationship between increased collagen II expression and cancer progression 
in human disease is therefore a complex one. Going forward it would be 
interesting to stain the same TMA for tRNAiMet expression to understand whether 
tumours with high TSP and high collagen II expression also correlate with 
increased tRNAiMet levels, to enable us to fully understand whether levels of 
tRNAiMet can modulate ECM secretion to facilitate increased tumourigenesis in 
human cancer patients. 
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Figure 4-16- Collagen II expression in a breast cancer tissue microarray. 
(A) Representative cores from collagen II IHC of breast cancer TMA, scored for low, medium or 
high collagen II expression based on the intensity of the predominant stromal stain. (B) Patient 
survival assessed according to low, medium or high collagen II staining intensity, including all 
patients together, and then separating patients with low TSP compared to high TSP, and those with 
a ER negative and positive status. Total N indicates initial patient numbers included. Vertical dash 
indicates censored patients, indicative of survival or cause of death other than breast cancer. N of 
events indicates breast cancer related death.………………………………………………………………  
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4.3 Discussion  
As our understanding of tRNA biology grows we are beginning to appreciate that 
these small non-coding RNAs are much more than just housekeepers that 
translate mRNA to protein, and recognise that controlling the expression of 
tRNAs adds a complexity to protein synthesis in health and disease. The data 
described in this chapter demonstrate that expression of tRNAs is differentially 
regulated in immortalised cancer-associated fibroblasts compared to normal 
fibroblasts, and a stromal environment that has increased levels of tRNAiMet can 
promote an increase in the vascularity and growth of tumours. Indeed, the 
ability of iCAFs to constitute a drive to tumour growth in vivo is well established 
(Orimo et al., 2005), and here we show that tRNAiMet overexpressing fibroblasts 
can generate an ECM that supports increased migration of endothelial cells for 
vascularisation, and of fibroblasts themselves for further ECM remodelling. Our 
results indicate that this effect is due to increased secretion of extracellular 
proteins, with striking differences in the synthesis and secretion of various 
collagens and collagen related peptides. Specifically, we find that increased 
secretion of collagen II is responsible for the pro-migratory effects of the ECM 
derived from tRNAiMet-overexpressing fibroblasts, whilst we also show that 
compromising the secretion of collagens in vivo opposes the ability of tRNAiMet to 
promote increased tumour vascularity and growth. These findings are of great 
interest for three reasons: firstly, because they show that the relative levels of 
tRNA expression play an essential role in the tumour promoting abilities of CAFs; 
secondly, they indicate that tRNAiMet levels are closely linked to the cellular 
secretome and to ECM synthesis in particular; and thirdly, they provide the first 
pro-tumorigenic link to collagen II expression.  
Fibroblasts are one of the most abundant cell types in the stromal compartment, 
and much work has been done to understand their role in promoting 
carcinogenesis. This pro-tumorigenic ability has been attributed to secretion of a 
number of pro-angiogenic factors, including SDF-1 (Orimo et al., 2005). Using 
qPCR we were able to show that tRNA expression was differentially regulated in 
iCAFs compared to iNFs, including increased expression of our tRNA of interest, 
tRNAiMet (Figure 4-1). However, as may be expected, tRNAiMet was not the only 
tRNA differentially regulated in CAFs compared to controls. It would therefore 
be interesting to use custom arrays to compare the whole tRNAome of cancer-
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associated and normal fibroblasts to understand whether there are global 
changes in tRNA expression in these stromal cells, and to investigate whether 
overexpression of other specific tRNAs could also influence the ECM and its 
ability to promote tumourigenicity. 
We have shown in vivo that mice with increased expression of tRNAiMet can 
generate a microenvironment that facilitates increased tumour cell growth, and 
this could be attributed in part to the increased vascularity of those tumours 
(Figure 4-3). This has been mechanistically dissected using an in vitro approach 
which demonstrates the ability of tRNAiMet-overexpressing fibroblasts to generate 
an ECM that supports increased migration velocity of both fibroblasts and 
endothelial cells (Figure 4-4 & Figure 4-5). As tumours can essentially be 
described as “wounds that do not heal” (Dvorak, 1986), these effects on tumour 
growth in vivo and cell migration in vitro highlight the role of the tRNAiMet-
derived ECM in the desmoplastic response of tumour progression. Increased 
migration of fibroblasts is a characteristic of the CAF response seen in 
carcinogenesis (Ishii et al., 2010) while the ECM-induced increase in migration of 
endothelial cells provides a link to the increased vascularity of tumours in the 
2+tRNAiMet mice. Endothelial cell migration is an essential process in 
angiogenesis, and involves three major mechanisms – chemotaxis, haptotaxis, 
and mechanotaxis.  Chemotaxis refers to cell movement in response to soluble 
chemoattractants, haptotaxis describes directed migration towards immobilised 
ligand(s), and mechanotaxis is migration in response to mechanical stimuli 
(Lamalice et al., 2007). As we were unable to demonstrate any significant 
difference in thickness or stiffness of the ECM following tRNAiMet overexpression 
(Figure 4-6), it seems unlikely that increased endothelial cell migration is due to 
difference in mechanotaxis. The pro-migratory effects of the ECM from tRNAiMet-
overexpressing cells are therefore most probably owing to chemotaxis and/or 
haptotaxis. Although the in vitro ECM experiments performed are not capable of 
distinguishing between the contribution of chemotaxis and haptotaxis, they do 
suggest that both processes may be involved in the ability of ECM from tRNAiMet-
overexpressing cells to support increased endothelial cell migration. 
Characterisation of the fibroblast secretome revealed that overexpression of 
tRNAiMet led to increased secretion of molecules such as angiopoietin-4 (Figure 
4-11B). Angiopoietins have essential roles in angiogenic chemotaxis (Fagiani and 
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Christofori, 2013). Published data on the role of angiopoietin-4 in angiogenesis is 
however conflicting; with some studies suggesting a pro-angiogenic role 
(Brunckhorst et al., 2010) and others reporting inhibitory effects (Olsen et al., 
2006). However, the results of the collagen II knockdown experiments and the 
ability of the prolyl-hydroxylase inhibitor DHB to block the increase in 
vascularity and growth of tumours in the 2+tRNAiMet mice suggest that the main 
driver of the increased tumourigenicity is most probably via haptotaxis; with 
tRNAiMet’s ability to increase collagen deposition into the ECM directly influencing 
the migration of endothelial cells in a pro-angiogenic manner. Cell surface 
collagen receptors are therefore likely to play a role in this process. While 
angiogenesis can be coordinated by a number of different integrin receptors 
(reviewed in (Silva et al., 2008)), integrin α2β1 preferentially binds fibrillar 
collagens and is expressed on the surface of both endothelial cells and 
fibroblasts. This receptor could therefore be important in both facilitating 
endothelial migration in angiogenesis and in fibroblast-mediated remodelling of 
the collagen-rich TME (Hu et al., 2011). Receptor tyrosine kinases from the 
discoidin domain receptor (DDR) family that recognise and respond to collagen 
could also influence tumour progression, including DDR2 which preferentially 
binds collagen II (Leitinger et al., 2004), and whose activity has been associated 
with tumour progression in squamous cell carcinoma of the lung (Hammerman et 
al., 2011) and cancers of the head and neck (Chua et al., 2008). The collagen 
rich matrix generated following tRNAiMet overexpression could therefore be 
promoting an increase in tumour growth through a number of different but 
complementary processes.  
Our SILAC characterisation of protein secretion following tRNAiMet overexpression 
was key to beginning to understand the mechanism by which tRNAiMet could 
promote generation of a pro-tumourigenic ECM. The role of other translation 
factors, associated ribosomal proteins, and their contribution to tumour 
progression, has already been well established (Loreni et al., 2014, Rubio et al., 
2014, Wolfe et al., 2014, Ruggero, 2013). Oncogenic and tumour suppressor 
signals are known to converge on pathways that promote protein synthesis, and 
control of translation is regarded as an essential requirement in cancer 
progression. Moreover, this control is performed with an element of specificity, 
and translation of particular mRNAs can be achieved through a number of 
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mechanisms, including the presence of secondary structure in the 5’ UTR, in 
addition to IRES sites and uORFs (Wolfe et al., 2014, Hsieh et al., 2012, Thoreen 
et al., 2012). The importance of the translation initiation machinery in driving 
translational selectivity is also now apparent. The RNA-cap binding protein, 
eIF4E, is commonly overexpressed in cancer, and its ability to drive an increase 
in tumourigenicity has been attributed to its selective effects on the translation 
of the anti-apoptotic protein, MCL1 (Wendel et al., 2007). More recently eIF4A, 
an RNA helicase, has also been shown to favour translation of oncoproteins such 
as Myc, Notch and BCL2, all of which possess G-quadruplex structures in their 5’-
UTRs (Wolfe et al., 2014). Furthermore, TORC1, the mTOR-containing kinase 
complex which phosphorylates the eIF4E-binding protein (4E-BP1) leading to 
activation of eIF4E, has also been shown to contribute to metastasis by favouring 
translation of a cohort of mRNAs with pyrimidine-rich translational elements 
(PRTEs) or terminal oligopyrimidine tracts (TOPs) in their 5’-UTRs (Hsieh et al., 
2012). Amongst these transcripts are the gene products of YB1, vimentin and 
CD44, which are all thought to cooperate to generate an invasive cancer 
phenotype. Moreover, we also now know that changes in the cellular tRNA 
repertoire can further dictate the efficiency of translational programmes to 
define cell fates (Gingold et al., 2014). A positive correlation between tRNA 
expression and codon usage for ECM genes has been previously observed in 
breast cancer cells (Pavon-Eternod et al., 2009), and so a dose dependency 
between tRNA expression and translational efficiency could therefore influence 
gene expression. Whilst knockdown of tRNAs is technically difficult with standard 
siRNA methods, the advent of CRISPR gene editing technologies now provides a 
strategy to knockout specific tRNA genes, and so use of these methods could 
further contribute to this work and advance our understanding of the influence 
of tRNA expression in translational control. 
Gene expression studies have identified distinct subtypes of CAFs with differing 
tumour promoting abilities. Furthermore, many of these gene expression 
analyses have shown that expression levels of collagen XV, collagen XI and 
biglycan, a cartilage proteoglycan with a role in assembling collagen fibrils 
including collagen II, are commonly upregulated in CAFs (Costea et al., 2013). 
Whilst the RNA-Seq data we have generated here indicates that the level of gene 
expression is increased for some of the differentially regulated ECM proteins 
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following tRNAiMet overexpression, such as collagen II, this is not consistent 
across all iMEF pools tested. The increase in tRNAiMet expression is much larger in 
iMEF pool 1 compared to iMEF pool 2, and as a consequence drives a much larger 
increase in collagen II protein secretion. It is therefore possible that this larger 
increase in protein synthesis may consequently feed forward into the cells 
transcriptional cycle, either increasing the level of transcription of collagen II 
itself, or stabilising expression of the collagen II transcript. However, not all 
tRNAiMet regulated proteins are upregulated at the level of transcription. 
Collagen I and collagen XI are both secreted proteins that have increased total 
protein levels and increased protein secretion following tRNAiMet overexpression, 
but have no corresponding change in the levels of their mRNAs, indicating that 
tRNAiMet can influence gene expression at the level of translational control. 
Future work to investigate the effect of tRNAiMet on translational efficiency 
would further complement the transcriptome and proteomic changes that we 
have already described, and provide a more detailed understanding of how 
tRNAiMet can control the expression of specific ECM proteins. The use of 
techniques such as ribosome profiling and ribosome footprinting would help 
capture more information regarding which transcripts are being actively 
transcribed following tRNAiMet overexpression, whilst detailed bioinformatic 
analysis of hits would also enable us to understand whether particular sequence 
elements are responsible for tRNAiMet’s specificity. ECM production constitutes a 
significant commitment to the cell, both in terms of load on the endoplasmic 
reticulum (ER) and the biosynthetic machinery, highlighting the need for special 
mechanisms to control the translation of ECM proteins and other abundant 
components of the fibroblast secretome. For example, it is already known that 
expression of collagen I, a fibril-forming collagen, can be controlled at the level 
of mRNA stability and translation, due to unique stem loops in its 5’ UTR 
(Manojlovic and Stefanovic, 2012), and a role for collagen I in cancer progression 
has been previously shown (Cheng and Leung, 2011, Zou et al., 2013). It may 
therefore be possible that tRNAiMet is selectively increasing translation of 
proteins that have specific structures, or sequences, in their flanking regions, 
and control of this selectivity may play an important role in maintaining cellular 
fitness.  
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Collagen II, the most upregulated secreted protein following tRNAiMet 
overexpression, is a fibril-forming collagen, composed of three α1(II) chains, 
with alternative splicing contributing to two different isoforms of the α1(II) 
chains, type IIA and type IIB (Ricard-Blum, 2011). Collagen II is an abundant 
component of cartilage and is produced in large quantities by chondrocytes. By 
contrast, normal fibroblasts are not thought to secrete collagen II and, 
consistently, our SILAC data show that this collagen is a minor component of the 
fibroblast secretome. Thus, acquisition of type II collagen secretion when 
tRNAiMet levels are increased may represent a shift to a more chondrocyte-like 
phenotype, and this may be consistent with a role for the tRNA repertoire in 
influencing cellular differentiation states (Gingold et al., 2014).  
Chondrocytes synthesise cartilage ECM, and this matrix is predominantly 
composed of type IIB collagen II. Synthesised as procollagens, NH2- and COOH- 
terminal extension peptides are cleaved and removed prior to type IIB collagen II 
incorporation into the ECM, however in the case of type IIA collagen II the NH2- 
propeptide is not removed, and the entire procollagen is deposited into the ECM 
(Wang et al., 2010). The cleaved NH2- propeptide of collagen type IIB has been 
shown to induce tumour cell death, however the intact NH2- domain of type IA 
collagen II, although able to bind tumour cells through αvβ3 and αvβ5 integrins, 
does not induce tumour cell death (Wang et al., 2010). Type IIA collagen II is 
also able to bind growth factors, such as BMP-2 and TGF-β, and so it is possible 
that this isoform could promote tumour cell proliferation and migration via these 
growth factors. Indeed, type IIA collagen II is the collagen that is most 
upregulated following tRNAiMet overexpression, and so the desmoplastic response 
in cancer and increased tumour growth seen in our transgenic mouse models 
could be due to a dynamic interplay between tRNA controlled translation and 
the consequent upregulation of a type IIA collagen II-rich ECM. 
With regard to relevance in human disease, we found that high levels of collagen 
II expression in tumour stroma from breast cancer patients correlated with 
increased survival when analysing the patient cohort as a whole. Whilst this 
result initially seemed contradictory to our in vitro and in vivo findings, it may 
simply mean that the tRNAiMet driven effects on collagen II secretion do not 
contribute to tumour progression in breast cancer, but may still have effects in 
other human cancer types. However, in light of the differential activity of the 
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alternative splice forms of collagen II it is also possible that it is type IIB collagen 
II expression that is differentially regulated in the stroma of breast cancer 
patients. The antibody used to stain the breast cancer TMA is unable to 
differentiate between type IIA and type IIB collagen II splice variants, and so if 
type IIB collagen II expression is specifically increased in breast cancer patients 
then this could indeed correlate with anti-tumour effects and increased survival. 
Thus, it may be that expression of type IIA (but not type IIB) collagen II is pro-
tumourigenic and responsible for the increase in vascularity and tumour cell 
growth in the 2+tRNAiMet mice. It would therefore be interesting to use CRISPR 
gene editing approaches to knock-out the specific splice variants of collagen II in 
fibroblasts and assess the ability of ECM deposited by these cells to support 
migration ex vivo, while a more detailed in vivo analysis could include using 
fibroblast specific knockouts of type IIA collagen II in 2+tRNAiMet mice and 
consequent assessment of syngeneic tumour growth. Alternatively, if we 
consider only tumour cores that were judged to have high TSP, then we could 
also conclude that having a moderate amount of collagen II promotes increased 
survival whilst having an extreme amount, be it either low or high, can generate 
a stroma that promotes disease progression. Whilst this may initially seems like a 
paradox, it is reflective of the many opposing mechanisms that can contribute to 
tumour progression and highlights the fine balance between them. 
Collagens are large, bulky proteins, whose synthesis and secretion requires 
dedicated vesicular transport pathways, including the use of modified COPII 
protein vesicles to encapsulate the large procollagen molecules for transport 
from the ER to the Golgi complex (Jin et al., 2012) and the implementation of a 
specialised budding process to allow the formation of post-Golgi vesicles of 
sufficient size to carry collagens (Nogueira et al., 2014). Thus general 
upregulation of secretory capacity and secretory protein vesicular transport 
suggests the possibility that the pro-tumourigenic effects of tRNAiMet are not 
solely owing to direct effects of collagen II, but to other molecule(s) that are co-
secreted with it. To investigate this possibility it would be interesting to use 
SILAC mass spectrometry to characterise the fibroblast secretome in tRNAiMet 
overexpressing cells in which collagen II expression is stably knocked-out using 
CRISPR, and compare this to the secretome previously obtained for tRNAiMet 
overexpressing cells. This would help us understand whether the effects of 
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tRNAiMet on generation of a pro-migratory ECM are specifically due to collagen II 
expression, or due to a collagen II-dependent secretome that impacts the 
tumour microenvironment. 
In conclusion, we have found compelling evidence indicating that increased 
expression of tRNAiMet in fibroblasts has profound non-cell autonomous effects on 
tumour progression. Through increasing the synthesis and secretion of particular 
ECM components, specifically collagen II, the ECM generated from fibroblasts 
overexpressing tRNAiMet is able to promote increased cell migration, increased 
angiogenesis and increased tumour growth (Figure 4-17). Combined with data 
presented in the previous chapter, the work presented in this thesis collectively 
shows that increased expression of tRNAiMet in fibroblasts can influence their 
behaviour to promote an increase in cell migration and an increase in 
tumourigenicity. 
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Figure 4-17- Schematic representation of the non-cell autonomous effects of tRNAiMet 
overexpression.  
(1) Fibroblasts with increased expression of tRNAiMet increase the translation and secretion of 
specific proteins such as collagen II. (2) This collagen II-rich ECM increases the migration of (3) 
fibroblasts and endothelial cells contributing to the (4) increased vascularity and (5) growth of 
tumours. Image made using items from Image Bank in Servier Medical Art.  
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Chapter 5 Final Discussion  
Misregulation of translational control is one mechanism that enables cancer cells 
to evade normal cellular homeostasis and drive an increase in their 
tumourigenicity. We show here that overexpression of tRNAiMet, an integral 
component of the translation initiation machinery, can drive increases in cell 
migration and can selectively influence  the fibroblast secretome. This leads to 
production of an ECM that is rich in collagen II, a normally minor component of 
the fibroblast-derived ECM, which then provides a microenvironment that 
supports increased migration of endothelial cells, increased angiogenesis, and 
increased fibroblast migration, which can all collectively increase the rate of 
tumour progression (Figure 5-1).  
 
Figure 5-1- Proposed model of the tRNAiMet effect on tumour progression.  
Stromal fibroblasts with increased tRNAiMet levels can increase the synthesis and secretion of 
specific ECM proteins, including collagen II. The collagen II-rich ECM can then facilitate increased 
tumour growth through increased endothelial cell migration and angiogenesis. Further speculative 
effects of the ECM on tumour growth are suggested in italic font, including the possibility that the 
ECM could be internalised and used as substrate for increased protein synthesis and cancer cell 
metabolism. The cancer cells could also stimulate a paracrine signalling pathway to the adjacent 
fibroblasts for continual remodelling of the matrix, whilst the increase in vascularity could also result 
in an increase in metastasis at distant sites. Image made using items from Image Bank in Servier 
Medical Art. 
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A recent publication revealed that there are differential requirements for the 
level of eIF4E, the major cap-binding protein in translation initiation, in normal 
development compared to cancer (Truitt et al., 2015). This study showed that 
eIF4E is expressed in excess throughout normal development, and only becomes 
limiting under the specific conditions of oncogene-induced transformation. 
Cancer cells consequently utilise this excess eIF4E to drive their transformation 
by directing the translation of specific subsets of mRNAs which can support 
tumour cell growth and survival. It is well-established that reactive oxygen 
species (ROS) can influence many aspects of tumour development (reviewed in 
(Liou and Storz, 2010)). This study identified that a number of transcripts for 
proteins functioning as ROS scavengers are characterised by specific motifs in 
their 5’ UTRs, and increased translation of these transcripts was supported by 
high levels of eIF4E. Our study has marked analogies to the study by Truitt et al. 
in that we also find a dose-dependent effect of a translation initiation 
component that seems to be particularly important to cancer progression, but 
that has less relevance to normal growth and development. Indeed, we find that 
excess tRNAiMet in the 2+tRNAiMet mouse also does not affect normal mouse 
development or the overall rates of protein synthesis in normal cells. However, 
the increased tRNAiMet levels in stromal cells increases secretion of specific ECM 
proteins, and whilst this does not exert an overt phenotypic effect in the normal 
animal, when exposed to a specific insult, such as the introduction of 
transformed cells as a syngeneic allograft, the altered matrix secreted by the 
tRNAiMet-overexpressing fibroblasts then facilitates more rapid tumour 
progression. 
Deregulated translational control can contribute to each step of cellular 
transformation, from the initial expression of specific oncogenes owing to 
structures in their untranslated regions, to the increase in ribosome biogenesis 
and global protein synthesis required for increased cell growth and cell division 
(Ruggero, 2013). By facilitating protein enrichment at its site of function, the 
spatial location of translation is another important mechanism that enables 
protein synthesis to influence cell behaviour. Eukaryotic initiation factors have 
been shown to localise to the leading edge of migrating fibroblasts, with eIF4E 
and eIF4G associating with Golgi apparatus at membrane microdomains that also 
co-localise with sites of active translation (Willett et al., 2011). Translation of 
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intracellular proteins, such as β-actin, at the leading edge of migrating cells 
could promote increased cell migration through the local synthesis of new β-
actin which is thought to be more efficiently polymerised than older, more 
modified, actin molecules (Liao et al., 2015), and local synthesis of proteins 
required for new membrane formation could also be important in generating 
new cell protrusions. Translation of secretory proteins at such sites could also 
facilitate their efficient secretion from the cell, especially considering the large 
size of matrix proteins such as collagen, thus promoting cell motility in a manner 
that is energetically favourable to the cell, and supporting generation of a 
microenvironment that can promote tumour growth.  
The increase in migration that we have characterised in fibroblasts following 
tRNAiMet overexpression is dependent on the role of tRNAiMet in the TC and the 
ability of integrin α5β1 to bind fibronectin. As initial fibronectin deposition and 
fibrillogenesis are important in subsequent fibrillar collagen assembly (Egeblad 
et al., 2010), and cells are able to secrete their own matrix to promote motility 
(Sung et al., 2011), the integrin α5β1-fibronectin dependent effects on cell 
migration are likely to play an important role in the early stages of ECM 
remodelling, and so may also be a pre-requisite for the non-cell autonomous pro-
tumourigenic effects of the tRNAiMet-driven collagen II-rich ECM. 
With regard to relevance in human cancer, it seems that the relationship 
between collagen II expression and disease progression is likely to be complex. 
Previous studies have found that modifications in collagen metabolism in breast 
cancer can result in decreased collagen content in breast tumour tissue 
(Cechowska-Pasko et al., 2006) and collagen α1 (XI) has been found to be 
downregulated in the immediate stroma surrounding breast tumours (Halsted et 
al., 2008). Similar to collagen II, collagen α1 (XI) is also mainly expressed in 
chondrocytes under normal conditions, however recent work has shown that it 
becomes highly expressed in stromal cells associated with other aggressive 
cancers such as glioblastoma, and has consequently been proposed to be a 
biomarker for carcinoma-associated stromal cells and aggressive cancer 
progression (Vazquez-Villa et al., 2015). Although this work was not specifically 
focused on collagen II, collagen α3 (XI) is the same gene product as collagen II 
and differs only by hyperglycosylation (Burgeson and Hollister, 1979, Morris and 
Bachinger, 1987), and so it is likely that collagen II could also follow a similar 
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expression pattern to collagen α3 (XI). Studies in prostate cancer, lung cancer 
and colorectal cancer have found increased expression of collagens in cancerous 
compared to normal tissues (Fischer et al., 2001, Chang et al., 2004, Banyard et 
al., 2007), and so investigating the contribution of a collagen II-rich stroma to 
tumour progression in these cancer types may also be appropriate. In the future 
it would be interesting to understand exactly how a collagen II-rich tumour 
microenvironment affects cancer cells, and whether the increase in tumour 
growth that we see in our in vivo models is simply due to the increase in 
vascularity of the tumours, or whether there are also other processes that 
contribute to this. Changes in collagen metabolism associated with the Gleeson 
grade of tumour have been identified in prostate cancer (Burns-Cox et al., 
2001). Thus, in addition to increasing the migration of stromal and endothelial 
cells, endocytosis of the altered matrix could also fuel cellular metabolism, 
protein synthesis and cell growth. The increased collagen content of the ECM 
could essentially act as a proline reservoir for cancer cells, and consequent 
proline metabolism may serve not only as an energy source but can also increase 
formation of signalling ROS (Phang et al., 2015). Increased rates of ROS have 
been found across a variety of different cancer types, and have been shown to 
influence a number of signalling pathways associated with cell proliferation, 
motility and metastasis (reviewed in (Liou and Storz, 2010)). The metabolism of 
proline from a collagen-rich tumour microenvironment could therefore provide 
additional mechanisms to fuel an increase in tumourigenicity. 
Tumour cells are also known to secrete cytokines and chemokines (Zheng et al., 
2015, Maxwell et al., 2014), and these molecules can signal to stromal cells in a 
paracrine fashion to further promote a reactive microenvironment. Whilst the 
inflammatory response to tumour growth is well established, recent data has 
also shown how NF-κB, a transcription factor known to mediate inflammatory 
signals, can also directly regulate the Pol III mediated transcription of tRNAs in 
macrophages to influence their cytokine secretion and phagocytic response 
(Graczyk et al., 2015). The NF-κB mediated increase in Pol III transcription 
described in macrophages could therefore also be a potential mechanism 
exploited by cancer cells, not only in driving immune activity in the tumour 
microenvironment, but if cytokine release from cancer cells could also mediate 
NF-κB-stimulated transcription of tRNAs in stromal cells, then it would provide a 
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means for cancer cells to co-opt their neighbours into increasing expression of 
tRNAs to ignite a positive feedback loop and further promote increased tumour 
growth.  
Throughout the course of this work we have only discussed the effects of 
tRNAiMet  overexpression with regard to absolute tRNA expression levels, and 
although the increases in expression of tRNAiMet in both our in vivo and in vitro 
models are analogous to those increases found in human cancer populations 
(Pavon-Eternod et al., 2009), we are unable to comment on what influence the 
modification of tRNAiMet may be having in these systems. The nucleobases and 
ribose sugars of tRNAs are highly modified by various enzymes to form 
chemically different tRNA structures, and changes in expression of these 
enzymes and consequent shifts in the levels of tRNA modification have been 
associated with a variety of cancer types (Shimada et al., 2009, Begley et al., 
2013). Furthermore, tRNA modifications can be dynamically controlled in 
association with the cell’s stress response (Chan et al., 2010), and these 
modifications can shift translational efficiency through codon bias to 
consequently effect the expression of specific genes (Chan et al., 2012). The 
ability of cells to modify their tRNAs in response to external stimuli has been 
likened to the regulatory networks that influence epigenetic changes (Dedon and 
Begley, 2014), and so the regulatory function of tRNA modification may provide 
another mechanism that enables tRNA expression to influence disease states.   
The data presented in this thesis is also specific to the effects of tRNAiMet in 
fibroblasts. However, increased Pol III transcription is also a common feature of 
cancer cells themselves. Using fibroblasts as a model, it is likely that increased 
expression of specific Pol III products, such as tRNAiMet, could also contribute to 
increased migration and invasion of cancer cells. Any cellular functions that are 
sensitive to small changes in tRNAiMet levels could not only provide an effective 
route to target the tumour stroma, but could also be useful in treating more 
metastatic and invasive cancers that may rely on tRNAiMet to support their own 
cell migration. Targeting the tumour stroma has become an attractive strategy 
in cancer therapy (Zhou et al., 2015, Lunardi et al., 2014, Teichgraber et al., 
2015) and if the pro-tumourigenic effects of tRNAiMet are indeed common to both 
stromal fibroblasts and cancer cells, then therapeutics aimed at suppressing 
levels of tRNAiMet could have dual effectiveness in halting tumour progression.  
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Whilst initial proposals to target the translational machinery for therapeutic use 
were dismissed owing to a lack of specificity, it has since been demonstrated 
that targeting initiation factors in vivo can be efficacious (Loreni et al., 2014, 
Bhat et al., 2015). Translation plays an essential role in mediating dysregulated 
signalling across a variety of different cancer types, and a number of inhibitors 
of the TC have already been developed as potential anti-cancer therapies, 
including drugs that prevent binding of tRNAiMet to eIF2 (Robert et al., 2006). 
Whilst efficacy of the latter is yet to be reported, a small molecule inhibitor of 
RNA polymerase I (Pol I) has been effective in preventing tumour growth in 
mouse allograft models (Drygin et al., 2011). Pol I is also responsible for the 
transcription of non-coding RNAs, and so in vivo success with Pol I inhibitors may 
provide future promise for targeting Pol III and its transcripts. 
Collectively, the data presented throughout this thesis highlights how increased 
levels of specific tRNAs are not merely a consequence of tumourigenesis, but are 
important in driving increased tumour progression. Translation is a process that 
is tightly controlled via a number of different mechanisms, and elegant 
adaptations have evolved to increase translational efficiency, including changes 
in the cells tRNAome. Whilst in health this can essentially increase cellular 
fitness, in disease it may be hijacked to detrimental effect. Cancer provides a 
prime example of this, and we show here how overexpression of tRNAiMet in 
stromal fibroblasts can significantly influence the tumour microenvironment to 
promote increased tumour growth. Continuing to develop a more detailed 
understanding of tRNA functionality may therefore not only uncover new layers 
of complexity in cell biology, but could also potentially highlight new targets for 
future cancer therapies. 
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Appendices  
Appendix I: Secretome dataset 
Protein name Gene 
Symbol 
MW 
kDa 
Forward 
SILAC ratio 
Reverse 
SILAC ratio 
Unique 
peptides 
Collagen alpha-1(II) Col2a1 135 5.96 6.15 37 
Otoraplin Otor 14 4.70 4.57 4 
Secreted frizzled-related 
protein 2 
Sfrp2 33 4.58 4.24 11 
Angiopoietin-4 Angpt4 58 4.50 4.51 9 
Tenascin-N Tnn 173 3.77 4.17 18 
ABI family member 3 NESH 
binding protein 
Abi3bp 130 3.73 3.49 21 
C-type lectin domain 
family 11 member A 
Clec11a 36 3.43 3.28 12 
Procollagen C-
endopeptidase enhancer 2 
Pcolce2 45 3.35 3.39 6 
Pappalysin 2 Pappa2 199 3.32 2.83 4 
Transforming growth factor 
beta-2 
Tgfb2 48 3.31 3.03 8 
Plasminogen activator 
inhibitor 1 
Serpine1 45 3.14 3.09 15 
Pentraxin-related protein 
PTX3 
Ptx3 42 3.13 2.83 17 
Immunoglobulin 
superfamily containing 
leucine-rich repeat protein 
Islr 46 3.10 3.15 7 
Semaphorin-3A Sema3a 89 3.03 2.60 19 
Atrial natriuretic peptide 
receptor 3 
Npr3 60 2.89 2.88 11 
Osteomodulin Omd 50 2.88 3.08 5 
Heat shock protein beta-1 Hspb1 22 2.66 3.02 8 
Dickkopf-related protein 3 Dkk3 38 2.59 2.53 6 
Phospholipid transfer 
protein 
Pltp 54 2.51 2.42 13 
Collagen alpha-1(XI) chain Col11a1 171 2.48 2.56 26 
Fibromodulin Fmod 43 2.44 2.71 7 
Follistatin-related protein  Fstl1 35 2.35 2.15 15 
A disintegrin and 
metalloproteinase with 
thrombospondin motifs 1 
Adamts1 106 2.34 2.10 6 
Protein NOV homolog Nov 39 2.33 2.37 7 
SPARC-like protein 1 Sparcl1 72 2.31 2.04 12 
Peptidyl-prolyl cis-trans 
isomerase 
Fkbp10 65 2.31 2.15 28 
Collagen alpha-1(XII) chain Col12a1 340 2.30 2.13 199 
Mimecan Ogn 34 2.29 2.11 22 
Clusterin Clu 52 2.29 2.23 5 
Fibulin-5 Fbln5 50 2.25 2.03 12 
Periostin Postn 93 2.24 2.58 19 
Procollagen-lysine,2-oxo Plod3 85 2.23 2.04 20 
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glutarate 5-dioxygenase 3 
Twisted gastrulation 
protein homolog 1 
Twsg1 25 2.23 2.84 2 
DnaJ homolog subfamily B 
member 11 
Dnajb11 41 2.20 2.02 4 
Complement C1q tumor 
necrosis factor-related 
protein 5 
C1qtnf5 23 2.17 2.60 4 
Platelet-derived growth 
factor D 
Pdgfd 42 2.15 2.11 3 
Amyloid beta A4 protein App 87 2.07 2.09 10 
Nidogen-2 Nid2 154 2.06 2.02 39 
EGF-containing fibulin-like 
extracellular matrix 
protein 2 
Efemp2 49 1.90 1.97 12 
Vitamin K-dependent 
protein S 
Pros1 75 1.90 1.75 10 
Acyl-coenzyme A 
thioesterase 2 
Acot2; 
Acot1 
50 1.90 1.84 9 
Immunoglobulin 
superfamily member 10 
Igsf10 286 1.89 1.67 37 
Latent-transforming 
growth factor beta-binding 
protein 3 
Ltbp3 134 1.88 2.19 8 
Thrombospondin-1 Thbs1 130 1.88 1.96 15 
Coiled-coil domain-
containing protein 80 
Ccdc80 108 1.82 1.73 18 
Platelet-derived growth 
factor receptor-like 
protein 
Pdgfrl 42 1.80 1.63 16 
Lysyl oxidase homolog 4 Loxl4 85 1.79 1.89 11 
SPARC Sparc 34 1.77 1.74 18 
Peptidyl-prolyl cis-trans 
isomerase C 
Ppic 23 1.76 1.67 11 
Peptidyl-prolyl cis-trans 
isomerase FKBP9 
Fkbp9 63 1.73 1.59 10 
Calumenin Calu 37 1.69 1.53 3 
Membrane-bound 
transcription factor site-1 
protease 
Mbtps1 117 1.66 1.42 9 
Carboxypeptidase E Cpe 53 1.64 1.43 25 
Protein FAM3C Fam3c 21 1.56 1.48 11 
EMILIN-1 Emilin1 108 1.53 1.54 45 
Thrombospondin-3 Thbs3 100 1.52 1.47 8 
Sulfated glycoprotein 1 Psap 61 1.52 1.63 10 
Calreticulin Calr 48 1.49 1.34 25 
Protein canopy homolog 2 Cnpy2 21 1.49 1.44 10 
Thioredoxin domain-
containing protein 12 
Txndc12 19 1.48 1.46 4 
Serpin H1 Serpinh1 47 1.48 1.39 28 
Granulins Grn 63 1.48 1.54 3 
Metalloproteinase inhibitor 
2 
Timp2 24 1.47 1.45 17 
Collagen alpha-2(I) chain Col1a2 130 1.46 1.50 110 
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Peroxidasin homolog Pxdn 165 1.46 1.35 50 
Vasorin Vasn 72 1.44 1.50 12 
F-box only protein 2 Fbxo2 34 1.44 1.56 2 
Guanine nucleotide-binding 
protein G(o) subunit alpha 
Gnao1 40 1.43 1.61 8 
Roundabout homolog 1 Robo1 176 1.43 2.06 7 
Collagen alpha-1(I) chain Col1a1 138 1.40 1.50 92 
Protein-lysine 6-oxidase Lox 47 1.35 1.31 19 
78 kDa glucose-regulated 
protein 
Hspa5 72 1.29 1.23 46 
Collagen, type VI, alpha 3 Col6a3 354 -0.80 -1.06 191 
Carbonic anhydrase 13 Ca13 30 -0.96 -1.10 8 
DnaJ (Hsp40) homolog, 
subfamily C, member 13 
Dnajc13 254 -1.01 -1.02 53 
Glutathione S-transferase 
A4 
Gsta4 26 -1.01 -1.14 16 
Aldo-Keto Reductase 
Family 1, Member B10 
Akr1b10 36 -1.07 -1.16 7 
Laminin subunit alpha-5 Lama5 404 -1.10 -1.38 40 
Aldose reductase-related 
protein 2 
Akr1b8 36 -1.11 -1.11 9 
Serine/threonine-protein 
kinase SMG1 
Smg1 402 -1.13 -1.34 4 
Cadherin-11 Cdh11 88 -1.14 -1.18 27 
5'-Nucleotidase Domain 
Containing 2 
Nt5dc2 46 -1.27 -1.22 6 
Cellular retinoic acid-
binding protein 2 
Crabp2 16 -1.28 -1.62 4 
Matrix Gla protein Mgp 12 -1.31 -1.58 3 
Glypican-1;Secreted 
glypican-1 
Gpc1 61 -1.47 -1.10 17 
Apolipoprotein B-
100;Apolipoprotein B-48 
Apob 504 -1.88 2.99 3 
Versican core protein Vcan 367 -2.00 -1.95 5 
Serine protease inhibitor 
A3G 
Serpina3g 49 -2.07 -2.39 10 
Ubiquitin-like protein 
ISG15 
Isg15 18 -2.13 -2.51 4 
Interleukin-1 receptor 
antagonist protein 
Il1rn 18 -2.40 -2.72 6 
Osteopontin Spp1 32 -2.81 -3.13 3 
Stromelysin-1 Mmp3 54 -3.01 -2.13 18 
Appendix I – Secreted proteins significantly changed in the conditioned media of 
iMEF.tRNAiMet cells versus iMEF.Vector cells (pool 1). 
The secretome was analysed following tRNAiMet overexpression using quantitative SILAC mass 
spectrometry. iMEF.Vector and iMEF.tRNAiMet cells were labelled with heavy and light amino acids, 
secreted proteins isolated from the conditioned media, separated by gel electrophoresis, and then 
analysed by mass spectrometry. Forward experiment corresponds to iMEF.tRNAiMet cells labelled 
with heavy amino acids combined with iMEF.Vector cells labelled with light amino acids, and the 
reverse experiment corresponds to iMEF.Vector cells labelled with heavy amino acids combined 
with iMEF.tRNAiMet cells labelled with light amino acids.  Forward SILAC ratio is calculated as (Log2 
tRNAiMet / Vector), and reverse SILAC ratio as (1/(Log2 tRNAiMet / Vector)), MW = molecular weight, 
and unique peptides refers to the number of peptides identified that exist only in that one protein of 
interest. Data generated in collaboration with David Sumpton, CR-UK Beatson Institute, Glasgow.
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Appendix II: Cellular proteome dataset 
Protein name Gene  
Symbol 
MW  
kDa 
Forward 
SILAC ratio 
Reverse  
SILAC ratio 
Unique 
peptides 
ABI family member 3 
NESH binding protein 
Abi3bp 118 3.70 2.91 9 
Immunoglobulin 
superfamily containing 
leucine-rich repeat 
protein 
Islr 46 2.90 2.87 6 
Collagen alpha-1(II)  Col2a1 132 2.82 2.39 12 
Cytochrome P450 26B1 Cyp26b1 57 2.63 2.80 3 
Atrial natriuretic peptide 
receptor 3 
Npr3 60 2.61 2.62 16 
Angiopoietin-4 Angpt4 58 2.59 3.63 8 
Transforming growth 
factor beta-2 
Tgfb2 48 2.26 2.61 4 
Collagen alpha-1(XI) 
chain 
Col11a1 171 2.04 2.35 14 
Heat shock protein beta-1 Hspb1 23 1.96 2.33 8 
Cytokine receptor-like 
factor 1 
Crlf1 47 1.91 1.82 6 
Dickkopf-related protein 
3 
Dkk3 38 1.86 2.13 3 
Aryl hydrocarbon 
receptor 
Ahr 95 1.82 1.76 12 
Guanine nucleotide-
binding protein G(o) 
subunit alpha 
Gnao1 40 1.77 1.56 12 
Collagen alpha-1(XII) 
chain 
Col12a1 334 1.70 1.77 97 
Prolyl 3-hydroxylase 2 Leprel1 80 1.67 1.55 17 
Acyl-coenzyme A 
thioesterase 2 
Acot2; 
Acot1 
50 1.67 1.71 10 
Core histone macro-H2A.2 H2afy2 40 1.62 1.76 13 
F-box only protein 2 Fbxo2 34 1.62 1.72 5 
Midline-1 Mid1 75 1.61 1.77 14 
Membrane primary amine 
oxidase 
Aoc3 85 1.61 2.10 10 
Sulfate transporter Slc26a2 82 1.54 1.91 4 
C-type lectin domain 
family 11 member A 
Clec11a 36 1.53 2.12 2 
Galactocerebrosidase Galc 77 1.49 1.27 5 
Protein bicaudal C 
homolog 1 
Bicc1 105 1.45 1.25 11 
Sodium/potassium-
transporting ATPase 
subunit beta-1 
Atp1b1 35 1.43 1.48 7 
Pentraxin-related protein 
PTX3 
Ptx3 42 1.39 1.25 7 
Protocadherin Fat 4 Fat4 540 1.39 1.56 39 
TSC22 Domain Family, 
Member 2 
Tsc22d2 78 1.36 1.87 4 
Transmembrane protein 2 Tmem2 154 1.33 1.49 22 
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Alpha-1-syntrophin Snta1 53 1.33 1.21 8 
Interferon-induced 
helicase C domain-
containing protein 1 
Ifih1 116 1.29 1.29 20 
Calponin-1 Cnn1 33 1.28 1.25 15 
Solute carrier family 12 
member 2 
Slc12a2 131 1.28 1.45 29 
Eukaryotic initiation 
factor 4A-II 
Eif4a2 46 1.23 1.45 9 
Netrin receptor UNC5B Unc5b 102 1.23 1.29 13 
Protein FAM115A Fam115a 103 1.23 1.34 14 
Alpha-(1,3)-
fucosyltransferase 11 
Fut11 56 1.21 1.52 2 
MAGUK p55 subfamily 
member 2 
Mpp2 62 1.21 1.59 7 
Thrombospondin-1 Thbs1 130 1.21 1.44 24 
Eukaryotic translation 
initiation factor 2A 
Eif2a 64 1.19 1.22 19 
Semaphorin-3A Sema3a 79 1.19 1.07 8 
Mimecan Ogn 34 1.18 1.56 10 
Methylmalonate-
semialdehyde 
dehydrogenase 
Aldh6a1 58 1.17 1.55 5 
Nucleobindin-2 Nucb2 50 1.15 1.23 11 
Fibronectin type-III 
domain-containing 
protein 3A 
Fndc3a 127 1.15 1.40 10 
Absent In Melanoma 1 Aim1 185 1.14 1.38 28 
Immunoglobulin 
superfamily member 10 
Igsf10 286 1.10 1.09 33 
Probable ATP-dependent 
RNA helicase DHX36 
Dhx36 114 1.08 1.15 26 
FAT Atypical Cadherin 1 Fat1 506 1.06 1.08 85 
Selenoprotein T Selt 22 1.06 0.97 5 
Uncharacterized protein 
KIAA1671 
Kiaa1671 35 1.05 1.19 6 
Coiled-coil domain-
containing protein 80 
Ccdc80 108 1.01 1.23 10 
Peptidyl-prolyl cis-trans 
isomerase C 
Ppic 23 1.00 1.15 6 
Ubiquitin carboxyl-
terminal hydrolase 15 
Usp15 112 1.00 1.01 28 
Collagen alpha-1(I) chain Col1a1 138 0.99 1.19 45 
Palladin Palld 108 0.89 0.86 28 
Collagen alpha-1(V) chain Col5a1 184 0.87 1.07 23 
Collagen alpha-2(I) chain Col1a2 130 0.86 1.12 50 
Utrophin Utrn 393 0.77 0.84 116 
UTP-glucose-1-phosphate 
uridylyltransferase 
Ugp2 57 0.74 0.80 24 
Serpin H1 Serpinh1 47 0.73 0.74 22 
Myosin-10 Myh10 229 0.69 0.76 69 
Alanine--tRNA ligase, 
cytoplasmic 
Aars 107 0.57 0.68 45 
Glucose-6-phosphate Gpi;Gm18 63 -0.67 -0.66 17 
167 
 
isomerase 40 
Protein S100-A4 S100a4 12 -0.69 -0.66 4 
Serpin B6 Serpinb6 43 -0.78 -0.79 18 
Heat shock 70 kDa 
protein 4L 
Hspa4l 94 -0.82 -0.90 26 
Prostaglandin F2 receptor 
negative regulator 
Ptgfrn 99 -0.91 -1.01 13 
Apolipoprotein B-
100;Apolipoprotein B-48 
Apob 504 -0.91 2.11 4 
Serine 
hydroxymethyltransferas 
cytosolic 
Shmt1 53 -0.91 -0.93 22 
Thymidine kinase, 
cytosolic 
Tk1 26 -0.95 -0.98 7 
Calcium-binding 
mitochondrial carrier 
protein SCaMC-1 
Slc25a24 53 -0.97 -1.07 17 
Hematopoietic progenitor 
cell antigen CD34 
Cd34 35 -0.97 -1.00 5 
Voltage-dependent 
calcium channel subunit 
alpha-2/delta-1 
Cacna2d1 123 -0.98 -1.19 13 
Latexin Lxn 25 -0.99 -1.03 6 
ATPase WRNIP1 Wrnip1 72 -1.00 -1.04 13 
Serine/threonine-protein 
phosphatase 6 regulatory 
ankyrin repeat subunit A 
Ankrd28 113 -1.00 -0.96 13 
Coiled-coil domain-
containing protein 109B 
Ccdc109b 40 -1.00 -0.99 4 
Protocadherin-19 Pcdh19 121 -1.00 -2.02 3 
Peptidyl-prolyl cis-trans 
isomerase FKBP5 
Fkbp5 51 -1.01 -1.12 11 
Plakophilin 2 Pkp2 52 -1.04 -0.97 5 
Microtubule-associated 
protein 1B 
Map1b 270 -1.09 -1.09 51 
N-acylglucosamine 2-
epimerase 
Renbp 48 -1.11 -1.08 8 
Ras Association And 
Pleckstrin Homology 
Domains 1 
Raph1 67 -1.11 -1.01 9 
Lymphocyte antigen 6C1 Ly6c1;Ly6
c2 
14 -1.11 -1.14 2 
Argininosuccinate 
synthase 
Ass1; 
Gm5424 
47 -1.13 -1.09 18 
Caspase-12 Casp12 48 -1.14 -1.07 7 
High mobility group 
protein HMG-I/HMG-Y 
Hmga1 12 -1.15 -1.09 2 
Leukocyte elastase 
inhibitor A 
Serpinb1a 43 -1.17 -1.18 12 
Integrin alpha-6 Itga6 120 -1.18 -1.16 6 
Testin Tes 47 -1.19 -0.93 16 
KH domain-containing, 
RNA-binding, signal 
transduction-associated 
protein 3 
Khdrbs3 39 -1.21 -1.31 5 
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Carbonic anhydrase 13 Ca13 30 -1.23 -1.15 7 
Interferon-activable 
protein 204 
Ifi204 69 -1.26 -1.20 6 
DEP domain-containing 
mTOR-interacting protein 
Deptor 46 -1.26 -0.93 9 
Ectonucleotide 
pyrophosphatase/ 
phosphodiesterase family 
member 1 
Enpp1 103 -1.29 -1.73 11 
Interferon-activable 
protein 202 
Ifi202 50 -1.31 -1.51 10 
Pirin Pir 28 -1.33 -1.40 4 
UDP-glucuronosyl 
transferase 1-6 
Ugt1a6 60 -1.34 -1.23 7 
Aldo-Keto Reductase 
Family 1, Member B10 
Akr1b10 36 -1.42 -1.29 6 
Glutathione S-transferase 
A4 
Gsta4 26 -1.44 -1.49 8 
Receptor-interacting 
serine/threonine-protein 
kinase 3 
Ripk3 53 -1.45 -1.32 8 
Aldose reductase-related 
protein 2 
Akr1b8 36 -1.53 -1.56 5 
Nestin Nes 202 -1.55 -1.46 35 
Tight junction protein 
ZO-2 
Tjp2 131 -1.58 -1.29 14 
Collectin-12 Colec12 81 -1.63 -1.87 14 
Collagen, Type VI, Alpha 
3  
Col6a3 354 -1.68 -1.76 78 
Neuropilin-1 Nrp1 103 -1.73 -1.28 3 
Matrix Gla protein Mgp 12 -1.78 -1.56 2 
Protein-glutamine 
gamma-
glutamyltransferase 2 
Tgm2 77 -1.82 -1.19 8 
Stimulator of interferon 
genes protein 
Tmem173 43 -1.84 -1.90 7 
Cadherin-11 Cdh11 88 -1.87 -1.96 11 
Fos-related antigen 1 Fosl1 30 -1.88 -1.29 3 
Ceruloplasmin Cp 121 -1.94 -1.51 3 
Epidermal growth factor 
receptor kinase substrate 
8 
Eps8 92 -1.94 -1.84 17 
Histone H1.1 Hist1h1a 22 -1.96 -2.02 4 
Stromal cell-derived 
factor 1 
Cxcl12 10 -1.97 -1.96 2 
Cellular retinoic acid-
binding protein 2 
Crabp2 16 -2.01 -1.87 4 
Tudor and KH domain-
containing protein 
Tdrkh 62 -2.16 -2.57 2 
Versican core protein Vcan 263 -2.25 -1.81 8 
Interleukin-1 receptor 
antagonist protein 
Il1rn 18 -2.51 -3.10 4 
Serine protease inhibitor 
A3G 
Serpina3g 49 -2.86 -3.22 7 
Ubiquitin-like protein Isg15 18 -3.06 -2.25 5 
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ISG15 
Interferon-induced 
protein with 
tetratricopeptide  
repeats 1 
Ifit1 54 -3.13 -2.95 12 
Collagen triple helix 
repeat-containing  
protein 1 
Cthrc1 26 -3.27 -1.92 4 
Osteopontin Spp1 32 -3.83 -1.88 3 
Appendix II – Cellular proteins significantly changed in iMEF.tRNAiMet cells versus 
iMEF.Vector cells (pool 1). 
The cellular proteome was analysed following tRNAiMet overexpression using quantitative SILAC 
mass spectrometry. iMEF.Vector and iMEF.tRNAiMet cells were labelled with heavy and light amino 
acids, protein lysates were prepared in 4% SDS lysis buffer, samples combined and analysed by 
liquid chromatography-mass spectrometry. Forward experiment corresponds to iMEF.tRNAiMet cells 
labelled with heavy amino acids combined with iMEF.Vector cells labelled with light amino acids, 
and the reverse experiment corresponds to iMEF.Vector cells labelled with heavy amino acids 
combined with iMEF.tRNAiMet cells labelled with light amino acids.  Forward SILAC ratio is 
calculated as (Log2 tRNAiMet / Vector), and reverse SILAC ratio as (1/(Log2 tRNAiMet / Vector)), MW 
= molecular weight, and unique peptides refers to the number of peptides identified that exist only 
in that one protein of interest. Data generated in collaboration with David Sumpton, CR-UK 
Beatson Institute, Glasgow. ………………………………………………………………………………… 
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Appendix II: RNA-Sequencing dataset 
Gene Name Gene symbol Fold change P-value 
mesenchyme homeobox 1 Meox1 26.28 3.28E-41 
collagen, type II, alpha 1 Col2a1 25.41 8.12E-76 
pregnancy-associated plasma protein A Pappa 8.64 1.13E-32 
potassium channel tetramerisation domain 
containing 12b 
Kctd12b 6.59 7.03E-24 
ABI gene family, member 3 (NESH) binding 
protein 
Abi3bp 6.43 1.74E-23 
secreted frizzled-related protein 2 Sfrp2 5.01 4.43E-18 
dickkopf homolog 2 Dkk2 3.98 2.66E-13 
F-box protein 2 Fbxo2 3.97 2.12E-09 
a disintegrin-like and metallopeptidase 
with thrombospondin type 1 motif, 1 
Adamts1 3.77 3.35E-18 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
Atp1b1 3.61 7.05E-13 
H2A histone family, member Y2 H2afy2 3.44 3.38E-11 
nephroblastoma overexpressed gene Nov 3.22 5.62E-14 
homeobox D13 Hoxd13 3.19 3.61E-10 
absent in melanoma 1 Aim1 2.88 2.71E-10 
platelet-derived growth factor, D 
polypeptide 
Pdgfd 2.82 1.29E-09 
carbohydrate (N-acetylglucosamino) 
sulfotransferase 7 
Chst7 2.82 3.72E-08 
aryl-hydrocarbon receptor Ahr 2.81 3.23E-10 
family with sequence similarity 198, 
member B 
Fam198b 2.80 9.97E-09 
SUN domain containing ossification factor Suco 2.69 2.06E-09 
heat shock protein 1 Hspb1 2.68 6.21E-06 
coxsackie virus and adenovirus receptor Cxadr 2.55 1.44E-08 
MDS1 and EVI1 complex locus Mecom 2.52 2.29E-08 
DEAH (Asp-Glu-Ala-His) box polypeptide 36 Dhx36 2.46 5.27E-08 
eukaryotic translation initiation factor 2A Eif2a 2.44 1.82E-07 
natriuretic peptide receptor 3 Npr3 2.43 3.73E-08 
deleted in liver cancer 1 Dlc1 2.42 3.36E-08 
selenoprotein T Selt 2.41 2.67E-08 
GLIS family zinc finger 3 Glis3 2.40 1.99E-07 
family with sequence similarity 188, 
member A 
Fam188a 2.38 1.24E-06 
lysophosphatidic acid receptor 6 Lpar6 2.38 6.08E-05 
unc-5 homolog B Unc5b 2.37 1.99E-07 
fibronectin type 3 and SPRY domain-
containing protein 
Fsd1 2.37 5.17E-04 
ankyrin repeat domain 1 (cardiac muscle) Ankrd1 2.33 3.37E-07 
semaphorin 3A Sema3a 2.31 7.73E-08 
C-type lectin domain family 11, member a Clec11a 2.30 3.59E-04 
transforming, acidic coiled-coil containing 
protein 1 
Tacc1 2.25 1.42E-06 
TSC22 domain family, member 2 Tsc22d2 2.25 3.53E-07 
UDP-glucose pyrophosphorylase 2 Ugp2 2.18 3.43E-06 
sorting nexin 7 Snx7 2.16 5.05E-06 
solute carrier family 5 (inositol 
transporters), member 3 
Slc5a3 2.15 5.43E-06 
ecotropic viral integration site 2a Evi2a 2.15 2.91E-03 
GULP, engulfment adaptor PTB domain Gulp1 2.12 1.55E-05 
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containing 1 
apelin Apln 2.11 9.55E-05 
ezrin Ezr 2.09 1.56E-05 
epithelial membrane protein 1 Emp1 2.08 1.18E-05 
serine palmitoyltransferase, small subunit 
A 
Sptssa 2.06 3.48E-05 
melanoma cell adhesion molecule Mcam 2.06 6.15E-04 
4-nitrophenylphosphatase domain and non-
neuronal SNAP25-like protein homolog 1 
(C. elegans) 
Nipsnap1 2.05 6.78E-04 
serine (or cysteine) peptidase inhibitor, 
clade E, member 1 
Serpine1 2.05 1.15E-05 
dickkopf homolog 3 (Xenopus laevis) Dkk3 2.04 5.27E-05 
GTP cyclohydrolase I feedback regulator Gchfr 2.04 2.86E-03 
nidogen 2 Nid2 2.02 2.08E-04 
eyes absent 4 homolog Eya4 2.02 7.19E-05 
a disintegrin-like and metallopeptidase  
with thrombospondin type 1 motif 5 
Adamts5 2.02 7.39E-06 
semaphorin 3E Sema3e 1.98 8.66E-05 
follistatin-like 1 Fstl1 1.98 5.46E-05 
paternally expressed 10 Peg10 1.97 9.37E-05 
FAT tumor suppressor homolog 4 Fat4 1.96 8.74E-05 
stress-associated endoplasmic reticulum 
protein 1 
Serp1 1.96 8.41E-05 
WW domain binding protein 4 Wbp4 1.93 1.77E-03 
RIKEN cDNA 4921524J17 gene 4921524J17Rik 1.92 5.54E-03 
integrin alpha 3 Itga3 1.92 2.37E-04 
procollagen C-endopeptidase enhancer 2 Pcolce2 1.91 9.84E-04 
T-box18 Tbx18 1.91 1.33E-03 
fibronectin type III domain containing 3A Fndc3a 1.90 3.48E-04 
high mobility group AT-hook 2 Hmga2 1.89 8.68E-04 
zinc finger protein 938 Zfp938 1.88 1.51E-02 
ubiquitin-conjugating enzyme E2 variant 2 Ube2v2 1.86 1.79E-03 
cytokine receptor-like factor 1 Crlf1 1.86 3.10E-02 
fucokinase Fuk 1.86 9.57E-03 
E2F transcription factor 6 E2f6 1.86 1.40E-02 
ubiquitin specific peptidase 15 Usp15 1.86 4.93E-04 
osteoglycin Ogn 1.86 1.88E-04 
component of oligomeric golgi complex 6 Cog6 1.85 9.41E-03 
protein kinase C, iota Prkci 1.84 5.42E-04 
membrane protein, palmitoylated 5  Mpp5 1.84 1.96E-03 
heparan sulfate 6-O-sulfotransferase 2 Hs6st2 1.83 2.61E-03 
sirtuin 1 Sirt1 1.83 4.12E-03 
phosphatidylinositol 3-kinase, C2 domain 
containing, alpha  
Pik3c2a 1.83 8.53E-04 
suppressor of G2 allele of SKP1  Sugt1 1.83 2.42E-03 
polymerase (DNA directed), beta Polb 1.82 8.12E-03 
amyloid beta (A4) precursor protein App 1.81 6.83E-04 
low density lipoprotein receptor-related 
protein associated protein 1 
Lrpap1 1.80 6.92E-03 
RIKEN cDNA 2610008E11 gene 2610008E11Rik 1.80 1.82E-03 
Fgfr1op N-terminal like Fopnl 1.80 8.64E-03 
ADP-ribosylation factor 2 Arf2 1.79 7.94E-03 
charged multivesicular body protein 2B Chmp2b 1.79 1.25E-02 
adenosine kinase Adk 1.79 3.38E-03 
forty-two-three domain containing 1 Fyttd1 1.78 1.74E-03 
deltex 3 homolog  Dtx3 1.77 2.51E-02 
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ATP-binding cassette, sub-family B 
(MDR/TAP), member 10 
Abcb10 1.77 3.26E-03 
NADH dehydrogenase (ubiquinone) 1, 
subcomplex unknown, 1 
Ndufc1 1.76 2.92E-02 
testis-specific protein, Y-encoded-like 1 Tspyl1 1.76 3.36E-03 
fibroblast growth factor 7 Fgf7 1.75 1.22E-03 
glutathione S-transferase, mu 5 Gstm5 1.74 3.12E-02 
TATA box binding protein (Tbp)-associated 
factor, RNA polymerase I, B 
Taf1b 1.74 3.81E-02 
kinesin family member 16B Kif16b 1.74 1.03E-02 
E2F-associated phosphoprotein Eapp 1.74 1.19E-02 
Cnksr family member 3 Cnksr3 1.74 1.98E-02 
F-box protein 30 Fbxo30 1.74 5.09E-03 
vestigial like 3 Vgll3 1.73 6.46E-03 
protocadherin 18 Pcdh18 1.73 3.26E-03 
UFM1-specific peptidase 2 Ufsp2 1.73 1.35E-02 
cytochrome b-245, alpha polypeptide Cyba 1.72 4.02E-02 
LEM domain containing 3 Lemd3 1.72 1.74E-02 
stathmin-like 2 Stmn2 1.72 4.83E-03 
transmembrane protein 30A Tmem30a 1.71 6.06E-03 
stannin Snn 1.71 2.41E-02 
SMAD specific E3 ubiquitin protein ligase 2 Smurf2 1.70 5.82E-03 
ring finger protein 13 Rnf13 1.70 2.11E-02 
TGF-beta activated kinase 1/MAP3K7 
binding protein 2 
Tab2 1.70 6.50E-03 
formin homology 2 domain containing 1 Fhod1 1.70 2.58E-02 
twist basic helix-loop-helix transcription 
factor 1 
Twist1 1.69 4.56E-02 
zinc finger, DHHC domain containing 17 Zdhhc17 1.69 2.88E-02 
frizzled homolog 1  Fzd1 1.69 1.64E-02 
muscleblind-like 1 Mbnl1 1.68 4.43E-03 
signal peptidase complex subunit 3 
homolog 
Spcs3 1.67 4.08E-03 
fibulin 5 Fbln5 1.67 2.51E-02 
transmembrane protein 62 Tmem62 1.67 3.75E-02 
annexin A3 Anxa3 1.67 4.83E-03 
dynein light chain Tctex-type 3 Dynlt3 1.67 1.68E-02 
interferon induced with helicase C domain 
1 
Ifih1 1.67 2.00E-02 
tRNA methyltransferase 11 Trmt11 1.66 4.21E-02 
cysteine rich protein 61 Cyr61 1.66 3.57E-03 
zinc finger protein 617 Zfp617 1.66 3.03E-02 
RIKEN cDNA 1700021K19 gene 1700021K19Rik 1.66 2.07E-02 
family with sequence similarity 107, 
member B 
Fam107b 1.66 1.32E-02 
CD151 antigen Cd151 1.66 1.56E-02 
transmembrane protein 2 Tmem2 1.65 1.28E-02 
phosducin-like Pdcl 1.65 2.04E-02 
kinase D-interacting substrate 220 Kidins220 1.65 2.16E-02 
host cell factor C2 Hcfc2 1.64 3.80E-02 
microtubule associated monooxygenase, 
calponin and LIM domain containing 1 
Mical1 1.64 3.31E-02 
LSM4 homolog, U6 small nuclear RNA 
associated  
Lsm4 1.64 3.08E-02 
Rho family GTPase 3 Rnd3 1.64 4.92E-03 
phosphorylase kinase alpha 2 Phka2 1.64 4.29E-02 
exocyst complex component 5 Exoc5 1.63 8.65E-03 
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high mobility group box transcription 
factor 1 
Hbp1 1.63 2.60E-02 
transmembrane 4 superfamily member 1 Tm4sf1 1.63 1.24E-02 
disabled 2, mitogen-responsive 
phosphoprotein 
Dab2 1.63 2.47E-02 
FK506 binding protein 3 Fkbp3 1.63 3.96E-02 
proteasome (prosome, macropain) 26S 
subunit, ATPase, 6 
Psmc6 1.62 1.19E-02 
striatin, calmodulin binding protein 3 Strn3 1.62 1.46E-02 
G protein-coupled receptor 126 Gpr126 1.62 2.47E-02 
REV3-like, catalytic subunit of DNA 
polymerase zeta RAD54 like  
Rev3l 1.62 2.10E-02 
store-operated calcium entry-associated 
regulatory factor 
Saraf 1.62 3.19E-02 
microfibrillar-associated protein 3-like Mfap3l 1.62 4.51E-02 
C1D nuclear receptor co-repressor C1d 1.61 3.31E-02 
scavenger receptor class F, member 2 Scarf2 1.61 4.10E-02 
procollagen lysine, 2-oxoglutarate 5-
dioxygenase 2 
Plod2 1.61 4.73E-02 
serine incorporator 1 Serinc1 1.61 1.59E-02 
dermatan sulfate epimerase Dse 1.60 1.70E-02 
pyridoxal-dependent decarboxylase 
domain containing 1 
Pdxdc1 1.60 2.35E-02 
Rho guanine nucleotide exchange factor 
(GEF) 25 
Arhgef25 1.60 3.05E-02 
regulator of chromosome condensation 
(RCC1) and BTB (POZ) domain containing 
protein 2 
Rcbtb2 1.60 3.32E-02 
peptidylprolyl isomerase (cyclophilin)-like 
4 
Ppil4 1.59 4.02E-02 
heat shock protein 70 family, member 13 Hspa13 1.59 3.14E-02 
NUAK family, SNF1-like kinase, 1 Nuak1 1.59 4.54E-02 
vacuolar protein sorting 26 homolog A  Vps26a 1.58 3.83E-02 
RB1-inducible coiled-coil 1 Rb1cc1 1.58 1.71E-02 
succinate-Coenzyme A ligase, ADP-
forming, beta subunit 
Sucla2 1.58 4.28E-02 
family with sequence similarity 115, 
member A 
Fam115a 1.58 3.33E-02 
lin-7 homolog C  Lin7c 1.57 1.75E-02 
semaphorin 3F Sema3f 1.57 4.48E-02 
LIM and senescent cell antigen-like 
domains 1 
Lims1 1.57 2.17E-02 
pleckstrin homology-like domain, family B, 
member 2 
Phldb2 1.57 2.70E-02 
caldesmon 1 Cald1 1.56 2.60E-02 
myosin, light polypeptide 6, alkali, smooth 
muscle and non-muscle 
Myl6 1.56 2.87E-02 
myosin light polypeptide 6 alkali smooth 
muscle and non-muscle protein, 
pseudogene 
Gm8894 1.56 2.87E-02 
proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 6 
Psmd6 1.56 4.07E-02 
A kinase (PRKA) anchor protein 11 Akap11 1.56 4.52E-02 
collagen, type XII, alpha 1 Col12a1 1.55 2.65E-02 
methionine sulfoxide reductase B3 Msrb3 1.54 3.92E-02 
transmembrane emp24 protein transport 
domain containing 5 
Tmed5 1.53 4.22E-02 
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CD24a antigen Cd24a 1.52 4.53E-02 
G protein-coupled receptor 124 Gpr124 -1.51 4.55E-02 
glyceraldehyde-3-phosphate 
dehydrogenase 
Gapdh -1.52 3.80E-02 
predicted gene, 20899 Gm20899 -1.52 3.80E-02 
ubiquitin specific peptidase 9, X 
chromosome 
Usp9x -1.52 4.66E-02 
lysosomal-associated membrane protein 2 Lamp2 -1.52 4.03E-02 
H1 histone family, member 0 H1f0 -1.53 4.66E-02 
parathymosin Ptms -1.53 3.83E-02 
nucleolin Ncl -1.54 4.70E-02 
CD34 antigen Cd34 -1.54 3.57E-02 
moesin Msn -1.54 3.01E-02 
LIM domain and actin binding 1 Lima1 -1.55 2.75E-02 
predicted gene 2444 Gm2444 -1.55 3.77E-02 
DAZ associated protein 2 Dazap2 -1.55 3.77E-02 
golgi transport 1 homolog B Golt1b -1.55 4.90E-02 
HEAT repeat containing 1 Heatr1 -1.55 3.88E-02 
forkhead box P1 Foxp1 -1.56 3.56E-02 
NOP2 nucleolar protein Nop2 -1.56 2.29E-02 
antizyme inhibitor 1 Azin1 -1.57 2.39E-02 
NADH dehydrogenase subunit 1 ND1 -1.57 2.65E-02 
glucose-6-phosphate dehydrogenase X-
linked 
G6pdx -1.57 4.19E-02 
transducer of ERBB2, 2 Tob2 -1.57 4.96E-02 
collagen, type V, alpha 1 Col5a1 -1.58 1.63E-02 
integrin alpha 6 Itga6 -1.58 4.57E-02 
block of proliferation 1 Bop1 -1.58 2.43E-02 
NHP2 ribonucleoprotein Nhp2 -1.58 4.22E-02 
mannosidase 2, alpha 1 Man2a1 -1.59 1.63E-02 
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
Slc7a1 -1.59 3.75E-02 
eukaryotic translation initiation factor 4E 
binding protein 1 
Eif4ebp1 -1.59 2.15E-02 
UTP15, U3 small nucleolar 
ribonucleoprotein, homolog  
Utp15 -1.59 4.48E-02 
cysteinyl-tRNA synthetase Cars -1.59 4.02E-02 
discoidin domain receptor family, member 
2 
Ddr2 -1.59 1.69E-02 
glutamate receptor, ionotropic, N-methyl 
D-aspartate-associated protein 1 
(glutamate binding) 
Grina -1.59 1.49E-02 
four and a half LIM domains 3 Fhl3 -1.59 3.88E-02 
protein kinase C, delta Prkcd -1.60 2.63E-02 
PHD finger protein 10 Phf10 -1.60 2.92E-02 
tight junction protein 1 Tjp1 -1.60 1.65E-02 
interleukin-1 receptor-associated kinase 1 Irak1 -1.60 3.88E-02 
serine (or cysteine) peptidase inhibitor, 
clade B, member 6a 
Serpinb6a -1.60 1.85E-02 
zinc finger CCCH type, antiviral 1 Zc3hav1 -1.61 1.48E-02 
RAS p21 protein activator 1 Rasa1 -1.61 2.24E-02 
sideroflexin 1 Sfxn1 -1.61 2.65E-02 
platelet derived growth factor receptor, 
beta polypeptide 
Pdgfrb -1.61 1.16E-02 
ribosomal RNA processing 1 homolog B  Rrp1b -1.62 3.34E-02 
mitochondrial ribosomal protein L12 Mrpl12 -1.62 4.29E-02 
ZPR1 zinc finger Zpr1 -1.63 4.35E-02 
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threonyl-tRNA synthetase Tars -1.63 9.93E-03 
ring finger protein 150 Rnf150 -1.64 1.82E-02 
clustered mitochondria (cluA/CLU1) 
homolog 
Cluh -1.64 1.48E-02 
RUN and FYVE domain containing 1 Rufy1 -1.64 4.37E-02 
eukaryotic translation initiation factor 3, 
subunit B 
Eif3b -1.64 9.89E-03 
ArfGAP with SH3 domain, ankyrin repeat 
and PH domain1 
Asap1 -1.64 7.91E-03 
aldo-keto reductase family 1, member B3 
(aldose reductase) 
Akr1b3 -1.65 3.31E-02 
NA NA -1.65 3.42E-02 
suppressor of variegation 3-9 homolog 1  Suv39h1 -1.65 2.22E-02 
docking protein 1 Dok1 -1.66 1.88E-02 
mediator of DNA damage checkpoint 1 Mdc1 -1.66 2.07E-02 
tubulin tyrosine ligase-like family, member 
12 
Ttll12 -1.66 1.52E-02 
interferon induced transmembrane protein 
3 
Ifitm3 -1.66 8.16E-03 
NADH dehydrogenase subunit 2 ND2 -1.66 5.74E-03 
tumor necrosis factor receptor 
superfamily, member 1a 
Tnfrsf1a -1.67 1.63E-02 
pleckstrin homology domain containing, 
family O member 1 
Plekho1 -1.67 2.59E-02 
cerebellar degeneration-related protein 2-
like 
Cdr2l -1.67 2.05E-02 
PAP associated domain containing 7 Papd7 -1.68 3.08E-02 
calcium channel, voltage-dependent, beta 
3 subunit 
Cacnb3 -1.68 1.56E-02 
angiopoietin 1 Angpt1 -1.68 3.05E-02 
septin 9 Sept9 -1.69 3.56E-03 
gem (nuclear organelle) associated protein 
5 
Gemin5 -1.69 7.89E-03 
plectin Plec -1.69 4.92E-03 
solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 
2 
Slc11a2 -1.70 1.26E-02 
four and a half LIM domains 2 Fhl2 -1.70 1.09E-02 
fibrillin 1 Fbn1 -1.70 2.61E-03 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
Mthfd1l -1.71 7.34E-03 
mitochondrial ribosomal protein S27 Mrps27 -1.71 4.55E-02 
adaptor-related protein complex 3, sigma 
1 subunit 
Ap3s1 -1.71 2.97E-02 
glucose phosphate isomerase 1 Gpi1 -1.71 4.06E-03 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 
Kdelr3 -1.71 1.91E-02 
transmembrane protein 173 Tmem173 -1.72 3.63E-02 
serine hydroxymethyltransferase 1 
(soluble) 
Shmt1 -1.72 1.12E-02 
protein tyrosine phosphatase, receptor 
type, S 
Ptprs -1.73 1.40E-03 
high mobility group AT-hook 1 Hmga1 -1.73 7.27E-03 
high mobility group AT-hook I, related 
sequence 1 
Hmga1-rs1 -1.73 7.27E-03 
processing of precursor 1, ribonuclease 
P/MRP family 
Pop1 -1.73 5.76E-03 
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AFG3-like AAA ATPase 2 Afg3l2 -1.73 1.69E-02 
interferon-induced protein 35 Ifi35 -1.74 2.95E-02 
NOL1/NOP2/Sun domain family member 2 Nsun2 -1.74 2.23E-03 
poly(A) binding protein, cytoplasmic 1 Pabpc1 -1.74 2.54E-03 
myosin X Myo10 -1.74 1.92E-03 
hexokinase 2 Hk2 -1.75 8.35E-03 
sterile alpha motif domain containing 9-
like 
Samd9l -1.75 8.57E-03 
glypican 1 Gpc1 -1.75 2.11E-03 
tubulin, beta 2A class IIA Tubb2a -1.75 5.09E-03 
erythrocyte protein band 4.1-like 1 Epb4.1l1 -1.76 2.88E-03 
family with sequence similarity 102, 
member B 
Fam102b -1.76 3.10E-03 
receptor (TNFRSF)-interacting serine-
threonine kinase 1 
Ripk1 -1.76 6.45E-03 
translocator protein Tspo -1.77 1.87E-03 
CNDP dipeptidase 2 (metallopeptidase M20 
family) 
Cndp2 -1.77 4.08E-02 
forkhead box M1 Foxm1 -1.77 7.66E-03 
Ras and Rab interactor 1 Rin1 -1.77 2.35E-03 
coagulation factor II (thrombin) receptor F2r -1.77 2.56E-03 
phosphoserine aminotransferase 1 Psat1 -1.77 1.47E-03 
rho/rac guanine nucleotide exchange 
factor (GEF) 2 
Arhgef2 -1.78 3.98E-03 
biglycan Bgn -1.78 1.10E-03 
5'-nucleotidase domain containing 2 Nt5dc2 -1.78 2.12E-03 
branched chain aminotransferase 1, 
cytosolic 
Bcat1 -1.78 1.63E-03 
copine VIII Cpne8 -1.78 5.89E-03 
40S ribosomal protein S16-like LOC100862433 -1.79 1.34E-03 
ribosomal protein S16 Rps16 -1.79 1.34E-03 
integrin alpha 5 (fibronectin receptor 
alpha) 
Itga5 -1.79 1.34E-03 
prostaglandin F2 receptor negative 
regulator 
Ptgfrn -1.80 2.67E-03 
dihydropyrimidinase-like 3 Dpysl3 -1.80 8.68E-04 
high mobility group AT-hook I, related 
sequence 1 
Hmga1-rs1 -1.81 6.45E-03 
high mobility group AT-hook 1 Hmga1 -1.81 6.45E-03 
spermidine synthase Srm -1.82 2.50E-03 
mannose receptor, C type 2 Mrc2 -1.82 9.97E-04 
ral guanine nucleotide dissociation 
stimulator 
Ralgds -1.82 2.76E-03 
interactor of little elongation complex ELL 
subunit 1 
Ice1 -1.82 1.54E-03 
nuclear receptor subfamily 3, group C, 
member 1 
Nr3c1 -1.83 2.69E-03 
coiled-coil domain containing 109B Ccdc109b -1.83 1.20E-02 
methylenetetrahydrofolate dehydrogenase 
(NAD+ dependent) 
Mthfd2 -1.84 2.56E-03 
renin binding protein Renbp -1.84 2.76E-03 
neuropilin 1 Nrp1 -1.84 9.56E-04 
layilin Layn -1.85 1.98E-02 
active BCR-related gene Abr -1.85 9.49E-04 
plasminogen activator, urokinase Plau -1.86 6.24E-03 
centromere protein H Cenph -1.86 1.71E-02 
inverted formin, FH2 and WH2 domain Inf2 -1.86 4.16E-03 
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containing 
dpy-19-like 1 Dpy19l1 -1.86 1.61E-03 
nischarin Nisch -1.87 1.17E-04 
sperm antigen with calponin homology and 
coiled-coil domains 1 
Specc1 -1.87 3.78E-04 
growth arrest specific 1 Gas1 -1.88 2.23E-04 
vacuole membrane protein 1 Vmp1 -1.88 2.76E-04 
enolase 3, beta muscle Eno3 -1.89 8.06E-04 
glutamate dehydrogenase 1 Glud1 -1.89 1.86E-04 
oncostatin M receptor Osmr -1.89 6.83E-04 
MYB binding protein (P160) 1a Mybbp1a -1.89 1.14E-04 
strawberry notch homolog 2 Sbno2 -1.89 1.34E-03 
heparan sulfate 6-O-sulfotransferase 1 Hs6st1 -1.89 3.47E-03 
aldehyde dehydrogenase 18 family, 
member A1 
Aldh18a1 -1.89 3.16E-04 
AXL receptor tyrosine kinase Axl -1.90 1.11E-04 
glutathione S-transferase, theta 1 Gstt1 -1.90 3.27E-03 
tubulin, beta 6 class V Tubb6 -1.90 2.26E-04 
glycophorin C Gypc -1.90 2.59E-03 
Treacher Collins Franceschetti syndrome 1, 
homolog 
Tcof1 -1.91 3.66E-04 
glutathione S-transferase, mu 1 Gstm1 -1.91 1.80E-03 
Ngfi-A binding protein 1 Nab1 -1.92 1.39E-03 
poly (ADP-ribose) polymerase family, 
member 8 
Parp8 -1.93 2.96E-03 
cathepsin L Ctsl -1.93 8.65E-05 
glutamic pyruvate transaminase (alanine 
aminotransferase) 2 
Gpt2 -1.93 2.69E-04 
fibronectin 1 Fn1 -1.94 5.98E-05 
matrix metallopeptidase 2 Mmp2 -1.94 9.21E-05 
sterol O-acyltransferase 1 Soat1 -1.94 1.24E-04 
plasminogen activator, tissue Plat -1.94 9.07E-05 
early growth response 1 Egr1 -1.96 7.14E-03 
WNT1 inducible signaling pathway protein 
1 
Wisp1 -1.96 8.56E-05 
histocompatibility 2, K1, K region H2-K1 -1.97 1.15E-03 
cathepsin Z Ctsz -1.99 5.44E-04 
extracellular matrix protein 1 Ecm1 -2.00 1.92E-03 
inhibitor of DNA binding 2 Id2 -2.00 6.50E-03 
tensin 3 Tns3 -2.00 1.04E-04 
interferon, alpha-inducible protein 27 Ifi27 -2.00 2.09E-04 
KH domain containing, RNA binding, signal 
transduction associated 3 
Khdrbs3 -2.01 5.62E-04 
abhydrolase domain containing 17C Abhd17c -2.02 8.31E-04 
tissue inhibitor of metalloproteinase 1 Timp1 -2.02 8.74E-05 
fibulin 1 Fbln1 -2.03 1.12E-04 
desumoylating isopeptidase 1 Desi1 -2.03 8.46E-04 
caspase 12 Casp12 -2.06 6.39E-04 
NA NA -2.08 6.06E-03 
predicted gene 2115 Gm2115 -2.09 1.47E-04 
solute carrier family 25 (mitochondrial 
carrier, phosphate carrier), member 24 
Slc25a24 -2.10 1.42E-05 
tubulin, alpha 4A Tuba4a -2.12 4.01E-04 
nestin Nes -2.12 3.14E-06 
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 5 
B4galt5 -2.13 1.02E-04 
DEP domain containing MTOR-interacting Deptor -2.13 8.84E-06 
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protein 
suppressor of cytokine signaling 5 Socs5 -2.14 8.50E-05 
lysocardiolipin acyltransferase 1 Lclat1 -2.14 3.09E-05 
nuclear factor of kappa light polypeptide 
gene enhancer in B cells 2, p49/p100 
Nfkb2 -2.15 9.17E-06 
TAP binding protein Tapbp -2.17 1.83E-06 
exostoses (multiple) 1 Ext1 -2.19 1.61E-06 
ribosomal protein S6 kinase, polypeptide 2 Rps6ka2 -2.20 2.91E-05 
ankyrin repeat domain 28 Ankrd28 -2.21 2.48E-06 
signal-induced proliferation-associated 1 
like 2 
Sipa1l2 -2.22 1.24E-05 
suppressor of cytokine signaling 3 Socs3 -2.23 1.49E-04 
death-associated protein Dap -2.25 5.79E-07 
solute carrier family 1 (neutral amino acid 
transporter), member 5 
Slc1a5 -2.25 4.98E-06 
asparagine synthetase Asns -2.25 6.57E-07 
matrix Gla protein Mgp -2.26 4.80E-08 
E26 avian leukemia oncogene 2, 3' domain Ets2 -2.26 9.48E-06 
schlafen 9 Slfn9 -2.26 1.38E-05 
endoplasmic reticulum metallopeptidase 1 Ermp1 -2.29 3.88E-07 
thioredoxin 2 Txn2 -2.29 7.27E-06 
epidermal growth factor receptor pathway 
substrate 8 
Eps8 -2.29 4.66E-07 
tripartite motif-containing 44 Trim44 -2.30 1.68E-06 
serine (or cysteine) peptidase inhibitor, 
clade F, member 1 
Serpinf1 -2.30 9.84E-08 
NA NA -2.36 3.98E-05 
CCAAT/enhancer binding protein (C/EBP), 
beta 
Cebpb -2.41 1.06E-06 
phosphatidic acid phosphatase type 2B Ppap2b -2.44 2.47E-06 
ChaC, cation transport regulator 1 Chac1 -2.45 6.41E-06 
SH3-domain kinase binding protein 1 Sh3kbp1 -2.46 8.09E-08 
AE binding protein 1 Aebp1 -2.50 5.02E-09 
small nucleolar RNA host gene 9 Snhg9 -2.50 4.64E-02 
signal transducer and activator of 
transcription 2 
Stat2 -2.51 7.71E-07 
solute carrier family 48 (heme 
transporter), member 1 
Slc48a1 -2.52 1.10E-07 
prune homolog 2 (Drosophila) Prune2 -2.54 1.25E-08 
transmembrane protein 119 Tmem119 -2.54 3.98E-07 
microtubule-associated protein 1B Map1b -2.55 5.11E-09 
paired related homeobox 1 Prrx1 -2.56 1.00E-08 
phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) 
Pik3r1 -2.64 3.42E-08 
chemokine (C-X3-C motif) ligand 1 Cx3cl1 -2.65 1.49E-08 
ring finger protein 213 Rnf213 -2.66 8.23E-11 
carbonic anhydrase 13 Car13 -2.67 2.22E-07 
chemokine (C-X-C motif) ligand 5 Cxcl5 -2.68 8.08E-07 
tripartite motif-containing 25 Trim25 -2.69 3.39E-08 
latexin Lxn -2.73 4.07E-08 
vascular endothelial growth factor A Vegfa -2.73 1.58E-08 
lymphocyte antigen 6 complex, locus E Ly6e -2.76 5.49E-08 
neuroepithelial cell transforming gene 1 Net1 -2.80 7.99E-10 
twist basic helix-loop-helix transcription 
factor 2 
Twist2 -2.85 3.53E-08 
cystathionase (cystathionine gamma-lyase) Cth -2.86 2.47E-07 
protocadherin 19 Pcdh19 -2.91 1.21E-11 
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OAF homolog (Drosophila) Oaf -2.93 7.87E-10 
aldehyde dehydrogenase 1 family, member 
L2 
Aldh1l2 -2.94 2.35E-11 
CD14 antigen Cd14 -2.95 1.09E-06 
jade family PHD finger 1 Jade1 -2.98 1.14E-09 
interferon regulatory factor 1 Irf1 -3.00 3.40E-10 
musculoskeletal, embryonic nuclear 
protein 1 
Mustn1 -3.00 2.98E-07 
elastin microfibril interfacer 2 Emilin2 -3.04 5.09E-09 
collagen, type III, alpha 1 Col3a1 -3.05 6.67E-14 
aldo-keto reductase family 1, member B8 Akr1b8 -3.08 2.71E-10 
tumor necrosis factor receptor 
superfamily, member 1b 
Tnfrsf1b -3.11 5.89E-11 
cellular retinoic acid binding protein II Crabp2 -3.12 3.34E-07 
CD47 antigen (Rh-related antigen, 
integrin-associated signal transducer) 
Cd47 -3.14 1.50E-10 
six transmembrane epithelial antigen of 
the prostate 1 
Steap1 -3.18 1.26E-08 
olfactomedin-like 3 Olfml3 -3.24 1.22E-12 
LIM and cysteine-rich domains 1 Lmcd1 -3.26 3.17E-09 
actin, gamma 2, smooth muscle, enteric Actg2 -3.37 1.19E-14 
glutathione S-transferase, alpha 4 Gsta4 -3.43 9.50E-12 
C-type lectin domain family 2, member d Clec2d -3.45 6.11E-10 
histone cluster 1, H1a Hist1h1a -3.55 1.29E-12 
platelet derived growth factor receptor, 
alpha polypeptide 
Pdgfra -3.75 2.65E-14 
interferon-activable protein 202-like LOC100044068 -3.75 1.29E-12 
interferon activated gene 202B Ifi202b -3.75 1.29E-12 
neuregulin 1 Nrg1 -3.83 2.46E-13 
leucine-rich repeats and immunoglobulin-
like domains 1 
Lrig1 -3.84 8.86E-16 
activating transcription factor 5 Atf5 -3.88 6.71E-14 
collagen, type V, alpha 3 Col5a3 -3.94 1.28E-16 
lymphocyte antigen 6 complex, locus C1 Ly6c1 -4.19 3.98E-13 
myristoylated alanine rich protein kinase C 
substrate 
Marcks -4.25 1.58E-21 
serine (or cysteine) peptidase inhibitor, 
clade B, member 1a 
Serpinb1a -4.26 8.52E-11 
lymphocyte antigen 6 complex, locus A Ly6a -4.49 1.25E-22 
Iroquois related homeobox 1 Irx1 -4.64 7.24E-15 
corneodesmosin Cdsn -4.92 8.10E-16 
collectin sub-family member 12 Colec12 -5.13 1.49E-25 
bone marrow stromal cell antigen 2 Bst2 -5.63 1.53E-11 
pleiotrophin Ptn -5.70 3.86E-18 
chemokine (C-X-C motif) ligand 12 Cxcl12 -6.16 2.44E-32 
interleukin 13 receptor, alpha 1 Il13ra1 -6.68 7.04E-29 
insulin-like growth factor binding protein 7 Igfbp7 -6.85 1.72E-23 
progressive ankylosis Ank -6.94 3.93E-35 
interleukin 1 receptor-like 1 Il1rl1 -6.95 3.75E-39 
apolipoprotein L 10B Apol10b -9.00 3.36E-26 
versican Vcan -9.14 1.05E-44 
interferon-induced protein with 
tetratricopeptide repeats 1 
Ifit1 -9.60 1.92E-38 
ISG15 ubiquitin-like modifier Isg15 -10.55 4.65E-23 
chemokine (C-X-C motif) ligand 10 Cxcl10 -10.94 4.42E-33 
chemokine (C-C motif) ligand 7 Ccl7 -11.25 1.07E-35 
chemokine (C-C motif) ligand 2 Ccl2 -11.89 1.04E-41 
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collagen, type VI, alpha 3 Col6a3 -12.42 9.39E-60 
metallothionein 1 Mt1 -13.00 1.97E-37 
secreted phosphoprotein 1 Spp1 -13.54 6.16E-63 
cadherin 11 Cdh11 -14.04 9.48E-59 
metallothionein 2 Mt2 -14.13 1.23E-26 
embigin Emb -14.68 1.93E-33 
transmembrane protein 176B Tmem176b -16.34 1.13E-52 
transforming growth factor, beta induced Tgfbi -16.76 1.02E-39 
chemokine (C-C motif) ligand 5 Ccl5 -19.41 4.47E-40 
transmembrane protein 176A Tmem176a -20.58 1.22E-45 
tetraspanin 11 Tspan11 -25.68 5.21E-62 
matrix metallopeptidase 3 Mmp3 -54.25 2.12E-56 
Appendix III - Transcripts significantly changed in iMEF.tRNAiMet cells versus iMEF.Vector 
cells (pool 1). 
The transcriptome was analysed following tRNAiMet overexpression. RNA was extracted and 
ribodepleted from three biological replicates of iMEF.tRNAiMet and iMEF.Vector cell preparations. 
The RNA-Seq library was prepared with an Illumia TruSeq RNA Sample Prep Kit, with sequencing 
being performed on the NextSeq500 platfrom using a High Output 75 cycle kit. The number of 
reads was normalised for library size, and the mean calculated from the three biological replicates. 
Fold change represents the ratio of iMEF.tRNAiMet / iMEF.Vector, with the corresponding adjusted 
P-value. Only transcripts with a FPKM (fragments per kilobase of exon per million reads) greater 
than 10 are presented. RNA-Seq conducted by Billy Clark and data analysed by Ann Hedley, CR-
UK Beatson Institute, Glasgow. 
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